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RESUMEN 
La demencia es un síndrome clínico caracterizado por un deterioro cognitivo progresivo, lo 
suficientemente severo como para impedir un funcionamiento autónomo a nivel personal y 
social del individuo. La enfermedad de Alzheimer (EA) representa la primera causa de 
demencia en nuestro país. Según datos del Centro Nacional de Epidemiología, el 7,3% de la 
población mayor de 65 años podría padecer esta enfermedad en la actualidad. En total, la 
EA constituye alrededor del 75% de la etiología de las demencias, bien de forma aislada 
bien en combinación con la patología cerebrovascular. Como consecuencia del incremento 
de la esperanza de vida y del progresivo envejecimiento de la población en los países 
occidentales, la demencia representa un enorme reto para los sistemas de salud públicos. 
En nuestro país, se estima que en el año 2050 un tercio de la población tendrá más de 65 
años, por lo que aproximadamente un millón de españoles podría padecer demencia. 
La EA es una enfermedad silenciosa que comienza con una degeneración cerebral muchos 
años antes de que se emita el primer diagnóstico clínico. Hay una larga fase asintomática. 
La transición desde un estado cognitivamente sano a la demencia debida a EA es un 
proceso continuo en el que pueden reconocerse diferentes estadios preclínicos y 
prodrómicos. Dichos estadios se caracterizan por la presencia de un deterioro cognitivo 
incipiente que incrementa la probabilidad de conversión a demencia en el futuro. Una 
intervención terapéutica eficaz en estas fases previas a la EA podría eventualmente retrasar 
la evolución del deterioro y disminuir así la prevalencia de la enfermedad. Por este motivo, 
uno de los desafíos a los que se enfrenta actualmente la investigación es el desarrollo de 
instrumentos útiles que permitan el diagnóstico precoz de la EA. 
El hallazgo de nuevos marcadores para esta fase podría facilitar la prevención de la 
enfermedad. En este trabajo, hemos analizado el deterioro cognitivo subjetivo (DCS), como 
marcador temprano adecuado para describir la fase asintomática de la EA. El DCS se define 
como la experiencia individual de deterioro cognitivo expresado a través de quejas 
cognitivas, que podría ser importante para predecir la transición desde la normalidad a la 
aparición del deterioro cognitivo leve (DCL). Sin embargo, la operativización de estas quejas 
no es homogénea en la literatura ya que pueden verse afectadas por diversos factores. Una 
forma de obtener datos fiables es observar una cohorte amplia de sujetos en su transición a 
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DCL. En nuestro estudio hemos analizado alrededor de mil personas en una franja de edad 
comprendida entre 70 y 85 años en riesgo de dicha transición.  
Para evitar la heterogeneidad que existe a la hora de recoger dichas quejas, hemos seguido 
las indicaciones de la Subjective Cognitive Decline Iniciative (SCD-I). Este grupo, propone 
una serie de características que podrían ser de interés para evaluar el riesgo de transición a 
DCL.  
Nuestro punto de partida fue analizar la estructura subyacente del cuestionario Everyday 
Memory Questionnaire (EMQ), a partir de ahí, extrajimos dos importantes conclusiones: i) 
las quejas involucran distintos dominios cognitivos, no exclusivamente memoria y ii) 
determinadas quejas cognitivas son capaces de distinguir entre sujetos sanos y con DCL.  
El siguiente paso, fue utilizar en nuestra cohorte las características indicadas por la SCD-I 
para clasificar a nuestra población en función de la presencia o ausencia de quejas 
cognitivas. Para ello, dividimos a los participantes en tres grupos: a) Sin quejas (NC), b) con 
quejas cognitivas de diverso tipo (SCD) y c) con quejas cognitivas que además cumplen una 
serie de características que incrementan la severidad de las mismas (SCD-Plus). Nuestros 
resultados concluyen que el grupo SCD-Plus tiene un riesgo 4 veces mayor de desarrollar 
DCL que los  sujetos sin quejas en solo un año. 
Sin embargo, apreciamos que las medidas para operativizar el DCS tomadas en una sola 
ocasión pueden no ser lo suficientemente robustas y, por tanto, podrían carecer de 
adecuada consistencia interna. Dicho de otro modo, sería importante tener la certeza de 
que las quejas son estables a lo largo del tiempo, ya que dos puntuaciones tomadas en dos 
momentos distintos pueden ser diferentes. Para ello, llevamos a cabo un estudio 
longitudinal a tres años para analizar si el DCS es un marcador preclínico fiable en EA. Por 
último, el estudio de la dinámica temporal de las quejas cognitivas mediante cadenas de 
Markov da evidencia de que el grupo de SCD define realmente un periodo preclínico 
perteneciente a la fase asintomática de la EA. Especialmente los individuos que se clasifican 
dentro del grupo SCD-Plus necesitan de una atención especial y son óptimos candidatos 
para una intervención terapéutica temprana. Aportamos un modelo teórico que describe 
de una forma dinámica cómo se producen las distintas transiciones en la fase preclínica en 
el continuo de la EA. 
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ABSTRACT 
Alzheimer's disease (AD) is the leading cause of dementia in our environment. According to 
the National Epidemiology Center, 7.3% of the population over 65 years could suffer from 
this disease nowadays. In total, AD constitutes about 75% of the etiology of dementias, 
either alone or in combination with cerebrovascular disease. Because of increased life 
expectancy and the progressive aging of the population in Western countries, dementia 
represents a huge challenge for public health systems. In our country, it is estimated that by 
2050 a third of the population will be over 65 years, so that approximately one million 
Spaniards could have dementia by then. 
AD is a silent disease that begins with brain degeneration many years before the first 
clinical diagnostic is noticeable. There is a long asymptomatic phase. The transition from a 
cognitively healthy stage to an AD-type dementia is a continuum in which some 
intermediate stages, preclinical and prodromal can be recognized. These stages are 
characterized by the presence of an incipient cognitive impairment that increases the 
probability of conversion to dementia in the future. An effective therapeutic intervention in 
these phases prior to AD could eventually slow the progression of deterioration and thus 
reduce the prevalence of the disease. For this reason, one of the challenges currently faced 
by research is the development of useful tools that allow early diagnosis of AD.  
The finding of new markers for this phase could facilitate the prevention of the disease. In 
this work, we have analyzed Subjective Cognitive Decline (SCD), as a suitable early marker 
for the asymptomatic phase of Alzheimer disease. SCD is a self-experienced persistent 
decline in cognitive capacity that could be important to predict the transition from a normal 
status to the onset of mild cognitive impairment (MCI). However, the measurements of 
cognitive complaints could be heterogeneous since could be affected by several factors. 
One way to get reliable data is to look at a large cohort of subjects in the transition to MCI 
In our study, we have analyzed around on thousand people in an age (70-85) with risk for 
that transition.  
To avoid the present heterogeneity in the measured features, we have taken into account 
some of the recommendations of the Subjective Decline Initiative (SCD-I). The SCD-I 
proposed a set of features that could be of interest to know the risk for MCI transition. 
viii 
Although, there are different questionnaires to evaluate SCD, at first we used the Every 
Memory Questionnaire (EMQ). From that first step, we concluded there is an underlying 
structure that involves different cognitive domains (not only memory, although its name) 
and also, that there are cognitive complaints that can distinguish between healthy controls 
and MCI.  
By using the set of features that could indicate a higher risk of transition to MCI, as 
indicated by the SCD-I, we have divided in our study, the participants in 3 different groups: 
a) without complaints (NC), b) with some complaints that could be different among the 
subjects of the group (SCD) and c) subjects with the same set of factors expressed in all the 
members of the group (SCD-Plus). Our results indicated that SCD-Plus have about four 
times higher risk for developing prodromal AD in just 1 year, than subjects without 
complaints.  
However, we found that SCD measurements performed only once could not be robust 
enough and could lack internal consistency. Thus, it will be important to have stability of 
complaints over the time since some scores collected in two different occasions may be 
different. Thus, we performed a longitudinal study to look for SCD as a robust and stable 
(for three years period) factor that could be used as a reliable preclinical marker for AD, and 
we found that this is the case. Thus, we described that SCD subjects with stable complaints 
could define a new prodromal period, taking phase in the asymptomatic phase for AD and 
in particular SCD-Plus subjects may need special attention and can be an optimal candidate 
for a possible therapeutic intervention. We close this work providing a theoretical tracking 
of the preclinical phase in AD, not in a static manner, instead we draw the dynamic 
transitions that take place across de AD continuum across time. 
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1. INTRODUCTION 
1.1. Dementia and Alzheimer´s Disease 
The increase in the quality of Medicine during the last century has allowed increasing the 
length of the human life. This increase has favored the presence of a higher proportion of 
cases for those diseases having aging as main risk factor. One of these disorders is dementia 
which is a clinical syndrome characterized by a progressive cognitive impairment severe 
enough to affect personal and social functioning of an individual. 
According to the Spanish Confederation of Alzheimer´s Associations (CEAFA), the number of 
cases that suffer from AD nowdays in Spain ranges 500,000-800,000 (Estado del Arte EA - 
Publicaciones - Ceafa, 2017). Alzheimer's disease (AD) is the most prevalent cause of 
dementia in our environment. In total, AD constitutes about 75% of the etiology of 
dementias, either alone or in combination with cerebrovascular disease. Because of 
increased life expectancy and the progressive aging of the population in Western countries, 
dementia represents a huge challenge for public health systems. In our country, it is 
estimated that by 2040 1.5 million of people over 65 will suffer from dementia(Worldwide 
Cost of Living 2017 - The Economist Intelligence Unit, n.d.). The impact of dementia is not 
only produced directly on the patient, but also has a great influence his/her family and 
social environment concerning affective, organizational and economic aspects. In this 
sense, dementia should be understood as a social problem that must be approached in a 
comprehensive manner. 
The transition from a cognitively healthy stage to an AD-type dementia is a continuum in 
which some intermediate stages, preclinical and prodromal, can be recognized. These 
stages are characterized by the presence of an incipient cognitive impairment that 
increases the probability of conversion to dementia in the future. An effective therapeutic 
intervention in these phases prior to AD could eventually slow the progression of 
deterioration and thus reduce the prevalence of the disease. For this reason, one of the 
challenges currently faced by research is the development of useful tools that allow early 
diagnosis of AD. 
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The clinical continuum of AD 
Current knowledge understands AD as a continuum process starting 10 to 20 years before 
the onset of clearly noticeable symptoms. A high degree of agreement has been reached 
around the different stages of the disease, namely preclinical phase (brain changes without 
symptoms), prodromal mild cognitive impairment (MCI) phase (mild symptoms and signs 
without dementia), and dementia phase which usually lasts 10-15 years and leads to a total 
dependence and finally patient's death (Amariglio, Townsend, Grodstein, Sperling, & Rentz, 
2011; Dubois et al., 2010; Rami et al., 2011; Sperling et al., 2011b). Figure 1.1. shows the 
trajectories of these three AD stages. The preclinical phase is defined by the incipient 
presence of amyloid plaques, but objective cognitive function remains normal. At the end 
of this phase, the individual might subjectively experience some kind of cognitive decline 
(Sperling et al., 2011b). The second stage, called prodromal AD or MCI implies objective 
cognitive deficits, but not severe enough to significantly affect everyday activities (Albert et 
al., 2011). And finally the last dementia phase in which the extent of the cognitive 
deterioration leads to a functional impairment that defines a dementia syndrome (Rovio et 
al., 2005). This stage usually lasts 10-15 years, leading to total dependence and, eventually 
patient´s death (Dubois et al., 2010). 
Figure 1, Alzheimer´s Disease Stages. (Taken from Sperling et al., 2011).
Asymptomatic Phase
MCI
Dementia
Healthy Aging
Aging
Alzheimer´s Disease
Cognitive
Performance
 
Fig  1.1. Alzheimer´s Disease stages (adapted from Sperling et al., 2011b) 
MCI: Mild Cognitive Impairment 
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In practical terms, the recognition of the clinical and biological features of people that 
convert from a cognitively normal state to MCI and from MCI to dementia is of utmost 
interest, as well as the factors that may accelerate or prevent those transits. The transition 
from cognitive normality to early, mild signs of cognitive impairment is specifically difficult 
to categorize and isolate. It has been proposed that a potential state may arise during the 
preclinical phase, although this hypothetical state has received different names (for 
example, “subjective memory complaints”, “subjective memory impairment” or “subjective 
cognitive impairment”). Possibly also due to the lack of a precise definition, studies 
addressing the conversion from normal cognition to MCI have been scarce, with incidence 
rates varying between 51 and 77 per 1,000 persons a year. The most frequently reported 
risk factors for incident MCI are higher age, lower education, and hypertension (Luck et al., 
2010). Conversion from MCI to dementia has been more widely studied, with duration of 7-
10 years for the MCI stage and annualized conversion rates of 8-17 per 100 persons a year 
(Ward, Tardiff, Dye, & Arrighi, 2013). Additionally, cognitive performance, cortical amyloid 
deposition, hippocampal atrophy, hypometabolism in the parietotemporal cortex, and 
alteration in the cerebrospinal fluid (CSF) levels of 42-aminoacid amyloid beta peptide (Aβ-
42) and phosphorylated tau protein (p-tau) have been consistently associated with higher 
conversion rates from MCI to AD dementia (Brooks & Loewenstein, 2010; Heister et al., 
2011). Other markers or co-morbidities (e.g., vascular factors, sleep disturbance) may also 
be of relevance in the transition from healthy state to AD, particularly in the very old 
(Frisardi et al., 2010). 
Two types of AD, the familial (FAD) and the sporadic (SAD) Alzheimer´s diseases (Colin L 
Masters et al., 2015)might be distinguished. FAD is a presenil dementia that usually appears 
below 65 years old, whereas SAD is a senil form of dementia whereby aging is one of the 
most important risk factors. Since SAD accounts for more than 99% of the cases of AD, we 
are mainly focusing in this type of disease. In any case, both forms of AD follow similar 
phases for the development of the neurological disorder (Hampel, Lista, & Khachaturian, 
2012). 
In AD there are some common anatomic features like the presence of two aberrant brain 
structures, senile plaques and neurofibrillary tangles and the presence of neuronal death 
(Stelzmann, Norman Schnitzlein, & Reed Murtagh, 1995). The main component of senile 
plaques is aggregates of the beta amyloid (Aβ) peptide (C L Masters et al., 1985) whereas 
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the main component of neurofibrillary tangles is tau protein, a neuronal protein (Grundke-
Iqbal et al., 1986). The appearance of senile plaques, at least in FAD, takes place very early 
in the asymptomatic phase, and that neurofibrillary tangles take place few years before the 
transition to mild cognitive impairment (Bateman et al., 2012). The case of FAD is well 
known and it is related to mutations in three different genes: app, psen-1, and psen-2. The 
consequence of those mutations was to increase the amount of Aβ and based on that, it 
was suggested the amyloid cascade hypothesis as a possible initial cause for the onset of 
FAD (Hardy, 2006). 
1.2. Biomarkers 
Even now with all the advances in the Alzheimer´s research context one of the most 
common questions from the general population is “What´s the difference between AD and 
dementia? In 1984 the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer´s Disease and Related Disorders Association (now the Alzheimer´s 
Association) published a diagnostic criteria, the NIDNCDS-ADRA Criteria to help answer that 
question (McKhann et al., 1984). Since that, science has made notable discoveries. Using 
certain biomarkers, we can now distinguish between AD and other causes of dementia 
(Karlawish, Jack, Rocca, Snyder, & Carrillo, 2017). The National Institute on Aging-
Alzheimer´s Association (NIA-AA) working group and the International Work Group (IWG) 
have proposed guidelines that use biomarkers and also clinical symptoms to define 
dementia caused by AD and also preclinical AD and MCI due to Alzheimer (Blennow, 2004; 
Mattsson et al., 2009). 
The fact of the evolving biomarker research made possible to identify the disease even at 
the preclinical stage before the occurrence of the first clinical symptoms, and as a matter of 
fact, to change the perspective, from a pathology consequence of lesions in the brain has 
made cognitively impaired individuals to a continuum disease in which we find an 
asymptomatic phase before the onset of the clinical phenotype, the initial clinical 
symptoms in mild impairment in specific cognitive functions, and the severe cognitive 
deficits making impossible independent daily living. 
AD is a silent disease having a long asymptomatic phase in which there is brain damage 
without clinical diagnosis (Bateman et al., 2012). Then, it will be suitable to get early 
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markers for the disease at that stage to allow a prompt prevention of the neurological 
disorder. In the case of FAD, it is well-established that the presence of specific mutations 
for app, psen-1 or psen-2, will result in the appearance of the disease at the 40s and 50s. 
Thus, from the birth time it is possible to have a precise genetic biomarker. In the case of 
SAD it is not possible to have very early biomarkers like that and, usually, the combination 
of clinical neuropsychological studies, cerebrospinal fluid (CSF), structural and functional 
neuromaging techniques (MRI, PET, MEG, etc.), may facilitate an early prediction for the 
transition from the asymptomatic to a MCI stage. 
Lumbar puncture, using a needle, may facilitate the collection of CSF from a subject. In that 
CSF sample mainly two biomarkers are usually analyzed: Aβ and tau (total or in 
phosphorylated form) proteins. Cognitive decline should correlate with a decrease in the 
amount of amyloid peptide and an increase in the amount of tau protein in CSF (Herukka et 
al., 2017; Olsson et al., 2016). Also, analysis of CSF could facilitate the diagnostic evaluation 
of dementia (Simonsen et al., 2017). Less reliable is, at the present, the analysis in other 
fluids like blood. 
About neuroimaging techniques, mainly overall macroscopic changes throughout the brain 
are measured by MRI (Weiner et al., 2017); Aβ or tau aggregates may be quantified by 
positron emission tomography (PET), using specific compounds that could bind either 
amyloid or tau aggregates (Rinne et al., 2010; Shoghi-Jadid et al., 2002) 
1.3. Subjective Cognitive Decline 
The construct subjective cognitive decline (SCD) refers to a self-experienced persistent 
decline in cognitive abilities in comparison with a previously normal status and 
independently of the objective performance on neuropsychological tests. SCD has been a 
focus of debate within the research literature during the past two decades because of its 
potential clinical relevance in predicting the onset of future dementia in older adults. In 
fact, it has been described that subjects might experience some type of cognitive decline up 
to 15 years before they develop MCI an AD (Reisberg et al., 2008). Furthermore, in the 
absence of objective cognitive impairment, evidence has been reported about the 
relationship between SCD and some AD biomarkers such as brain amyloid deposition and 
cerebral hippocampal hypometabolism (Vannini et al., 2017). 
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Despite cognitive complaints have been traditionally treated as equivalent to memory 
failures, SCD is in fact heterogeneous and might affect all cognitive domains from a 
neuropsychological point of view. For instance, there are symptoms that may be specifically 
relate to memory (“forgetting recent events”), while others are associated with attention 
(being unable to follow a lecture) or executive functions (“perseverations in old daily 
routines). Although episodic memory impairment is usually the first cognitive manifestation 
of MCI due to AD, perception of memory failures might not be the primary complaint of 
cases with preclinical AD. Attentional symptoms like “following the thread of a 
conversation” have been proved to be more associated with risk of dementia than 
forgetfulness itself such as “problems to recall recent information” (Amariglio et al., 2011).  
Since the expression of cognitive complaints is affected by various factors (e.g. aging, 
personality, mood, drug side effects, etc.) SCD is not necessarily present in all AD patients. 
Nevertheless, cross–sectional (Rami et al., 2011) and longitudinal studies (Dufouil, Fuhrer, 
& Alpérovitch, 2005; Reisberg, Shulman, Torossian, Leng, & Zhu, 2010) have provided 
strong evidence of SCD occurring at preclinical AD.  
There are overwhelming epidemiological data in favor of the relationship between SCD an 
incident cognitive impairment. A meta-analysis focused on the longitudinal value of SCD for 
detecting later MCI and dementia has shown that, independently of the objective memory 
performance, 6.6% of older adults with SCD develop MCI per year (Mitchell, Beaumont, 
Ferguson, Yadegarfar, & Stubbs, 2014). In addition, the rate of progression to dementia 
among those who report complaints about their own cognitive performance is twofold 
during a 5 year follow-up period.  
Despite its emerging role as a marker of preclinical AD, the concept of SCD is not free from 
some limitations which are necessary to address. For instance, in Figure 1.2 appears the 
terminology evolution across time such as subjective memory complaints, subjective 
cognitive decline, or subjective memory impairment that have been used indistinctly to 
refer to the same concept.  
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Figure 1.2. Number of records by term of self-perception of cognitive decine. Search in 
PubMed (term inTittle/Abstract) filtering by date of publication. 
This lack of consensus on a single definition of SCD affects to the comparison of findings 
from different investigations and epidemiological studies. In addition, there is no accepted 
approach among researchers about the assessment of SCD, including the mode of 
administration, the cognitive domains to be examined, the number of items to be used, and 
the optimal way to respond the items. Finally, it becomes difficult to determine which 
complaints underlie AD because there is a close relationship between SCD and subjective 
variables such as depression (Crane, Bogner, Brown, & Gallo, 2007), anxiety (Comijs, Deeg, 
Dik, Twisk, & Jonker, 2002), personality (Pearman & Storandt, 2004) or quality of life 
(Montejo, Montenegro, Fernández, & Maestú, 2011). In sum, the heterogeneity in 
definitions and the different approaches for measuring SCD emphasize the necessity of 
searching for shared terminology and common standards of evaluation. This feature is 
expected to be progressively solved by using SCD as the most prevalent term. 
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Figure 1.3. Terminology used to refer to the same concept. Search in PubMed (term 
inTittle/Abstract; date of publication 2016-May 2018). 
To assess the potential usefulness of SCD for epidemiological studies and clinical trials, an 
international working group, the Subjective Cognitive Decline Initiative (SCD-I), agreed to a 
common terminology and research procedures to identify individuals with SCD at risk of 
preclinical AD (Jessen et al., 2014). The SCD-I aimed at knowing whether the self-experience 
of decline in cognition could actually represent the first manifestation of AD. In order to 
demonstrate that, some common specific features are required to stablish a complete 
profile of SCD and to characterize two distinct groups of individuals in accordance with such 
profile. 
Table 1.1. Features suggested for coding in studies on SCD (adapted from Jessen et al. 
2011). 
Features to be collected How to collect those features 
Setting in which SCD is expressed Clinical setting, population-based study, etc. 
Association of SCD with medical help seeking Yes/No 
How SCD is reported Spontaneously/On request 
How long SCD is present Number of months or years 
Age at onset of SCD Age in which SCD appeared 
There is self-perception of memory decline Yes/No 
There is self-perception of other non-memory decline Yes (specify)/No 
There are concerns associated with SCD Yes/No 
There is a feeling of worse performance than peers Yes/No 
SCD is associated with experience of impairment Yes/No 
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Confirmation of cognitive decline by an informant Yes/No 
Symptoms of depression or anxiety Score on scale 
APOE genotyping No alleles ε4/Heterozigous ε4/ Homozigous ε4 
The SCD-I recommendeds to collect information regarding features regarding cognitive 
complaints, which are summarized in Table 1.1. In addition, the SCD-I proposed a set of 
particular features which be helpful to identify individuals at risk of clinical progression, 
namely SCD Plus group (Table 1.2.). 
Table 1.2. Features that increase the likelihood of preclinical AD in individuals with SCD: SCD 
Plus (adapted from Jessen et al. 2011). 
- Subjective decline in memory rather than other cognitive domain 
- Onset of subjective cognitive decline within the last 5 years 
- Age at onset of subjective cognitive decline ≥ 60 
- Concerns associated with subjective cognitive decline 
- Feeling of worse performance than others of the same age group 
- If available: 
Confirmation of cognitive decline by an informant 
Presence of APOEɛ4 genotype 
Biomarker evidence for AD  
1.4. The Vallecas Project for early detection of Alzheimer's disease 
The transition from normality to early mild signs of cognitive impairment is difficult to 
characterize and isolate. A potential feature appearing during this transition is the SCD 
state. Perhaps due to the heterogeneity in the investigation of SCD that was commented 
previously in section 1.3., the prevalence rates of cognitive complaints in older adults vary 
from 11.5% to 95% (Garcia-Ptacek et al., 2016). Table 1.3. shows some differences among 
classical studies that have focused on complaints. 
Clearly the targets for early AD identification should be the stages of SCD and MCI, along 
with the characterization of those subjects with high risk of conversion to dementia. Under 
a multicausal model of aging-associated, late onset SAD, multiple markers are expected to 
be relevant for the detection of the groups of interest, and therefore, the most cost-
effective and safest procedures should be prioritized. 
The main objective of the Vallecas Project is therefore to elucidate, through tracking of 
progression, the best combination of clinical parameters and complementary tests (imaging 
and laboratory) that allow deciphering at medium- and long-term features that distinguish 
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those who will develop cognitive impairment (MCI and dementia) from those who will not. 
Thus, it intends to identify various markers to determine eventually the potential risk that 
each individual could have to develop the disease in the future. The study is focused on 
cognitive testing, comorbidities, multy-modal MRI and systematic blood collection. The final 
objective of this project is to facilitate testing of disease modifying therapies and next the 
treatment of the population at risk, before they become cognitively impaired or demented. 
Table 1.3. Epidemiological characteristic of subjective cognitive decline. 
Study Context Age Prevalence Evaluation 
Schofield et al., 1997 
Community 
dwelling 
- 31.0% 
Do you have problems 
with your memory?  
Geerlings et al., 1999 
Community 
dwelling 
65-84 11.5% 
Do you have complaints 
abot your memory?  
John & Montgomery, 2002 
Community 
dwelling 
>65 21.0% 
Did you have memory loss 
in the past years? 
Glodzik-Sobanska et al., 2007 Volunteers >65 81.3% GDS2 
Visser et al., 2009 Clinical >55 26.9% NR 
Nunes et al., 2010 Clinical 55-82 34.9% SMC scale 
Reisberg et al., 2010 
Community 
dwelling 
>40 76.9% GDS 
Sachdev et al., 2010 
Community 
dwelling 
70-90 95.5% MCA-Q and IQCODE 
Jessen et al., 2011 
Community 
dwelling 
>75 57.7% 
Do you fell your memory is 
becoming worse? 
Montejo et al., 2011 
Community 
dwelling 
>65 24.0% 
How would you describe 
your memory? 
Fernández Blázquez et al., 2016 
Community 
dwelling 
70-85 69.6% 
Clinical interview and 
questionnaire  
With those premises in 2011 CIEN Foundation Alzheimer´s Research Center launched the 
Vallecas Project, a single-center, community-based longitudinal cohort study with yearly 
evaluations to identify subjects at the initial stages of AD and to clinically and biologically 
characterize the transitions between healthy cognition, SCD, MCI and AD dementia 
(Olazarán et al., 2015). The participant recruitment phase for the Vallecas project lasted 
from October 2011 to December 2013. By then, 1,213 individuals of both genders, aged 70-
85 years were initially recruited and evaluated at baseline. Before entering the study, 
volunteers interested in participating in it were subjected to an initial assessment to 
determine whether they meet the criteria for inclusion and/or whether an exclusion 
criterion exists. Overall, all volunteers were required to meet four inclusion criteria in order 
to be considered for entering the study: i) signing an informed consent; ii) be aged between 
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70 and 85 years old; iii) availability and ability to reach the Alzheimer Centre for visits; and 
iv) visual and hearing abilities that allow conducting the study tests. In addition, a number 
of exclusion criteria were established, including the following: i) suspected or diagnosed 
dementia; ii) inability to perform neuroimaging studies; iii) alcohol abuse; iv) mental 
retardation; or v) history of certain psychiatric or neurological diseases (eg schizophrenia, 
stroke, severe head trauma, central nervous system infections, uncorrected vitamin 
deficiencies, etc.). The general procedure of the Vallecas Project is shown in Figure 1.2. 
 
Figure 1.4. General procedure and different parts of the study visit of the Vallecas Project. 
(Olazarán et al., 2015). 
Only 1,172 individuals fulfilled all inclusion and exclusion criteria and therefore were finally 
admitted to participate in the study. Once included in the study, all participants undergo an 
annual follow-up in order to assess their evolution trajectories, specifically identifying those 
that develop cognitive impairment and/or dementia. This is an ongoing study as the 
Vallecas Project has currently finished the fifth visit for the entire cohort and is about the 
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middle of the sixth and the beginning of the seventh visits. Table1.4. shows the figures of 
clinical evaluations conducted to date. 
Table 1 4. Longitudinal clinical diagnoses of the Vallecas Project cohort during the first five 
visits. 
 Baseline 
1-year 
follow-up 
2-year 
follow-up 
3-year 
follow-up 
4-year 
follow-up 
Sample Size 1,172 963 865 767 546 
Drop-outs - 209 (18%) 100 (10%) 98 (11%) - 
Controls 1091 869 768 680 486 
MCI 81 (7%) 93 (10%) 88 (10%) 62 (8%) 36 (7%) 
Dementia - 1 9 (1%) 25 (3%) 24 (4%) 
New MCI  52 23 17 6 
New Dementia  1 9 17 12 
In every visit participants undergo a detailed protocol of evalution comprising 
sociodemographic data, lifestyle scales, vital signs, blood samples, neuropsychological 
assessment, neurological exam, and MRI study. The complete study visit is carried out in a 
single day with a total duration of 4 hours including convenient breaks. 
a) Sociodemographic profile and lifestyle: a wide sort of information is collected by 
means of a semi-strutured interview regarding gender, date of birth, marital status, 
number of children, type and amount of income, occupation, educational 
attainment, hobbies, leisure activities, diet, physical exercise, quality of life and 
subjective well being (mobility, personal care, daily activities, pain/discomfort, 
anxiety/depression, perceived health status). 
b) Vital signs and morphometry: blood pressure (seated and standing), height and 
weight, and head and waist circumferences are measured by a nurse during all the 
study visits. 
c) Medical and neurological assessment: a semi-structured medical interview is 
conducted by a neurologist focusing on vascular risk factors, neurological disorders, 
psychiatric disorders, current medications, family history of dementia, and sleep. 
Also all subjects undergo a general and neurological standard examination: cranial 
nerves, muscle balance, coordination, extrapyramidal system, gait, osteotendinous 
reflexes, and midline release reflexes. Gait disturbances and some brief motor tasks 
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are specially analyzed(Ashendorf, Vanderslice-Barr, & McCaffrey, 2009; Podsiadlo & 
Richardson, 1991). 
d) Neuropsychological assessment: although the neuropsychological battery focuses 
especially on the evaluation of memory processes, attention and executive 
functions as potential early markers of AD, the neuropsychological profile is 
completed by getting information related to other cognitive domains such as 
language, visuospatial ability and visuoconstruction. All these data allow identifying 
the strengths and weaknesses in the cognitive profile and characterizing, if 
necessary, the type of cognitive impairment that an individual presents. Table 1.5 
shows the cognitive tests which comprise the neuropsychological battery of the 
Vallecas Project. 
Table 1.5. Neuropsychological assesment in the Vallecas Project. 
TEST DESCRIPTION 
Mini Mental State 
Examination (MMSE) 
This is a test of global cognitive assessment. It consists of 20 items that 
gather a rough information on the level of orientation, attachment, 
attention, calculation, recall, language and viso-constructive praxis of the 
subject. The score for this test is made over a maximum of 30 points to the 
extent that all items are answered correctly. Cognitive impairment diagnosis 
is performed based on a score of 24 points as the cutoff. 
Rey-Osterreith 
Complex Figure 
It is a classic neuropsychological evaluation task consisting in performing a 
copy of a complex pattern (the time it takes for copying is recorded) and 
subsequent immediate recall (within 3 minutes), after performing a 
distraction task, delayed (after 30 minutes) and a recognition task. This test 
allows to evaluate a large number of cognitive processes related to 
planning, visoconstruction, impulsiviness, episodic memory, incidental 
learning, etc. It has also been adapted and rated in the Spanish population 
over 60 years of age. 
Functional Activities 
Questionnaire (FAQ)  
It is a classic questionnaire to assess autonomously performing of 
instrumental activities of daily living. The questionnaire should be answered 
by a reliable informant. It consists of 11 items with 4 response options to 
assess the degree of dependence or independence of the subject in 
different daily tasks (managing finances, shopping, doing housework, 
preparing meals, pay attention and discuss news, remembering dates, 
managing medication or going out alone on the street). The diagnosis of 
Alzheimer disease occurs from a score of 6 as the cutoff point. 
Free and Cued It is based on the assessment of learning ability and verbal episodic 
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Selective Reminding 
Test  
memory. The test consists of the consecutive presentation of 4 sheets with 
4 words written each (a total of 16 words) that the subject must learn. To 
facilitate this task, the examiner provides a key for each of the words that 
will be helpful later to recall more items. After a simple 20 seconds task 
interference people are asked to remember as many words as possible 
spontaneously. After 90 seconds, clues to help the memory of those words 
that did not recalled by himself/herself will be provided. Then the words 
he/she could not recall with the help of the clue are reminded of and 
another interference task is proposed. This procedure is performed three 
times, so that there are three free recall tests and three facilitated recall 
through the clues. After 30 minutes the delayed free and with clues recall 
condition is carried out. The indexes that are considered in this test are the 
total free recall, the total learning, free delayed recall and the overall 
delayed recall. The test has Spanish ratings 
Semantic lexical 
evocation 
The task consist in providing the highest number of words beginning with a 
certain letter (P, M, and R) or belonging to a specific category (animals, 
fruits/vegetables, and cookware) for one minute. Furthermore, in the case 
of phonological evocation the contribution of people names or words that 
share the same lexical root is not allowed. The number of responses that 
the subject provides in periods of 15 seconds is recorded, as well as the 
total number of correct responses, intrusions and perseverations in the 
minute-long test. This task allows the systematic assessment of both the 
language proficiency as the semantic system of the subject. Moreover, it 
must be highlighted that this task has been validated and rated on Spanish 
population over 60 years. 
Clock drawing test It is an easily applicable screening test to evaluate both the visoconstructive 
ability as the semantic component associated with the knowledge of the 
hour. The subject is asked to draw the face of a clock, with all numbers in 
the correct place and with the hands pointing to 11 and 10. The score of the 
drawing is based on criteria related to the quality of the clock face, the 
presence and sequence of numbers, as well as the presence and location of 
the hands. The maximum score corresponds to 10, considering 6 as a cutoff 
for the diagnosis of cognitive impairment. 
Reading test of 
intelligence  
This test provides a measure of the level of pre-morbid intelligence of the 
patient through a reading task contained 60 words in the dictionary of the 
Royal Spanish Academy. An important feature of this test is that the items 
have a low frequency of use in our country, those who should carry written 
accent do not carry it and foreign words are also included between them. 
The subject's task is to read the words in the right way, for what is allowed 
to rectify if deemed appropriate. The test raw score is the number of words 
read correctly. 
Global Depression 
Scale 
Is a self-reported scale to evaluate depressive symptoms. It consists of 15 
questions related to the state of mind to which the subject must respond 
dichotomously (yes/no). The cutoff point beyond which the likelihood of 
major depressive disorder increases is 5 
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Digit-Symbol This is part of the Wechsler Adult Intelligence Scale (WAIS) for assessing 
intelligence. Natural numbers from 1 to 9, each of them associated with a 
different symbol, are presented on a test sheet. Below appear random 
numbers from 1 to 9 without any associated symbol. The task of the subject 
is to write the symbols for each number as quickly as possible for one 
minute. To avoid interference of possible memory alterations on test 
performance, the model with numbers and symbols for each of them 
remain in the top of the sheet. This test provides a measure of information 
processing speed and procedural learning ability to the extent of it will 
become less necessary for the subject to look at the model because 
unconscious learning 
State-Trait Anxiety 
Inventory (STAI) 
This self-reported test evaluates anxiogenic symptoms related to both a 
specific time and intensity variable period (anxiety state) as well as a more 
stable personality pattern tending to perceive situations as threatening 
(anxiety trait). Thus, there are two scales of this test, each consisting of 20 
items with 4 response options (scored by a Likert type scale of 0-3). The 
total score is the sum of the individual scores for each item. Spain has 
recently adapted this test in nonclinical populations. After the second visit 
the neuropsychological examination protocol suffered a slight 
transformation in order to optimize collection of cognitive information. For 
this purpose, a series of assessment tests that allow to obtain more 
information on attention, language, praxis and executive functions from all 
selected study subjects. 
Boston Naming Test  It is a reduced version of the classic subtest included in the Boston test for 
the diagnosis of aphasia. The Boston Naming Test is used in clinical 
consultations to assess the ability of naming visual stimuli by visual 
confrontation. The subject's task is to name each of the 15 drawings that 
are presented, for which he/she is given a maximum of 20 seconds per 
image. If the subject does not give the correct answer spontaneously, the 
examiner provides a semantic or phonological clue if the above is not 
enough. Total score is the sum of correct spontaneous responses and the 
number of drawings called using the semantic hint. The correct answers 
after the phonological key are considered as an indicator of the kind of 
difficulty to name drawings. 
Symbolic Gesture This test is part of the Revised Barcelona Test (RBT). It explores the 
performance of a series of symbolic gestures of communication. They are 
simple, intransitive gestures made with a single upper limb. The primary 
endpoint of the test is the body position in relation to space and the body. 
Imitation of Bilateral 
Postures  
Also as a part of part of the RBT, this test consists in the imitation by the 
subject of a number of postures that the examiner performed with both 
hands. This test evaluates the integrity of ideomotor praxis. 
Forward and reverse 
digits 
This test allows to evaluate the hearing attentional amplitude and the 
individual's central executive of the working memory. The subject's task 
consists in repeating the growing sequences of numbers that the evaluator 
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presents at one digit per second. The test is divided into two separate 
subtests, so that repetition of the first digit is applied in the same order of 
presentation (Direct digits) and then in reverse order (Inverse digits). The 
task ends when the subject is not able to repeat two sequences of the same 
length of digits. In both subtests, the number of correct repetitions and the 
maximum amplitude of digits that the subject is able to repeat are counted. 
Rule Card Shift This test is part of the Behavioral Assessment of the Dysexecutive Syndrome 
(BADS). It involves the presentation of a sequence of 21 cards from the 
French card deck. The subject must respond "yes" or "no" as fast as he/she 
can and as accurately as possible according to a rule that is in plain view. In 
the first part of the test rule is to respond "yes" when the card is red and 
"no" when is black. The second part introduces a variation of the first rule 
that the subject must respond "yes" when the card is the same color as 
above and "no" when it is a different color. The number of errors made by 
the subject in the second part of the test is registered and the score based 
on such errors is recorded. This test assesses the ability to fulfill one simple 
rule and the subject flexibility to adapt to a new different rule 
Five Points Test This is a test that measures the subject's cognitive flexibility regarding the 
ability to design novel visual shapes in a DIN A4 sheet of paper with 40 
identical matrices of 5 dots arranged in eight rows and five columns 
isprovided. The subject's task is to produce for 3 minutes as many figures as 
possible by connecting the dots within each matrix and the following rules: 
i) the figures may not be repeated; ii) only straight lines in any direction 
(horizontal, vertical or diagonal) can be used to connect the dots; and iii) it 
is not necessary to join the 5 points of the matrix. 
e) Laboratory: three types of evacuated blood collection tubes for serum, plasma and 
blood cells are obtained at each study visit. All individuals are genotyped for 
Apolipoprotein E from genomic DNA extracted from whole blood. The blood 
samples are labeled and kept refrigerated at -80 Celsius degrees, for future 
determinations. 
f) Neuroimaging: all studies are carried out in a 3 Tesla MRI (Signa HDxt GEHC, 
Waukesha, USA) equipped with a gradient system of 50mT/m. A phased array 8 
channels brain coil is used for all the subjects. The VP protocol includes a structural 
study with T1 sequences for volumetry and FLAIR and T2* sequences to assess 
white matter (WM) lesions and microhemorrages. Perfusion study with arterial spin 
labeling (ASL) technique was conducted to check for functional alterations and 
diffusion tensor imaging (DTI) study was performed for analysis of the anisotropy of 
WM. In addition, the DTI sequence permits to measure structural connectivity. A 
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resting state functional study is also conducted with blood oxygen level dependent 
(BOLD) sequences (rs-fMRI) to analize functional connectivity. 
Formal feedback is provided in the form of written clinical reports of the study that 
participants receive at home. These reports include general results of neuropsychological 
tests and MRI study, and, if clinical relevant, results from the nursing, medical and 
neurological assessments. Furthermore, if any procedure of the Vallecas Project reveals 
findings requiring medical or psychiatric attention, the subject is referred to the 
appropriate assistance resource or is contacted by telephone to provide information and 
the steps that must follow. 
1.4.1. SCD assesment in the Vallecas Project 
According to the evidence and the recommendations discussed in section 1.3., the Vallecas 
Project has combined different approaches to measure SCD accurately. Thus, there are four 
specific points that have been borne in mind when this longitudinal study was 
methodologically designed: 
1. To use both open-ended questions and structured questionnaires to measure different 
aspects of SCD. Specific questions inquire about clinical details of the self-experienced 
cognitive decline (e.g. age at onset, seeking medical help, memory performance compared 
to other people, etc.) as well as concerns and frequency of particular cognitive complaints 
(e.g. forgetting recent events, being unable to follow the thread of a story, difficulties to 
retrieve the adequate word, etc.). In addition a multiple choice approach varies from 
dichotomic to ordinal Likert-type scales to grasp the dimensionality of SCD in the best way 
possible. 
2. To collect information in different ways to ensure a greater internal consistency. 
Specifically, it has been combined the adquisition of self-perceived data by means of face-
to-face interviews with a healthcare professional along with self-administered 
questionnaires. Since it is relatively frequent that an individual reports qualitatively 
different features of SCD after a short period of time, this procedure ensures the evaluation 
of the stability of those complaints. 
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3. To inquire about SCD with regard to different timeframes (e.g. last months, last years, 
youth, etc.) in order to examine the change over time of the self-experienced cognitive 
decline. 
4. To include items to cover all cognitive and non-cognitive domains, not only episodic 
memory. Some cases of atypical AD or even non-AD dementias may begin with symptoms 
distinct from memory loss (e.g. problems to inhibit behavior may be indicative of 
frontotemporal dementias rather than AD). For this reason, it is important to request 
subjective information about the whole spectrum of cognition and other neuropsychiatric 
variables. 
1.4.1.1. Assessment of SCD during neurological and neuropsychological interviews 
Responses to every question of SCD are directly provided by the participants since family 
members are not available in all cases. To ensure the greatest reliability and internal 
consistency, SCD is assessed twice and independently within the same visit at the Vallecas 
Project. First, during the neurological examination participants are asked the following nine 
questions regarding specific cognitive domains: 
1) Attention: “Are you easily distracted?” 
2) Spatial orientation: “Do you get lost in familiar surroundings or have trouble finding your 
way when driving?” 
3) Episodic memory: “Do you often forget recent information or events?” 
4) Autobiographical memory: “Do you often forget autobiographical information?” 
5) Visual recognition: “Do you have trouble recognizing objects or faces?” 
6) Speech: “Do you have word-finding difficulties for people’s names or common words?” 
7) Language comprehension: “Do you understand simple verbal and written instructions?” 
8) Executive functions: “Do you have difficulty driving, managing finances or planning daily 
activities?” 
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9) Praxis: “Do you have difficulty sequencing movements (e.g. taking the necessary steps to 
prepare a bath)?” 
It is important to note that all those previous questions are merely tentative; thus, they are 
opened and spontaneously reported in such a way that alternative questions within the 
same cognitive domain could arise during the interview. Ultimately, subjective experience 
of complaints for every cognitive domain is coded in a dichotomic way (yes/no) based on 
the global impression of the neurologist. Additionally, there are other questions regarding 
psychiatric and behavioral symptoms which are a complement to the nine questions on 
cognitive complaints (see section 1.4.1.3.). 
Second, during the neuropsychological assessment individuals also complete an ordinal 
scale of cognitive complaints composed of four items with four points each (ranged 0-3). 
This scale addresses the following questions to be responded: 
1) “How do you perceive your memory in comparison with that of others of your age?” 
(“3-bad”; “2-somewhat worse”; “1-somewhat better”; “0-excellent”); 
2) “How do you perceive your memory today compared with your young adulthood?” 
(“0-better”; “1-equal”; “2-somewhat worse”; “3-much worse”); 
3) “Do you perceive your memory today is worse than compared with ten years ago?” 
(“0-no”; “1-a little worse”; “2-somewhat worse”; “3-much worse”); 
4) “Do you perceive your memory today is worse than compared with one year ago?” 
(“0-no”; “1-a little worse”; “2-somewhat worse”; “3-much worse”). 
The sum of these items resulted in a total score of cognitive concerns ranging from 0 (no 
complaints at all) to 12 (maximum complaints). Furthermore, five more open-ended 
questions are also collected during the neuropsychological interview: 
5) Age at onset of cognitive complaints: “How old were you when your cognitive 
performance began to decline?" 
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6) Years of SCD´s progression: “How long do you believe you are experiencing cognitive 
complaints?” 
7) Worries associated with self-perceived complaints: “Are you worried about your 
cognitive decline?” 
8) Type of onset of cognitive complaints: “How did you perceive the beginning of the 
cognitive decline?” (e.g. suddenly, progressive, etc.) 
9) Self-experienced functional impairment associated with SCD: “Do you believe your 
cognitive failures are impeding your daily life activities?” 
1.4.1.2. Assessment of SCD by means of self-administered questionnaire 
In addition to the whole information collected in both clinical interviews, individuals must 
accomplish a SCD scale, namely the Everyday Memory Questionnaire (EMQ) (Sunderland, 
Harris, & Gleave, 1984). This questionnaire is selected because it has been previously 
validated in our country and showed adequate psychometrical properties for older adults 
(Montejo et al., 2011). In our study, EMQ is self-administered by following the instructions 
provided in the validation study and always in the presence of a member of the research 
team; individuals are required to ask any doubt may arise. 
The EMQ comprised 28 items about cognitive failures that occur in everyday life. The items 
must be responded according to the frequency in which they are experienced by a subject. 
All items are scored pursuant to a 3-point Likert-type scale, with 0 indicating “never, 
rarely”, 1 “occasionally, sometimes”, and 2 “frequently, almost always”. The total score 
range from 0 to 56, with lower scores indicating fewer SCD. 
1.4.1.3. Assessment of non-cognitive complaints during medical interview 
As discussed earlier, non-cognitive symptoms may represent an initial manifestation of 
cognitive decline due to different etiologies. Therefore, open-ended questions should be 
included in the context of the medical interview in order to assess behavioral, functional, 
and psychiatric self-reported complaints. Specifically, the aspects that should be covered 
may be the following: 
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a) Depression: “Do you feel sad, lonely and depressed most of the time?” 
b) Anxiety: “Do you feel worried and anxious most of the time?” 
c) Apathy: “Do you feel a lack of emotion, motivation or interest in hobbies and previously 
activities enjoyed?” 
d) Disinhibition: “Do you feel difficulties to control your own behavior in some situations?” 
e) Irritability: “Do you feel in an irritable mood most of the time?” 
f) Hallucinations: “Do you feel you see or hear strange things which maybe are unreal?” 
g) Sleep: “Do you feel your sleep routine has changed?” 
h) Falls: “Have you had falls recently?” 
i) Gait: “Do you feel you have problems to walk?” 
1.4.1.4. Assessment of demographic, clinical and cognitive variables 
The assessment of demographic, clinical and cognitive variables should be inseparable from 
SCD whether one´s goal is to determine the properties of cognitive concerns for detecting 
preclinical AD and individuals at high risk of later MCI. To this end, the Vallecas Project 
cohort undergoes a detailed survey and assessment protocol to gather information on 
demographics (age, gender, level of education, marital status, living situation, 
socioeconomic status, occupation, etc.), lifestyle (physical activity, social support, eating 
and sleep habits, etc.), quality of life (well-being, perceived health, etc.), medical history 
(vital signs, physical symptoms, clinical anamnesis, medication, neurological examination, 
etc.), family history of dementia, and neuropsychological assessment. 
Cognitive diagnosis is always agreed between healthcare professionals at clinical consensus 
meetings. Every individual must be independently diagnosed according to his/her age, 
gender, cognitive reserve, functional information, and cognitive scores. Nevertheless, 
rather than psychometrically invariable cut-offs, diagnosis must be based on clinical 
impression. NIA-AA´s criteria (Albert et al., 2011) can be applied since they are very useful 
to diagnose core MCI and mild dementia. Cognitively healthy subjects are given a score of 0 
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in the global Clinical Dementia Rating (CDR) (Hughes, Berg, & Danziger, 1982) while MCI and 
mild dementia must score 0.5 and 1 respectively. 
The comprehensive neuropsychological battery is administered by trained 
neuropsychologists. This battery includes complete information about all cognitive domains 
such as visual perception, attention, memory, language, praxis, and executive functions. 
In addition, scales for measuring functional activities and neuropsychiatric variables are 
very important. For instance, to this end the Functional Activities Questionnaire (FAQ; 
Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982) can be administered to collect data with 
regard to instrumental activities of daily living; the Geriatric Depression Scale (GDS; 
Yesavage et al., 1982) and the State-Trait Anxiety Inventory (STAI; Spielberger, Gorsuch, & 
Leshene, 1970) might be also administered as part of the neuropsychological battery to 
quickly estimate mood and anxiety symptoms. 
1.4.2. Classification of individuals in SCD groups in the Vallecas Project. 
Finally, information about subjective complaints is examined according to the guidelines 
proposed by the SCD-I (Jessen et al., 2014). Following these guidelines, individuals are 
grouped in three different categories pursuant to the extent of SCD reported: 
1. No complaints (NC) when individuals do not report complaints with sufficient 
intensity; 
2. Subjective Cognitive Decline (SCD), when subjects report some kind of cognitive 
complaint; and 
3. Subjective Cognitive Decline Plus (SCD-P), when individuals show complaints in 
memory plus another cognitive domain and additionally they fulfill the rest of the 
criteria for SCD Plus. 
The classification in any of the three groups of SCD may be carried out in two steps (a full 
description of this procedure is shown on Figure 1.5.). Initially, based on the overall 
information gathered both in clinical interviews and in self-administered EMQ, SCD may be 
operationally defined as the self-rated presence of cognitive deterioration using two 
criteria: i) at least a positive response to any yes/no-type question regarding complaints in 
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any cognitive domain from the neurological interview; and ii) scores above 1 on the SCD 
scale administered in the neuropsychological assessment AND above 8 on the self-
administered EMQ. To be classified as SCD individuals have to mandatorily accomplish both 
conditions. Thus, subjects who only fulfill one criterion or neither of them will be 
considered as NC. 
The second step of classification is only applied for those cases categorized as SCD. For 
these individuals some specific features must be considered such as: age at onset of SCD 
beyond 60 years, turning up of complaints within the last 5 years, worry associated with 
SCD, and feeling of worse performance than others of the same age group. When all these 
conditions accompany the self-experience of decline then an individual is classified as SCD-
P. 
 
Figure 1.5. Flow diagram for SCD classification. 
EMQ: Everyday Memory Questionnaire; SCD: Subjective Cognitive Decline 
  
 
  
2. OBJECTIVES AND HYPOTHESIS 
2.1. General Objective 
TO DEFINE THE ROLE OF THE SUBJECTIVE COGNITIVE DECLINE IN THE ALZHEIMER´S 
CONTINUUM. 
2.2. Specific Objectives and Hypothesis 
Five specific and consecutively goals as well as their respective hypothesis can be 
considered in this investigation: 
1. TO STUDY THE UNDERLYING STRUCTURE OF THE SCD IN A SAMPLE OF OLDER ADULTS. 
The purpose of this aim was to analyze whether SCD has a unidimensional structure or on 
the contrary there is a factorial underlying structure. Historically researchers have implicitly 
assumed that the self-reported complaints are a monolithic concept which is referred 
almost exclusively to memory. Proof of that is there is barely research about the nature and 
implication of different types of complaints on objective cognitive impairment. The clinical 
evidence however seems to indicate that there may be distinct types of cognitive 
complaints beyond memory that could have different clinical values in practice. We 
propose to analyze the underlying structure of a widely used scale focused on assessing 
memory complaints, the EMQ, in a sample of older adults to confirm whether subjective 
complaints are uni or multidimensional. 
HYPOTHESIS 1: If we analyze a listed items of complaints as used in the EMQ, then we would 
find a multidimensional underlying structure of SCD. 
2. TO EXAMINE THE CROSS-SECTIONAL CLINICAL VALUE OF THE SCD IN DISTINGHISING 
BETWEEN HEALTHY ELDERLY CONTROLS AND INDIVIDUALS WITH MCI. 
As a second step we will test whether some specific cognitive complaints are more 
outstanding than others to distinguish between healthy ederly controls and individuals with 
MCI. To probe that, we will apply the underlying structure obtained from the previous 
EMQ´s factor analysis and study if those dimensions are able to differentiate between MCI 
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and healthy controls. The hypothesis which will be tested is patients with MCI have a 
different profile of cognitive complaints compared to cognitively healthy individuals. 
HYPOTHESIS 2: If we examine different types of complaints as those suposely obtained in 
objective 1, we will find some of them are able to distinguish between healthy ederly 
controls and individuals with MCI.  
3. TO ANALYZE THE LONGITUDINAL PREDICTIVE VALUE OF THE SCD AS A MARKER OF FAST 
CONVERSION TO MCI IN A SAMPLE OF OLDER ADULTS. 
As the second objective is confirmed, this goal will search for specific features of SCD 
that could predict conversion to MCI over time. The Vallecas Project cohort will be 
classified according to the guidelines provided by the SCD-I in three groups based on 
SCD´s features: No complaints, SCD, and SCD-Plus. Then, we will analyze whether the 
different subtypes of SCD are related to cognitive trajectory and are able to predict 
earlier the onset of MCI. 
HYPOTHESIS 3: If we use SCD-I recommendations and classify subjects in No SCD- SCD and 
SCD-Plus, then specific features that define SCD-Plus will predict fast conversion to MCI.  
4. TO INVESTIGATE THE RELIABILITY AND TEMPORAL STABILITY OF THE MEASUREMENTS 
OF THE SCD OVER TIME IN A SAMPLE OF OLDER ADULTS. 
Measures of subjective variables like SCD are actually assessing two different types of 
information: i) the construct of interest (i.e. SCD in our case); and ii) errors of 
measurement which comprised both the error variance and short-term fluctuations 
due to shifts in self-perception itself. In psychometry it is a well-established fact that 
when repeated subjective measurements are collected from an individual the scores on 
two different occasions may be different. If this were the case in the majority of 
individuals, the subjective variable would lack internal consistency. In other words, if 
two longitudinal measures are quite different and they do not converge, which one is 
the real to characterize the individual? This lack of temporal stability in measures, 
which can affect preferably to subjective variables rather than objective performance, 
represents an important bias to investigation. Specifically, if a construct do not probe to 
be stable enough over time it should not be considered as a target for research. In this 
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way, making use that SCD is systematically and repeatadely collected in the Vallecas 
Project, we will analyze the temporal stability of self-reported complaints over time for 
the whole cohort. We hypothesize that SCD may have enough internal consistency if 
the construct is operationally defined and consistently assessed. 
HYPOTHESIS 4: If we operationally define and consistenly assess SCD over time, then it will 
be a stable, reliable and robust concept.  
5. TO DETERMINE THE EXPRESSION AND THE TEMPORAL DYNAMICS OF THE SCD 
THROUGH THE AD CONTINUUM. 
This last objective depends on having previously demonstrated the temporal stability of 
SCD. If the latter were probed we will analyze the validity of the SCD as a very early 
marker of AD examining the dynamic transition from the preclinical to prodromal AD 
stages. Also we will examine whether diferent SCD subtypes could correlate with the 
different transition rates to MCI. 
HYPOTHESIS 5: If we focus at the preclinical substages of AD proposed by the NIA- AA, 
then we will find there is a temporal dynamic transition happening in the preclinical 
phase of AD that goes from NO SCD to SCD to SCD-Plus.  
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3.1. Summary of objectives 
1. To examine the dimensional structure of the EMQ.  
2. To report the existence of latent factors on the EMQ structure, not only the overall score. 
3 To determine whether specific cognitive complaints are more useful than others to 
discriminate MCI. 
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3.2. Abstract 
Introduction: Subjective memory complaints in the elderly have been suggested as an early 
sign of dementia. This study aims at investigating whether specific cognitive complaints are 
more useful than others to discriminate Mild Cognitive Impairment (MCI) by examining the 
dimensional structure of the Everyday Memory Questionnaire (EMQ). 
Material and Methods: A sample of community-dwelling elderly individuals was recruited 
(766 controls and 78 MCI). The Everyday Memory Questionnaire (EMQ) was administered 
to measure self-perception of cognitive complaints. All participants also underwent a 
comprehensive clinical and neuropsychological battery. Combined exploratory factor 
analysis and item response theory were performed to identify the underlying structure of 
the EMQ. Furthermore, logistic regression analyses were conducted to study whether single 
cognitive complaints were able to predict MCI. 
Results: A suitable five-factor solution was found. Each factor focused on a different 
cognitive domain. Interestingly, just three of them, namely forgetfulness of immediate 
information, executive functions and prospective memory proved to be effective in 
distinguishing between cognitively healthy individuals and MCI. Based on these results we 
propose a shortened EMQ version comprising 10 items (EMQ-10). 
Discussion: Not all cognitive complaints have the same clinical relevance. Only subjective 
complaints on specific cognitive domains are able to discriminate MCI. We encourage 
clinicians to the EMQ-10 as a useful tool to quantify and monitor the progression of 
individuals who report cognitive complaints. 
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3.3. Introduction 
Subjective memory complaints (SMC) can be defined as a self-experienced persistent 
decline in memory or any other cognitive ability in comparison with a previously normal 
status. Regarding the elderly, the topic of SMC has been a focus of intense debate within 
the research literature during the past two decades. Perhaps, the reason for that is the 
clinical importance of SMC in predicting the onset of memory impairment and future 
dementia. A recent meta-analysis has shown that, independently of the objective memory 
performance, 6.6% and 2.3% of older people with SMC develop mild cognitive impairment 
(MCI) and dementia per year (Mitchell et al., 2014), respectively. Since there is increasing 
evidence that SMC may represent a very early manifestation of Alzheimer´s Disease (AD) 
(Jessen et al., 2014), little is known about the clinical role of specific complaints on the 
transition between normal aging to cognitive impairment. 
Although SMC increase with age, complaints tend to show only mild or non-significant 
correlations with objective memory performance. Instead, many cross-sectional studies 
have reported a close relationship between SMC and other subjective variables such as 
depression (Crane et al., 2007), anxiety (Comijs et al., 2002), perceived health (Montejo et 
al., 2014), personality (Pearman and Storandt, 2004) and quality of life (Montejo et al., 
2011). 
Structured questionnaires are considered the best approach of gaining insight into older 
adults’ SMC (Montejo et al., 2014). Basically, these questionnaires consist of a list of 
common memory failures that must be rated according to the frequency in which they are 
experienced by subjects. Although there are many questionnaires that have been proposed 
to evaluate SMC, the Everyday Memory Questionnaire (EMQ) (Sunderland et al., 1984) is 
perhaps one of the most extended scales. The EMQ has been used to assess SMC in a 
variety of populations, including older adults (Garrett et al., 2010; Ossher et al., 2013). It 
consists of 28 items about memory failures that occur in everyday life. All items must be 
answered according to a Likert-type scale. 
Despite Sunderland et al. (1984) emphasized the unidimensionality of the EMQ, the analysis 
of its individual items evidences that a high percentage of them do not exactly correspond 
to memory complaints. Rather, some items would involve various cognitive domains like, 
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for instance, visual perception (“failed to recognize, by sight, close friends or relatives”), 
attentional processing (“been unable to follow the thread of a story”), language production 
(“found that a word is on the tip of your tongue”), or executive functions (“forgotten a 
change in your daily routine”). This may be the reason for what several studies have 
reported the existence of various latent factors on the EMQ structure (Calabria et al., 2011; 
Cornish, 2000; Royle and Lincoln, 2008). In any event, investigations using the EMQ with 
older adults have exclusively focused on the overall score (Alegret et al., 2015), and have 
not addressed the role of the specific underlying factors upon differentiation between 
healthy controls and people with MCI. 
This study aims at investigating whether specific cognitive complaints are more useful than 
others to discriminate MCI by investigating the underlying structure of EMQ´s items in a 
large community-dwelling older adult sample. We expect to find different cognitive 
complaints dimensions in the EMQ. Our secondary goals are, to propose a shortened 
version of EMQ based on discrimination and difficulty parameters of items within each 
factor, and to examine the ability of these specific dimensions to differentiate between MCI 
and healthy controls. 
3.4. Material and Methods 
3.4.1. Participants 
The participants of this study comprised 844 community-dwelling individuals aged 70 years 
and over. All of them were part of the Vallecas Project cohort, a community-based 
longitudinal investigation for early detection of AD. The Vallecas Project was launched by 
CIEN Foundation-Queen Sofia Foundation on October 2011 (Olazarán et al., 2015). The 
study was approved by the Research Ethics Committee of the Carlos III Institute of Health. 
Written informed consent was obtained by all the participants. 
All participants underwent a detailed assessment protocol including past medical history, 
neurological and neuropsychological examination, as well as biochemical and genetic blood 
test. The complete visit was usually carried out within four hours, with convenient breaks if 
necessary. 
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Every participant was independently diagnosed taking into account age, gender, cognitive 
reserve, functional information, and neuropsychological scores. Cognitive diagnoses were 
agreed between neurologists and neuropsychologists at consensus meetings. In all cases, 
cognitively healthy subjects had to obtain a score of 0 in the global Clinical Dementia Rating 
(CDR) (Hughes et al., 1982). Criteria from the National Institute on Aging-Alzheimer´s 
Association (NIA-AA) were used to diagnose MCI (Albert et al., 2011). A total of 766 
individuals were classified as controls and 78 met the criteria for MCI. 
3.4.2. Subjective complaints assessment 
We used the EMQ to measure cognitive complaints. This questionnaire was administered 
following the instructions provided in a previous Spanish validation study (Montejo 
Carrasco et al., 2012). Participants were asked to rate the 28 items according to the 
frequency with which they experienced each complaint. Items were scored on a 3-point 
scale, with 0 indicating “never, rarely”, 1 “occasionally, sometimes”, and 2 “frequently, 
almost always”. Thus, the total score ranged from 0 to 56. In all cases, individuals 
completed the EMQ in the presence of a member of the research team. 
3.4.3. Neuropsychological assessment 
A comprehensive neuropsychological battery was applied by trained neuropsychologists in 
order to obtain information about visual perception, attention, memory, language, praxis, 
and executive functions. A total of eleven cognitive tests were considered: Mini Mental 
State Examination (MMSE) (Folstein et al., 1975); Clock Drawing Test; Free and Cued 
Selective Reminding Test (FCSRT) (Buschke, 1984); Lexical and Semantic Verbal Fluency 
(Peña-Casanova et al., 2009); Forward and Backward Digit Span (Wechsler, 1997); Five Point 
Test (Lee et al., 1994); Rule Card Shifting Test (Wilson et al., 1996); Boston Naming Test (15-
items version) (Fernández-Blázquez et al., 2012); Imitation of Bilateral Postures and 
Symbolic Gesture (Peña-Casanova, 1990); and Digit Symbol Coding (Wechsler, 1997). In 
addition, the following three scales were also administered to collect further data with 
regard to functional performance and mood: Functional Activities Questionnaire (FAQ) 
(Pfeffer et al., 1982), Geriatric Depression Scale (GDS) (Yesavage et al., 1982), and State-
Trait Anxiety Inventory (STAI) (Spielberger et al., 1970). 
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3.4.4. Data analysis 
Analyses were conducted using R version 2.15. (R Development Core Team, 2012). 
Differences between healthy controls and MCIs on baseline characteristics were evaluated 
with Mann-Whitney tests and Pearson´s χ2 as appropriate. To identify latent constructs in 
the structure of correlations among the 28 items of the EMQ, an exploratory factor analysis 
(EFA) was performed using exclusively control subjects. Since response categories were 
ordinal scores, a polychoric correlation matrix resulted in a preferable approach for EFA 
(Brown, 2006). 
First, a descriptive analysis of items was developed in order to find out their individual 
distribution. Then, it was determined whether the assumptions of normality and sphericity 
were met. Due to no prior theory exists regarding the structure of data, Weighted Least 
Squares (WLS) with oblique Promax rotation was selected as the factor extraction method. 
The procedure for determining the number of factors was Parallel Analysis. In addition to 
χ2, the most common indexes of goodness-of-fit, Root Mean Square Error of Approximation 
(RMSEA) and Standardized Root Mean Square Residual (SRMR) were used. Values no 
greater than 0.06 for RMSEA and lower than 0.08 for SRMR indicate acceptable fit (Hu and 
Bentler, 1999).  
By means of an Item Response Theory (IRT) approach, we calibrated all retained items using 
single Graded Response Models (GRM), one for each factor. This kind of models are the 
most appropriate to examine ordinal items as well as they assume normality of the latent 
trait. GRM estimate a slope parameter and two location parameters for each 3-category 
item. After obtaining item´s parameters from the IRT calibration, we used this information 
to identify a shortened version of the EMQ that maintained adequate content coverage 
within each factor with maximum precision. To guide selection of items, we examined the 
item information functions of every single factor. Additionally, two quantitative criteria 
were established in order to produce the maximum amount of information (discrimination 
index >1) with optimal difficulty distribution (sum of location parameters ranged from 2 to 
4). Therefore, those items that did not fulfill both criteria were excluded from their 
corresponding factor. Finally, internal consistency was estimated by means of Cronbach’s 
alpha coefficient for ordinal categories. 
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Since distribution of most variables and components of the EMQ did not fulfill all the 
assumptions for using parametric statistics, a Spearman correlation analysis was carried out 
between the resulting factors and demographic and cognitive variables. In addition, Mann-
Whitney tests were to study differences between control and MCI groups. As proposed by 
Cohen (1988), non-parametric adjusted effect sizes were estimated through the 
approximation of the z distribution associated with the Mann-Whitney test. According to 
the value of r, a large effect is 0.5, a medium effect is 0.3, and a small effect is 0.1. 
Additionally, to facilitate the interpretation of results, measures of probability of superiority 
(PS) were also provided. 
Finally, we also performed logistic regressions to examine whether age, education, and 
gender along with the underlying EMQ´s factors were able to predict cognitive impairment. 
In order to measure the impact of the model upon data, a special consideration was given 
to tests of signification for the model estimators. Analysis of residuals and goodness-of-fit 
statistics were also performed to measure the degree of adjustment of the model to 
available data. 
3.5. Results 
3.5.1. Descriptive analysis of the sample 
The sample consisted of 766 controls (90.8%) and 78 MCIs (9.2%). Demographic and 
cognitive data, as well as differences between both groups, are shown in Table 1. 
Significant differences were found for age and years of education in such a way that MCIs 
were older and less educated than controls. A larger percentage of males were also 
classified as MCI. Moreover, as expected, the majority of cognitive variables showed large 
differences in favor of controls (p-value < 0.001), except for trait anxiety, where no 
statistically differences were found. 
3.5.2. Exploratory factor analysis 
First, descriptive statistics of individual items of EMQ were calculated (Table 2). Items 11, 
19 and 27 were excluded from further analysis due to their values of skewness and/or 
kurtosis were over |2.5|. Thus, a symmetrically distribution with the rest of 25 retained 
items was ensured to be applied the EFA. 
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Table 3.1. Descriptive analysis and mean differences between control and MCI groups. 
 
Control 
(n=766) 
MCI 
(n=78) p-value 
 Mean SD Mean SD 
Age (years) 74.07 3.80 76.08 4.06 < 0.001 
Education (years) 11.15 6.69 8.04 6.00 < 0.001 
Sex 63% Female 50% Female 0.032 
Cognitive performance    
MMSE 28.75 1.46 26.09 2.28 < 0.001 
Clock Drawing Test 9.42 1.26 8.20 1.88 < 0.001 
FCSRT free immediate 24.90 5.73 13.89 5.26 < 0.001 
FCSRT total immediate 42.84 4.45 30.78 8.29 < 0.001 
FCSRT free delayed 9.90 2.49 4.50 2.83 < 0.001 
FCSRT total delayed 14.79 1.51 10.13 3.35 < 0.001 
Lexical Verbal Fluency 39.76 12.95 27.31 10.33 < 0.001 
Semantic Verbal Fluency 49.54 10.11 34.57 8.49 < 0.001 
Forward Digits 7.40 1.87 6.37 1.55 < 0.001 
Backward Digits 4.64 1.85 3.77 1.51 < 0.001 
Five Point Test 21.88 8.19 14.77 5.81 < 0.001 
Rule Card Shifting 3.02 3.10 7.11 3.10 < 0.001 
Boston Naming Test-15 items 12.83 1.85 9.69 3.07 < 0.001 
Posture Imitation 7.27 1.20 6.31 1.26 < 0.001 
Symbolic Gesture 9.70 1.00 9.47 0.96 0.001 
Digit Symbol Coding 39.72 15.10 25.20 10.95 < 0.001 
FAQ 0.38 0.68 2.68 2.33 < 0.001 
GDS 1.47 2.17 2.73 2.78 < 0.001 
STAI state 14.51 8.80 17.76 10.97 0.037 
STAI trait 16.77 9.68 17.00 9.57 0.887 
Note. MMSE = Mini-Mental State Examination; FCSRT = Free and Cued Selective Reminding Test; FAQ = Functional Activities 
Questionnaire; GDS = Geriatric Depression Scale; MCI = Mild Cognitive Impairment; SD = Standard Deviation; STAI = State-Trait 
Anxiety Inventory 
The EMQ total score was not normally distributed (Shapiro-Wilk normality test, W=0.93; 
p<0.001). The mean of the EMQ total score was 13.18±7.84 (range 0-47). We did not obtain 
significant association between EMQ and gender (W=59,803; p=0.55) nor age (rho=0.04; 
p=0.28). Nevertheless, the correlation between EMQ total score and years of education was 
statistically significant (rho=-0.16; p<0.001), which meant that individuals with more years 
of education tended to report less cognitive complaints. The Cronbach’s alpha coefficient 
for the polychoric correlation matrix comprising the 25 items was 0.93. 
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Table 3.2. Descriptive statistics of individual items of EMQ. 
Items Mean SD Median Min Max Skew Kurtosis 
1 0.89 0.49 1 0 2 -0.23 0.79 
2 0.39 0.54 0 0 2 0.97 -0.14 
3 0.25 0.49 0 0 2 1.76 2.26 
4 0.26 0.50 0 0 2 1.70 2.02 
5 0.71 0.55 1 0 2 -0.01 -0.55 
6 0.74 0.53 1 0 2 -0.16 -0.38 
7 0.51 0.53 0 0 2 0.33 -1.16 
8 0.61 0.56 1 0 2 0.23 -0.82 
9 0.35 0.54 0 0 2 1.17 0.34 
10 0.31 0.51 0 0 2 1.32 0.71 
11 0.16 0.43 0 0 2 2.71 6.86 
12 0.58 0.61 1 0 2 0.54 -0.63 
13 0.89 0.50 1 0 2 -0.22 0.76 
14 0.44 0.58 0 0 2 0.91 -0.17 
15 0.48 0.55 0 0 2 0.59 -0.75 
16 0.29 0.49 0 0 2 1.35 0.76 
17 0.46 0.59 0 0 2 0.85 -0.27 
18 0.21 0.42 0 0 2 1.66 1.41 
19 0.09 0.33 0 0 2 4.02 16.63 
20 0.37 0.53 0 0 2 0.99 -0.14 
21 1 0.61 1 0 2 0 -0.32 
22 0.34 0.53 0 0 2 1.22 0.47 
23 0.52 0.62 0 0 2 0.79 -0.39 
24 0.73 0.57 1 0 2 0.08 -0.51 
25 0.26 0.50 0 0 2 1.71 2.06 
26 0.54 0.61 0 0 2 0.66 -0.52 
27 0.16 0.40 0 0 2 2.44 5.43 
28 0.35 0.53 0 0 2 1.18 0.38 
Note. SD = Standard Deviation 
Table 3 shows the factor loadings and the communalities and percentage of variance 
explained for the factors obtained. The measure of sample adequacy was appropriate for 
developing an EFA (KMO=0.92; Barlett χ21035=4,350.15; p<0.001). Although the Parallel 
Analysis determined six dimensions as the optimal solution from a statistical point of view, 
we finally adopted an explanation with five components because of it proved more 
reasonable in biological terms. The first factor corresponded to the items 2, 6, 8, 13, 15, 16, 
17, 20, 21, 23, and 28 and explained 17% of the total variance. This component was called 
Forgetfulness of Immediate Information (FII). The second component comprised the items 
3, 4, 5, 9, 10, and 12 and explained 11% of the total variance; it was termed as Executive 
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Functions (EF). A third component, named as Prospective Memory (PM), retained the items 
7, 14, 18 and 22. Finally, the fourth and fifth factors comprised, respectively, items 1 and 24 
and items 25 and 26. They were called Forgetfulness of Common Objects (FCO) and Spatial 
Orientation (SO). The analysis of the polychoric correlation matrix by using Mardia´s tests 
revealed data to be reached a suitable multivariate normality (skew statistic = 7146.36 with 
p < 0.001; kurtosis statistic = 36.02 with p < 0.001). Likewise, reliability of all factors was 
considered appropriate. 
Table 3.3. Exploratory Factor Analysis of the EMQ with component loadings of each item. 
 
I II III IV V Communalities 
Item 21 0.710 -0.254   
 
0.37 
Item 8 0.618 0.193 0.211  -0.288 0.57 
Item 20 0.605 
 
 -0.156 
 
0.40 
Item 13 0.576 -0.148 0.153  
 
0.40 
Item 15 0.528 
 
0.347  
 
0.54 
Item 17 0.502 0.425 -0.236  
 
0.56 
Item 6 0.502 
 
 0.144 
 
0.37 
Item 16 0.431 0.267   
 
0.52 
Item 28 0.339 
 
0.208 -0.107 0.109 0.31 
Item 2 0.328 0.313 -0.108  
 
0.40 
Item 23 0.312 
 
0.237 -0.176 
 
0.26 
Item 3 -0.106 0.786   
 
0.53 
Item 4 -0.249 0.718 0.221  
 
0.51 
Item 9 0.400 0.437 -0.155  -0.127 0.41 
Item 10 0.125 0.407   0.179 0.37 
Item 12 0.109 0.383   0.146 0.34 
Item 5 0.211 0.318  0.282 -0.118 0.44 
Item 18 0.180 
 
0.692 -0.149 
 
0.52 
Item 22 0.252 0.182 0.501  
 
0.61 
Item 14 0.400 
 
0.430  -0.127 0.62 
Item 7 -0.123 
 
0.349 0.328 0.188 0.42 
Item 1 
  
-0.128 1.002 
 
0.85 
Item 24 0.265 -0.220 0.120 0.568 
 
0.60 
Item 25 -0.150 
 
  0.955 0.91 
Item 26 0.109 
 
-0.105  0.688 0.51 
Eigenvalue 4.23 2.76 2.00 1.67 1.65  
Proportion variance 0.17 0.11 0.08 0.07 0.07  
Cronbach coeficient 0.80 0.66 0.63 0.65 0.65  
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3.5.3. IRT calibration 
Preliminary non-parametric Mann-Whitney tests were carried out in order to ascertain 
whether the five components of the EMQ were able to distinguish between healthy 
controls and MCIs. Thereby, FII (U=16510; p<0.001), EF (U=17176; p<0.001) and PM 
(U=19932.5; p=0.016) were found to differentiate between both groups. However, FCO 
(U=24588; p=0.381) and SO (U=23920; p=0.258) did not show relevant differences. Thus, 
according to the aims of this work, only FII, EF and PM were finally analyzed. FCO and SO 
were excluded for further analyses. 
Table 3.4. Parameters estimated from the three Graded Response Models (GRM). 
 a b1 b2 
FII    
Item 2 1.320 0.547 3.361 
Item 6 1.403 -0.820 2.765 
Item 8 1.887 -0.245 2.470 
Item 13 1.345 -1.451 2.373 
Item 15 1.714 0.168 2.867 
Item 16 1.816 0.787 3.107 
Item 17 1.278 0.332 2.911 
Item 20 1.353 0.601 3.444 
Item 21 1.174 -1.567 1.542 
Item 23 0.942 0.231 3.164 
Item 28 1.115 0.302 3.681 
EF    
Item 3 1.698 1.053 2.889 
Item 4 1.473 1.076 3.100 
Item 5 1.300 -0.805 2.792 
Item 9 1.068 0.831 3.781 
Item 10 1.238 0.315 3.612 
Item 12 1.224 -0.075 2.703 
PM    
Item 7 1.094 0.046 4.181 
Item 14 2.273 0.327 2.203 
Item 18 1.581 1.214 4.092 
Item 22 2.408 0.594 2.456 
Note. a = discrimination parameter; b1 = difficulty parameter response option 1; b2 = difficulty parameter response option 2; 
AIC = Akaike Information Criterion; FII = Forgetfulness of Immediate Information; EF = Executive Functions; PM = Prospective 
Memory. 
AIC FFI: 11,292.92; AIC EF: 5,938.43; AIC PM: 3,742.51 
The parameter estimates from the three GRM calibrations are shown in Table 4. The slope 
values for all items ranged from 0.942 to 2.408, indicating a considerable variation in 
discrimination among them. However, items 14 and 22 showed the best discrimination for 
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PM, while values for items of FII and EF were more homogeneous. On the other hand, 
despite the range of location parameters reflected a sizeable range of underlying cognitive 
complaints (-1.567 to 4.181), the majority of item response categories were selected by 
participants who had more complaints than average. These results pointed out that items 
allowed to differentiating among individuals at the end of the complaints continuum. 
Then, we selected the best combination of items within each factor to maximize the 
amount of information with optimal difficulty distribution. We used both discrimination 
and difficulty parameters of items to carry out the selection. To that end, items should have 
discrimination indexes greater than 1 and location parameters ranged from 2 to 4. These 
criteria were adopted because of the objectives of this work (the easiest or the most 
difficult items were considered not advisable to discriminate between controls and MCI). 
Overall, 10 items were finally selected as follows: i) FII: items 2, 8, 15, 16, 17 and 28; ii) EF: 
items 3, 10 and 12; and iii) PM: items 14 and 22. A final score of this shortened EMQ, called 
EQM-10, was also calculated by adding up these 10 items. 
3.5.4. Multivariate study 
As shown in Figure 1, FII, EF and PM correlated among them in a range from 0.33 to 0.53. 
Regarding to neuropsychological tests, the three factors showed low-moderate correlation 
coefficients with psychiatric symptoms, while the correlation with cognitive performance 
was mainly low. For depression and anxiety, the coefficients were positive, indicating that 
complaints increased as depression and anxiety scores were higher. On the contrary, the 
relationship with objective cognition showed negative coefficients, meaning larger 
complaints as cognitive performance decreased. Interestingly, FII was more associated with 
episodic memory (FCSRT), while EF was stronger related to language production (Fluency, 
BNT) and executive components (number of errors in RCS). Correlation coefficients 
between MMSE and every factor were very similar to those obtained in neuropsychological 
tests. Age and education showed low correlation coefficients with all factors. 
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Figure 3.1. Correlogram between the factors of the EMQ and demographic and cognitive 
variables. 
Note. FII = Forgetfulness of Immediate Information; EF = Executive Functions; PM = Prospective Memory; MMSE = Mini-
Mental State Examination; FCSRT = Free and Cued Selective Reminding Test; FAQ = Functional Activities Questionnaire; GDS = 
Geriatric Depression Scale; STAI = State-Trait Anxiety Inventory. 
Non-parametric Mann-Whitney tests were performed to determine whether the three 
factors were able to distinguish between healthy controls and MCIs. Figure 2 shows the 
scores of both groups for each component. FII (U=17,175; p<0.001), EF (U=17,651; p<0.001) 
and PM (U=19,015; p<0.001) were found to differentiate between both groups. According 
to the non-parametric effect size, FII, EF, and PM showed respectively the following sizes: 
0.16, 0.14, and 0.12. Total score of the EMQ-10 was also significant (U=14,098; p<0.001) 
and showed a mild increase in the effect size (r=0.18). 
Finally, four logistic regression models were carried out to study the impact of cognitive 
complaints upon the diagnostic of MCI. All these five models were adjusted for age, 
education and gender as covariates (Table 5). The three cognitive factors proved to be 
significant in their respective models after controlling for demographic variables. In 
addition, estimates of all factors were positive, what indicated that expressing complaints 
was associated with MCI. FII showed the best determination coefficient (model 1; R2=0.14) 
followed by EF (model 2; R2=0.10) and PM (model 3; R2=0.10). Indeed, total score of EMQ-
10 (model 4; R2=0.14) did not improve the association with diagnostic showed by FII. 
Hence, although the values of these determination coefficients were not too high, 
demographic variables and cognitive complaints were effective in distinguishing between 
cognitively healthy individuals and MCI. 
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Figure 3.2. EQM-10 factors scores differences between controls and MCIs. 
Note. MCI = Mild Cognitive Impairment; FII = Forgetfulness of Immediate Information; EF = Executive Functions; PM = 
Prospective Memory. 
*** p-value < 0.001 
3.6. Discussion 
In the current study, we have examined the latent structure of the EMQ and the ability of 
specific cognitive complaints to differentiate between MCI and healthy controls. To that 
end, it was analyzed a sample of 844 community-dwelling individuals above 70 years old 
who voluntarily participated in a longitudinal investigation for early detection of AD. Of 
them, only the 766 control individuals were used to study the factor structure of the EMQ. 
To our knowledge, this is the first study that investigates the dimensional structure of the 
EMQ and compares how well specific cognitive complaints are able to discriminate MCI. 
Our results highlight an adequate internal consistency of the EMQ, as well as a factorial 
structure. This outcome does not fit well with the Sunderland´s assumption on the 
unidimensionality of the questionnaire (Sunderland et al., 1984). Indeed, as already 
reported by other authors, the EMQ has proved to have an underlying structure composed 
of three (Calabria et al., 2011), four (Royle and Lincoln, 2008) or even five factors (Cornish, 
2000). Rather than a specific questionnaire focused on memory complaints, the EMQ 
seems to be a more complex scale that is able to measure various domains of subjective 
cognitive impairment. 
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Table 3.5. EQM-10 factors scores differences between controls and MCIs. 
Model 1: Age, Education, Sex and Forgetfulness of Immediate Information 
Variables B SE z value Sig. 
(Intercept) -10.88 2.55 -4.28 < 0.001 
Age 0.12 0.03 3.71 < 0.001 
Education -0.10 0.03 -3.68 < 0.001 
Female -0.94 0.27 -3.50 < 0.001 
FII 0.24 0.05 4.78 < 0.001 
Null Deviance=474.50 on 773 dg; Residual Deviance=410.23 on 769 dg; AIC: 
420.23 
 
Model 2: Age, Education, Sex and Executive Functions 
Variables B SE z value Sig. 
(Intercept) -9.25 2.47 -3.75 < 0.001 
Age 0.10 0.03 3.13 0.002 
Education -0.09 0.03 -3.37 < 0.001 
Female -0.70 0.27 -2.60 0.009 
EF 0.34 0.10 3.49 < 0.001 
Null Deviance= 466.38 on 779 dg; Residual Deviance= 417.76 on 775 dg; AIC: 
427.76 
 
Model 3: Age, Education, Sex and Prospective Memory 
Variables B SE z value Sig. 
(Intercept) -10.88 2.49 -4.37 < 0.001 
Age 0.12 0.03 3.82 < 0.001 
Education -0.07 0.02 -3.05 0.002 
Female -0.75 0.27 -2.83 0.005 
PM 0.38 0.12 3.09 0.002 
Null Deviance=467.31 on 784 dg; Residual Deviance=421.76 on 780 dg; AIC: 
431.76 
 
Model 4: Age, Education, Sex and EQM-10 
Variables B SE z value Sig. 
(Intercept) -11.43 2.62 -4.37 < 0.001 
Age 0.12 0.03 3.72 < 0.001 
Education -0.08 0.03 -3.11 0.002 
Female -0.79 0.28 -2.82 0.005 
EQM-10 0.15 0.03 4.78 < 0.001 
Null Deviance=444.97 on 739 dg; Residual Deviance=384.68.76 on 735 dg; AIC: 
394.68 
 
Note. Dg = degrees of freedom; AIC = Akaike Informative Criterion; Objects; SE = Standard Error; FII = Forgetfulness of 
Immediate Information; EF = Executive Functions; PM = Prospective Memory. 
In our study, items 11 (failed to recognize, by sight, close friends or relatives), 19 (forgotten 
important details about yourself) and 27 (repeat to someone what you have just told them) 
were excluded from the EFA since their skewed distribution. The reason for that exclusion 
may have to do with the fact that these three items seem to reflect severe symptoms which 
appear in mild dementia rather than in earlier stages (preclinical or prodromal phases). The 
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final solution with the remaining 25 items comprised of a five-factor structure which 
explained up to50% of EMQ´s total variance: i) FII was associated with fails in immediate 
retrieval, as well as naming impairment; ii) EF was related to distractibility, inhibition errors 
and monitoring; iii) PM referred to things that someone has to recall in the next future; iv) 
FCO had to do with forgetting personal details; and v) SO was associated with difficulties for 
spatial orientating. 
One crucial aim of the present study was to examine the association of SMC with 
neuropsychological performance and clinical diagnosis. EMQ´s factors exhibited higher 
correlation coefficients with psychiatric symptoms than with cognitive performance as 
other studies have already demonstrated (Balash et al., 2013). Global cognitive status 
assessed by means of MMSE was negatively correlated with all factors. In addition, as 
shown in Figure 1, FII and EF proved to be the factors that correlated higher with cognitive 
performance, especially episodic memory in the case of FII, and executive functions for EF. 
This outcome provides concurrent validity to the latent structure of the EMQ because the 
internal content of the factors is directly related to the cognitive domain supposedly 
assessed. Furthermore, the use of an IRT approach allowed us to find out the best 10-items 
that maximize the collection of information on cognitive complaints. 
Regarding the clinical implications of this work, it has been suggested that cognitive 
complaints are able to distinguish between cognitively healthy elders and MCI (Buckley et 
al., 2013). In our study, three types of cognitive concerns are able to discriminate between 
controls and MCI. Higher scores in specific complaints on retrieval of immediate events, 
executive functioning, and prospective memory are related to prodromal stages of 
dementia. Indeed, our results indicate that their effect sizes give a PS of nearly 60%. That is, 
if two individuals, one control and one MCI, were selected at random, the score in any of 
these three factors would be higher for the MCI patient on 60% of times. The fact that both 
forgetfulness of objects and spatial orientation do not show differences in control subjects 
and MCI could be explained because of the first of them refers to a high prevalent oversight 
in the elderly population (“Forgetting where you have put something”, “Forgetting where 
things are normally kept or looking for them in the wrong place”) and the other one is an 
idiosyncratic sign of mild dementia (“Getting lost or turning in the wrong direction on a 
journey, on a walk, or in a building where you have been before”). All these findings 
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emphasize that not all cognitive complaints have the same clinical significance for 
prediction of cognitive impairment.  
Concerning the limitations of the present study, the cross-sectional nature of our research 
is perhaps the most important one. Although our results suggest that specific cognitive 
complaints discriminate between controls and MCI, it remains unclear whether those 
specific complaints may be used to detect individuals at high risk of conversion to MCI in 
the future. Given that the Vallecas Project is still in progress, this is an important issue that 
shall be addressed in next visits. Another limitation is that family members of the 
participants were not available in all cases in order to confirm the severity of the cognitive 
complaints reported by subjects with MCI. This information could be very useful in future 
studies to minimize the effect of anosognosia, a common symptom in MCI that might 
somewhat bias the results. Finally, it should be desirable to study the link between 
cognitive complaints and other variables such as cognitive reserve that may influence on 
cognitive performance (Freret et al., 2015; Mondini et al., 2016). Since cognitive reserve has 
been positively related to both episodic and working memory (Lojo-Seoane et al., 2014), it 
could be hypothesized that self-perception of subjective deterioration could be increased in 
those individuals with low cognitive reserve. 
In summary, not all cognitive complaints are effective in distinguishing healthy elderly 
individuals from those with MCI. Specific complaints related to episodic memory, executive 
functions and prospective memory discriminate between controls and cognitive impaired 
subjects. Individuals who present these particular complaints and do not yet have a 
diagnosis of MCI may need special attention in terms of close clinical follow-up or an early 
cognitive intervention. The use of the EMQ-10 is highly recommended to quantify 
subjective decline and to monitor the longitudinal progression of individuals who report 
those cognitive complaints. 
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3.7. Summary of conclusions 
1. EMQ has an adequate internal consistency, as well as a well-stablished factorial 
structure. 
2. EMQ is able to measure various domains of cognitive complaints. 
3. The SCD construct has a multidimensional structure. 
4. Three types of cognitive concerns are able to distinguish between contols and MCI 
subjects (retrieval immediate events/executive functioning/ prospective memory). 
5. Complaints associated with these three types of concerns give us a profile of a subject at 
a higher risk of developing MCI.  
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4.1. Summary of objectives 
1. To evaluate the clinical significance of SCD on the conversion from healthy stage to MCI. 
2. To assess the potential usefulness of SCD on its different subtypes. 
3. To determine SCD association with cognitive performance. 
4. To examine the risk of SCD for objective cognitive decline. 
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4.2. Abstract 
Background: Alzheimer´s disease (AD) is a silent disorder that needs the earliest possible 
intervention in order to reduce its high economic and social impact. It has been recently 
suggested that Subjective Cognitive Decline (SCD) appears at preclinical stages many years 
before the onset of AD. Therefore, SCD could become an ideal target for early therapeutic 
intervention. 
Objective: The goal of this study was to evaluate the clinical significance of SCD on the 
conversion from a cognitively healthy stage to a Mild Cognitive Impairment (MCI) in one-
year follow-up. 
Methods: A total of 608 cognitively intact individuals from the Vallecas Project´s cohort, a 
community-based prospective study to identify early markers of AD, were enrolled in this 
study. Participants were classified in three groups: i) No Complaints (NCg), ii) Subjects with 
complaints in one or more cognitive domains (SCDg), and iii) Subjects who, besides 
complaints, fulfilled the features of SCD Plus proposed by the International Working Group 
of SCD (SCD-Pg). 
Results: Individuals were followed up for a mean of 13.1 months (range 10.7-22.4). During 
this time, 41 volunteers developed MCI (6.7% of total sample). The conversion rate for SCD-
Pg (18.9%) was significantly higher than SCDg (5.6%) and NCg (4.9%). 
Conclusion: Specific features associated with SCD may help to identify individuals at high 
risk of fast conversion to MCI. These results highlight the importance of a close follow-up of 
subjects with SCD-P and include them in early intervention programs because of their 
increased risk for the development of MCI. 
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4.3. Introduction 
Sporadic Alzheimer´s Disease (AD) is a multifactorial neurodegenerative disorder that 
begins affecting the brain many years before cognitive impairment is noticeable. According 
to the National Institute on Aging-Alzheimer Association (NIA-AA) workgroups, there are 
three different stages of AD´s progression over time. First, there is a preclinical phase in 
which some of the disease hallmarks in the brain have taken place, such as the presence of 
amyloid plaques, but no objective cognitive impairment is present [1]. A second stage, 
called prodromal AD or Mild Cognitive Impairment (MCI) due to AD, involves minor 
cognitive changes which are noticeable to the patient and/or to others, but are not severe 
enough to significantly affect everyday activities [2]. Finally, there is a third stage in which 
the intensity of the cognitive disorder leads to a functional impairment that ends up with a 
dementia syndrome [3]. The difficulty in pharmachologically altering the progression of AD 
stages has fostered the growing consensus that therapeutic interventions are more likely to 
be effective at the earliest possible phase [4]. Currently, treatment efforts between stages 2 
and 3 have led to negative results. Thus, the search for early markers of preclinical AD is of 
paramount importance since disease-modifying therapeutic approaches are being 
developed for future use in at risk populations [5]. 
In dominantly inherited AD patients, the studies on pathophysiological changes occurring 
several years before symptoms onset support the existence of preclinical stages [6]. 
Biomarkers, based on the analysis of cerebrospinal fluid (CSF) samples or brain imaging [7], 
have shown evidence of neuropathological features in those preclinical (silent) stages of 
AD. However, these abnormalities do not seem to be accompanied by a clear cognitive 
marker. In fact, there is still no full consensus on the clinical significance of possible entities 
such as the Subjective Cognitive Decline (SCD) [8]. 
SCD refers to a self perception of progressive deterioration of cognitive abilities 
independently of the objective performance on neuropsychological tests. Since cognitive 
complaints are heterogeneous and their expression could be affected by various factors 
(e.g. normal aging, personality traits, depression, drug side effects, neurological disorders, 
etc.), SCD is not necessarily present in all prodromal cases. Nevertheless, both cross-
sectional [9–11] and longitudinal studies [12–14] have provided strong evidence of SCD 
occurring at preclinical stage of AD. Indeed, the combination of SCD and CSF biomarkers 
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has also proved to be the best predictors of clinical progression from preclinical to 
prodromal and dementia stages [15]. For all these reasons, during the last decades there 
has been an increasing interest in the study of SCD as a potential early sign of cognitive 
decline and future progression to AD [16,17]. 
To assess the potential usefulness of SCD for clinical trials, the Subjective Cognitive Decline 
Initiative (SCD-I) has recently agreed to a common terminology and research procedures to 
identify individuals with SCD at risk of preclinical AD [18]. The SCD-I aims at knowing 
whether the self-experience of decline in cognition may represent the first symptomatic 
manifestation of AD. In order to demonstrate that, some common specific features are 
needed to better establish the profile of SCD. Thus, the SCD-I recommended to collect 
information regarding features such as settings in which cognitive complaints are 
expressed, association of SCD with medical help seeking, number of years and age at onset 
of SCD, subjective decline in memory and non-memory domains, and association of SCD 
with experience of impairment. In addition, the SCD-I proposed a set of particular features 
which could be helpful to identify individuals at risk of clinical progression. Those features 
include a more acute subjective memory decline than any other cognitive domain, onset of 
complaints within the last 5 years, age at onset over 60 years, worries about SCD, and 
feeling of worse performance than other people from the same age group. This set of 
features makes up a more severe form of SCD referred to as SCD Plus. This new category 
could allow us to explain the transition from a non-symptomatic stage to the first 
symptomatic manifestation of AD. 
In the present study we have assessed the validity of different subtypes of SCD and to 
determine its association with neuropsychiatric and cognitive performance. Furthermore, 
we have examined the risk of SCD for objective cognitive decline rather than subjective 
one. SCD-I´s guidelines [18] were used in order to analyze whether specific features of SCD 
were more related to cognitive impairment. 
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4.4. Materials and methods 
4.4.1. Participants 
Subjects participating in this study were part of the Vallecas Project cohort, a community-
based prospective study on early detection of AD, recently launched by CIEN Foundation 
and Queen Sophia Foundation (Madrid, Spain) [19].  
Inclusion criteria for the Vallecas Project included community-dwelling individuals from 70 
to 85 years of age without dementia or any other mental disorder impeding daily 
functioning at the beginning of the study. After participants signed proper consent forms, 
trained neurologists and neuropsychologists conducted structured clinical interviews in 
order to collect demographic, clinical and cognitive data. The complete visit was usually 
carried out within four hours, with convenient breaks.  
Baseline and follow-up diagnosis were agreed between neurologists and 
neuropsychologists at consensus meetings. Every participant was independently diagnosed 
according to clinical criteria and taking into account age, gender, cognitive reserve, 
functional information, and cognitive scores. In all cases, cognitively healthy subjects were 
given a score of 0 in the global Clinical Dementia Rating (CDR). Criteria from NIA-AA [2] 
were used to diagnose core MCI.  
For the purposes of this study, 608 individuals were enrolled. To be considered eligible for 
participating in this investigation, subjects had to have been diagnosed as cognitively intact 
at baseline as well as they had to have completed all questions about subjective 
complaints. After follow-up, 41 participants progressed to MCI. 
4.4.2. Subjective Cognitive Decline assessment 
Questions on cognitive concerns were coded according to the guidelines suggested by SCD-I 
[18]. Responses to every question were directly provided by the participants since family 
members were not available in all cases. Cognitive complaints were assessed twice and 
independently in the Vallecas Project. First, during the neurological interview participants 
were asked the following nine yes/no-type questions regarding specific cognitive 
complaints: 1) Are you easily distracted? 2) Do you get lost in familiar surroundings or have 
trouble finding your way when driving? 3) Do you often forget recent information or 
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events? 4) Do you often forget autobiographically information? 5) Do you have trouble 
recognizing objects or faces? 6) Do you have word-finding difficulties for people’s names or 
common words? 7) Do you understand simple verbal and written instructions? 8) Do you 
have difficulty driving, managing finances or planning daily activities? 9) Do you have 
difficulty sequencing movements (e.g. taking the necessary steps to prepare a bath)?  
Second, during the neuropsychological interview participants also completed an ordinal 
scale of cognitive complaints (SCD scale) composed of four items with four points each 
(ranged 0-3). This SCD scale addressed the following questions: a) How do you perceive 
your memory in comparison with that of others of your age? (with four response 
alternatives scoring “3-bad”; “2-somewhat worse”; “1-somewhat better”; “0-excellent”); b) 
How do you perceive your memory today compared with your young adulthood? (“0-
better”; “1-equal”; “2-somewhat worse”; “3-much worse”); c) Do you perceive your 
memory today is worse than compared with ten years ago? (“0-no”; “1-a little worse”; “2-
somewhat worse”; “3-much worse”); d) Do you perceive your memory today is worse than 
compared with one year ago? (“0-no”; “1-a little worse”; “2-somewhat worse”; “3-much 
worse”). The sum of these items resulted in a total score of cognitive concerns ranging from 
0 to 12 (lower scores meaning fewer complaints). Information concerning age at and years 
of SCD onset, as well as worries associated with SCD, were also collected in the same 
neuropsychological interview.  
Based on information obtained in both clinical interviews, SCD was operationally defined as 
the self-rated presence of cognitive deterioration using two criteria: i) a positive response 
to any yes/no-type complaint question, and ii) scores above 1 on the SCD scale. Therefore, 
according to both criteria, the sample was classified in three different SCD groups: i) No 
Complaints group (NCg); ii) Subjective Cognitive Decline group (SCDg), involving some self-
reported cognitive complaint; and iii) Subjective Cognitive Decline Plus group (SCD-Pg), 
when memory and any other cognitive complaint was expressed and all the rest of the 
main criteria proposed by the SCD-I were fulfilled [18]. 
4.4.3. Objective Cognitive assessment 
A comprehensive neuropsychological battery was administered to assess all relevant 
cognitive domains. Overall, six tests were used at baseline: Mini Mental State Examination 
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(MMSE) [20]; Rey-Osterrieth Complex Figure (ROCF) [21,22]; Free and Cued Selective 
Reminding Test (FCSRT) [23–25]; Lexical and Semantic Verbal Fluency [26]; Clock Drawing 
Test [27]; and Digit Symbol Coding [28]. Moreover, Functional Activities Questionnaire 
(FAQ) [29] and Clinical Dementia Rating (CDR) [30] complemented the neuropsychological 
battery. 
For statistical purposes, individual indexes of ROCF (i.e. time and score of copy, and 
immediate and delayed recall) and FCSRT (i.e. total performance within each trial; free and 
total immediate recall; and free and total delayed recall) were separately assessed. 
4.4.4. Neuropsychiatric assessment 
The neurological protocol included three questions about self-reported depression (Do you 
feel sad, lonely and depressed most of the time?), anxiety (Do you feel worried and anxious 
most of the time?), and apathy (Do you feel a lack of emotion, motivation or interest in 
hobbies and previously activities enjoyed?). These three symptoms were collected as 
dichotomous questions (coded yes/no). In addition, Geriatric Depression Scale (GDS) [31] 
and State-Trait Anxiety Inventory (STAI) [32] were also administered as part of the 
neuropsychological battery. 
4.4.5. Apolipoprotein E ε4 genotyping 
APOE gene polymorphism status was studied with total DNA isolated from peripheral blood 
following standard procedures. Genotyping of APOE polymorphisms (rs429358 and rs7412) 
was performed by Real-Time PCR [33]. APOE was coded 1 for the APOE ε4 carriers, and 0 
for non-carriers. 
4.4.6. Statistical analyses 
We performed a preliminary analysis of demographic, cognitive and clinical variables at 
baseline to find out their distribution and possible associations with SCD. Diagnoses at 
baseline and follow-up, as well as conversion rate to MCI, were relevant variables to study 
the relationship between SCD groups and cognitive status. 
Associations between categorical variables were analyzed with the Pearson´s χ2 and 
Fisher´s test when appropriate. In addition, due to differences of sample size groups and 
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that most variables were not adjusted to the parametric assumptions, analysis of variance 
was based on non-parametric Kruskal-Wallis tests. SCD groups were treated as an 
independent variable with three levels (NCg, SCDg, and SCD-Pg) whereas demographic, 
cognitive and neuropsychiatric data at baseline were used as dependent variables. 
Although all neuropsychological variables were analyzed, special emphasis in memory tests 
was made. A multivariate-adjusted Cox proportional hazard regression models was used to 
study the relationship between SCD groups at baseline and conversion rate to MCI. Time to 
event was calculated as date of entry into the study to date of MCI diagnosis. Overall, 
according to the previous analyses, several covariates were adjusted for studying the 
impact of SCD upon progression to MCI in three consecutive models: a) Model 1: age, 
gender and years of education; b) Model 2: Model 1 covariates plus depression, anxiety and 
apathy; c) Model 3: Model 2 covariates plus FCSRT free immediate recall, FCSRT free 
delayed recall and APOE. A final model was calculated by retaining the covariates that met 
the following two conditions: first, they were found significant in any of the three previous 
models, and second, the minimum number of them had to explain the most part of 
conversion rate´s variance. These covariates proved to be gender, FCSRT free immediate 
recall and APOE. All the results were presented as hazard ratio (HR) with a 95% confidence 
interval (CI). 
We used 2-sided significance tests for all analyses, with statistical significance set at p-value 
< 0.05. The proportional hazards assumption was assessed for all variables using the 
Schoenfeld residuals graphs. Neither violation of assumptions in individual variables nor in 
the global model was found. All statistical analyses were performed using R version 2.14.2 
[34]. 
4.5. Results 
Participants were followed up for a mean of 13.1 months (SD 1.3, median 12.9, range 10.7-
22.4). During this time, 41 volunteers developed MCI (6.7% of the total sample). Regarding 
cognitive concerns, 69.6% of participants reported some type of complaint in any of the 
nine yes/no type questions. As expected, SCD scale showed significant differences between 
groups, especially when compared NCg and SCD-Pg. In addition, the correlation between 
the baseline score of the SCD scale and the follow-up SCD score showed a positive 
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correlation (ρ=0.66; p<0.001). This outcome was taken as indicative of an appropriate 
stability of cognitive concerns. 
Table 4.1. Baseline characteristics of the study sample by Subjective Cognitive Decline 
groups. 
 
Total Sample 
(n=608) 
NCg 
(n=185) 
SCDg 
(n=370) 
SCD-Pg 
(n=53) p-value 
Post-
hoc 
 Mean SD Mean SD Mean SD Mean SD 
Age (years) 74.14 3.83 74.23 3.96 74.21 3.83 73.32 3.36 0.344  
Education (years) 11.03 6.66 11.00 6.72 11.18 6.73 10.10 5.94 0.530  
Gender 62% Female 64% Female 59% Female 75% Female 0.079  
APOE ε4 (%) 17.7 16.5 16.7 29.4 0.074  
FAQ 0.42 0.80 0.22 0.54 0.48 0.86 0.68 0.94 < 0.001 b 
SCD       
SCD score 5.07 2.00 3.92 1.78 5.46 1.82 6.46 2.00 < 0.001 a,b,c 
Years of onset 7.30 6.13 6.58 6.86 8.10 6.06 3.28 1.35 < 0.001 a,b,c 
Age at onset 66.88 7.13 67.90 7.71 66.03 7.15 70.04 3.73 < 0.001 c 
Neuropsychiatric symptoms        
GDS 1.63 2.22 1.05 1.69 1.75 2.29 2.89 2.75 < 0.001 a,b,c 
STAI state 14.33 8.73 12.39 8.51 14.65 8.40 18.75 9.89 < 0.001 a,b 
STAI trait 17.20 9.77 14.16 8.20 17.70 9.97 24.17 9.30 < 0.001 a,b,c 
Depression (%) 21.2 7.0 26.2 35.8 < 0.001 a,b 
Anxiety (%) 15.5 4.3 19.2 28.3 < 0.001 a,b 
Apathy (%) 10.0 1.6 11.9 26.4 < 0.001 a,b,c 
Cognitive performance       
MMSE 28.61 1.49 28.60 1.63 28.61 1.43 28.57 1.45 0.734  
Clock Drawing Test 9.33 1.12 9.43 0.99 9.31 1.16 9.12 1.27 0.326  
ROCF time of copy 249.09 117.81 247.46 114.83 250.31 120.83 246.19 108.38 0.986  
ROCF copy 30.05 6.67 29.60 7.55 30.24 6.32 30.32 5.78 0.929  
ROCF immediate recall 12.68 6.17 12.82 6.33 12.81 6.14 11.25 5.80 0.186  
ROCF delayed recall 12.51 6.26 12.66 6.35 12.62 6.28 11.25 5.79 0.305  
FCSRT trial 1 12.57 2.65 12.97 2.61 12.52 2.59 11.55 2.98 0.001 b 
FCSRT trial 2 13.81 2.16 14.09 1.98 13.81 2.08 12.85 2.90 0.003 b 
FCSRT trial 3 14.64 1.70 14.75 1.55 14.69 1.58 13.87 2.57 0.008  
FCSRT free immediate 23.62 6.30 24.69 6.68 23.43 6.05 21.12 5.92 0.002 b 
FCSRT total immediate 41.09 5.55 41.81 5.41 41.03 5.52 39.00 5.74 0.002 b 
FCSRT free delayed 9.48 2.59 9.93 2.54 9.45 2.54 8.10 2.64 < 0.001 b,c 
FCSRT total delayed 14.33 1.82 14.46 1.78 14.35 1.81 13.75 1.90 0.018 b 
Phonemic Verbal Fluency 36.32 11.60 36.66 12.31 36.11 11.39 36.53 10.73 0.806  
Semantic Verbal Fluency 18.59 4.75 50.85 10.30 48.59 9.17 48.08 9.15 0.079  
Digit Symbol Coding 19.20 7.53 19.93 8.42 18.82 7.17 19.23 6.60 0.413  
CDR sum of boxes 0.11 0.21 0.08 0.19 0.10 0.20 0.23 0.27 < 0.001 b 
Annual conversion rate to 
MCI (%) 
6.7 4.9 5.6 18.9 0.001 b,c 
APOE: Apolipoprotein E; CDR: Clinical Dementia Rating; FAQ: Functional Activities Questionnaire; FCSRT: Free and Cued 
Selective Reminding Test; GDS: Geriatric Depression Scale; MCI: Mild Cognitive Impairment; MMSE: Mini Mental State 
Examination; NCg: No Complaints group; ROCF: Rey-Osterrieth Complex Figure; SCD: Subjective Cognitive Decline; SCDg: 
Subjective Cognitive Decline group; SCD-Pg: Subjective Cognitive Decline Plus group; SD: Standard Deviation; STAI: State-Trait 
Anxiety Inventory. 
Post-hoc analyses: a = NCg vs SCDg; b = NCg vs SCD-Pg; c = SCDg vs SCD-Pg. 
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Table 4.1. summarizes the descriptive statistics of the total sample and the three SCD 
groups at baseline. No differences in age or years of education among groups were found. 
Nevertheless, there was a trend for significance concerning gender and APOE status, being 
female and ε4 carrier more frequent for SCD-Pg than for other groups. SCDg and SCD-Pg 
reported more depression, anxiety, and apathy compared to NCg. Furthermore, GDS and 
STAI scores were also significantly lower in NCg. Differences in apathy, GDS, and STAI trait 
were also found between SCDg and SCD-Pg. Overall, these results highlighted that 
neuropsychiatric symptoms were more frequent in both SCD groups compared to NCg; and 
these symptoms were especially marked for SCD-Pg. Regarding cognitive assessment, 
statistical differences between groups were only found for instrumental activities of 
everyday (FAQ), verbal episodic memory (FCSRT), and clinical rating (CDR sum of boxes). 
Interestingly, the SCD-Pg showed the worst cognitive performance, while 
neuropsychological tests did not significantly differ between NCg and SCDg. Finally, 
conversion rate to MCI was significant especially high for SCD-Pg (18.9%) compared to NCg 
(4.9%) and SCDg (5.6%). 
A specific analysis between SCD-Pg converters (n=10; 19%) and SDC-Pg non-converters 
(n=43; 81%) was developed with the aim of finding out what variables could directly 
influence upon the diagnosis of MCI. In this case, due to the small sample size, a robust 
bootstraping procedure was carried out along with the standard non-parametric analysis 
(Table 4.2.). Significant differences were found in SCD scale, where converters reported 
more concerns than non-converters. Surprisingly, no differences were found in 
neuropsychiatric symptoms, neither depression nor anxiety questionnaires. Among 
cognitive variables, several indexes of FCSRT (trial 2, and free immediate and delayed recall) 
differed between groups. Figure 4.1. shows the magnitude of the differences between non-
converters and converters through three types of variables: subjective cognitive 
complaints, objective cognitive performance and psychiatric variables. All these results 
suggested that subjective and objective cognitive variables, but not psychiatric ones, were 
actually involved in conversion from SCD-Pg to MCI. 
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Table 4.2. Baseline comparisons between SCD-Pg non-converters and SCD-Pg converters. 
 
Non Converters 
(n=43) 
Converters 
(n=10) p-value 
 Mean SD Mean SD 
Age (years) 73.05 3.27 74.50 3.66 0.230 
Education (years) 9.89 5.76 11.00 6.96 0.608 
Gender 77% Female 70% Female 0.692 
APOE ε4 (%) 24.39 50.00 0.173 
FAQ 0.60 0.95 1.00 0.82 0.088 
SCD   
SCD score 6.19 1.68 8.00 3.06 0.033 
Years of onset 3.23 1.34 3.50 1.43 0.568 
Age at onset 69.81 3.65 71.00 4.11 0.356 
Neuropsychiatric symptoms    
GDS 2.65 2.68 3.90 2.96 0.146 
STAI state 18.09 9.56 21.60 11.29 0.466 
STAI trait 23.53 9.52 26.90 8.20 0.339 
Depression (%) 32.56 50.00 0.465 
Anxiety (%) 23.26 50.00 0.123 
Apathy (%) 25.58 30.00 0.999 
Cognitive performance    
MMSE 28.65 1.41 28.20 1.62 0.443 
Clock Drawing Test 9.28 1.11 8.45 1.71 0.152 
ROCF time of copy 257.63 108.30 197.00 99.11 0.053 
ROCF copy 30.35 5.63 30.20 6.70 0.732 
ROCF immediate recall 11.43 5.70 10.50 6.44 0.439 
ROCF delayed recall 11.69 5.80 9.40 5.66 0.165 
FCSRT trial 1 11.84 2.57 10.30 4.27 0.448 
FCSRT trial 2 13.42 2.00 10.40 4.65 0.038 
FCSRT trial 3 14.28 1.65 12.10 4.61 0.068 
FCSRT free immediate 21.95 5.70 17.11 5.56 0.040 
FCSRT total immediate 39.53 5.42 36.44 6.84 0.303 
FCSRT free delayed 8.42 2.63 6.56 2.19 0.045 
FCSRT total delayed 13.91 1.97 13.00 1.32 0.080 
Phonemic Verbal Fluency 36.05 10.81 38.60 10.68 0.517 
Semantic Verbal Fluency 49.16 9.02 43.40 8.59 0.106 
Digit Symbol Coding 19.21 6.35 19.30 7.97 0.847 
CDR sum of boxes 0.198 0.27 0.35 0.24 0.080 
APOE: Apolipoprotein E; CDR: Clinical Dementia Rating; FAQ: Functional Activities Questionnaire; FCSRT: Free and Cued 
Selective Reminding Test; GDS: Geriatric Depression Scale; MMSE: Mini Mental State Examination; ROCF: Rey-Osterrieth 
Complex Figure; SCD: Subjective Cognitive Decline; SD: Standard Deviation; STAI: State-Trait Anxiety Inventory. 
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Figure 4.1. Effect size of individual variables at baseline on conversion from SCD Plus to MCI. 
This graphic represents the effect size of the individual variables at baseline on the profiles of SCD-Pg non-converters and SCD-
Pg converters. Variables are clustered in three categories: i) subjective cognitive complaints (blue), ii) objective cognitive 
performance (red), and iii) psychiatric symptoms (green). As shown, SCD score had the largest effect size (Cohen´s d=0.94) 
among groups followed by cognitive performance variables, especially free recall of verbal information. Magnitude of 
depression and anxiety scores resulted less important to discriminate SCD-P subjects at risk of conversion to MCI. 
FCSRT: Free and Cued Selective Reminding Test; GDS: Geriatric Depression Scale; MMSE: Mini Mental State Examination; 
ROCF: Rey-Osterrieth Complex Figure; SCD: Subjective Cognitive Decline; STAI: State-Trait Anxiety Inventory. 
In unadjusted Cox proportional hazard regression models, SCDg had about a 32% increased 
risk of progression to MCI compared to NCg, whereas the increased risk for SCD-Pg was 
about 360%. Kaplan-Meier plots showed clear differences in risk by SCD-Pg after 14 months 
of follow-up (Figure 4.2.). On the other hand, adjusted Cox regression models were also 
conducted to control the influence of socidemographic, neuropsychiatric, 
neuropsychological and genetic variables upon SCD and its association with conversion to 
MCI. As shown in Table 4.3., after adjustment for all fitted models SCDg did not display 
differences compared to NCg. However, SCD-Pg showed a significant high risk of MCI, 
especially in Model 1 when control was only made for age, gender and education (HR 5.44, 
95% CI = 2.16-13.75). Additional adjustment for depression, anxiety and apathy (Model 2) 
yielded similar results for SCD-Pg. Finally, additional adjustment for both free immediate 
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and delayed memory, as well as APOE genotyping (Model 3), only marginally decreased the 
HR values for SCD-Pg. Hence, as expected, memory performance (HR 0.83; 95% CI 0.76–
0.91; p-value < 0.001) was the most significant predictor of progression to MCI, in such a 
manner that the lower the memory score, the higher the risk to convert to MCI. 
In order to confirm these outcomes, we conducted a more parsimonious final model 
controlling for gender, FCSRT free immediate recall and APOE as covariates. The reason for 
considering these three covariates and no others was because only those ones proved to be 
significant in their respective models. As a result, in our final model, the multivariate 
adjusted HRs in participants who reported SCD-P were 4.17 (95% CI: 1.52–11.43) compared 
to NCg, while SCDg did not differ from NCg. The value of the determination coefficient was 
0.13, almost the same as Model 3 with 9 covariates. This small value could indicate that 
other variables apart from SCD account for the rate of conversion to MCI. 
 
Figure 4.2. Kaplan-Meier survival curves for unadjusted rates of MCI by SCD groups. SCD-Pg 
shows the highest risk of conversion to MCI. 
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Table 4.3. Cox proportional hazard regression models of conversion rate to MCI with 
additional adjustment for potential mediators. 
HR (95% CI) 
Adjustment Model NCg SCDg SCD-Pg 
Model 1 1 [Reference] 1.30 (0.60-2.82) 5.44 (2.16-13.75)*** 
Model 2 1 [Reference] 0.10 (0.49-2.48) 4.40 (1.65-11.72)** 
Model 3 1 [Reference] 0.89 (0.35-2.22) 2.92 (0.96-8.86) 
Final Model 1 [Reference] 1.17 (0.52-2.65) 4.17 (1.52-11.43)** 
    
Model 1: adjusted for age, gender and education (years). R2=0.04 
Model 2: adjusted for Model 1 covariates and depression, anxiety and apathy. R2=0.05 
Model 3: adjusted for Model 2 covariates and FCSRT free immediate, FCSRT free delayed and APOE. R2=0.14 
Final Model: adjusted for sex, FCSRT free immediate and APOE. R2=0.13 
CI: Confidence Interval; FCSRT: Free and Cued Selective Reminding Test; HR: Hazard Ratio; NCg: Non Complaint group; SCDg: 
Subjective Cognitive Decline group; SCD-Pg: Subjective Cognitive Decline Plus group. 
** p<0.01; *** p<0.001 
4.6. Discussion 
The role of the clinical significance of SCD in the transition from a cognitively intact stage to 
MCI has been analyzed in a cohort that was followed-up approximately for 13 months. 
According to the guidelines proposed by the SCD-I [18], subjects were classified depending 
on their cognitive concerns. Thus, 69.6% of the sample reported some type of complaint, 
what is slightly higher than the common prevalence of SCD in the general population [35], 
but consistent with this age group [36,37]. Finally, based on self-reported complaints, three 
different groups of SCD were established (NCg, SCDg, and SCD-Pg). 
Although no statistical differences were found with regard to gender and APOE, a trend for 
significance was obtained between groups. Indeed, female gender and ε4 carrier were 
more associated with SCD-Pg than the two other groups. Since both features have been 
proved to increase the risk of AD [38], cognitive complaints could be somehow related to 
them. This relationship might occur at preclinical stages, before anosognosia and objective 
impairment appear. Nevertheless, to isolate the role of SCD as early sign of progression to 
MCI, gender and APOE were controlled in further analysis. 
Potential differences between groups were analyzed using neuropsychiatric and cognitive 
variables. Symptoms of depression, anxiety and apathy were strongly associated with SCD, 
and they were able to identify the NCg from the rest of SCD groups. This finding has been 
highlighted in a large number of studies [39–41], suggesting that complaints correlate more 
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closely to depression and anxiety than cognitive performance; thus, they could play a 
mediating role between mood and cognitive status [42]. However, our results did not 
support the fact that the combination of SCD and specific psychiatric symptoms increased 
the risk of conversion to MCI. Indeed, according to the Cox regression Model 2, psychiatric 
covariates neither resulted significant nor provided additional information to SCD. Perhaps, 
the explanation of these outcomes has to do with the fact that SCD would begin to decline 
the cognitive status some years before that of psychiatric symptoms. This explanation is 
somehow consistent with the literature since while depression and anxiety are mainly 
suggested to be risk factors for dementia in prodromal AD [43–45], SCD is proposed to be 
an early sign of MCI in preclinical stages [46,47]. Otherwise, although cognitive measures 
were related to SCD in a lesser degree than neuropsychiatric variables as expected 
[36,48,49], low memory performance at baseline allowed to better differentiate SCD-Pg. In 
addition, and most importantly, controlling for depression, anxiety and apathy, episodic 
memory performance was associated with a faster rate of MCI conversion in individuals 
with SCD Plus.  
In line with previous studies that have found an increased risk of AD in healthy subjects 
who reported SCD seven years earlier [12–14], our annual conversion rate to MCI for 
subjects with SCD Plus at baseline was almost 20%. This outcome was significant and 
differed from SCDg, which displayed a conversion rate of 5.6%. Indeed, while the HR 
obtained for SCDg were similar to other studies [50,51], and it did not significantly differ 
from NCg, individuals who reported SCD Plus had a higher risk of developing MCI (HR=4.17) 
compared to those subjects without complaints. In addition, the inclusion of gender, 
memory performance and APOE genotyping in the survival analyses did not decrease the 
predictive power of the SCD-Pg. 
Taking into account that the follow-up period covered less than two years, these results 
indicate that some particular features associated with cognitive complaints (i.e. onset of 
complaints within the last 5 years, age at onset over 60 years, worries associated with 
complaints, and feeling of worse performance than other people from the same age group) 
may identify those individuals at high risk of fast conversion to MCI. These findings have 
paramount implications for clinical settings. For instance, cognitive training programs 
should be implemented in subjects meeting all features of SCD Plus proposed by SCD-I [18]. 
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Regarding the weaknesses of the present study, it is recognized that the short follow-up 
could be seen as an important limitation. Nevertheless, we consider that the elapsed time 
is enough to examine the main objective of this paper, that is, to seek for the minimum 
time required for conversion to MCI in healthy subjects who report SCD. Our outcomes 
suggest the existence of different rates of conversion to MCI that depend on the features of 
SCD. Thus, SCD-Pg seems to exhibit a larger and faster risk of MCI. Given that the Vallecas 
Project is still in progress, the association between SCD and MCI shall be analyzed in next 
visits to explore deeply our present results. In addition, since the SCD data were collected in 
a volunteer sample of elderly people, generalization of results should be treated with 
caution. 
Although biomarkers have a clear value for diagnosis of early AD, we should not look down 
on the complementarity that behavioral markers hold for the disorder. Age-dependent 
neuropsychological and cognitive assessment has provided evidence that a decline in speed 
of information processing, executive function (working memory, task switching, inhibitory 
function) and reasoning goes along with normal aging. Longitudinal studies assessing 
cognitive function prior to dementia have also steadily shown a gradual cognitive decline in 
episodic memory as well as non-memory domains up to a decade before dementia onset. 
Interestingly, the preclinical path suggests a long and slow rate of presymptomatic changes 
as well as a period of acceleration of performance decline that may begin several years 
before MCI onset. However, current neuropsychological tests do not seem to be sensitive 
enough to discriminate SCD converters and non-converters which lead to the necessity of 
developing more sensitive tools for these preclinical stages of the disease. 
Self-report of subtle cognitive decline, even in the absence of significant objective 
impairment on testing, may predict future decline in older individuals. Subjects who report 
SCD Plus might need special attention in terms of an early cognitive or pharmacological 
intervention. Thus, combining biomarkers with measures sensitive to detect very subtle 
cognitive decline in longitudinal studies of older individuals could be extremely useful in 
coming years. For instance, it will be needed to prove whether individuals at preclinical 
stage with subjective complaints and positive biomarkers have a major risk of AD 
progression. If so, since at this preclinical phase the brain is supposed to be recoverable, 
the effectiveness of new clinical trials with AD modifying therapies should be examined. 
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4.7. Summary of conclusions 
1. Self-report of cognitive decline may predict future cognitive decline in older individuals. 
2. Mainly five specific features associated with SCD (SCDplus features) may help to identify 
individuals with a high risk of conversion to MCI. 
3. These individuals need frequent clinical monitoring. 
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5.1. Comment 
Subjective Cognitive Decline (SCD) during preclinical phase of Alzheimer´s Disease (AD) 
refers to a self-experienced persistent decline in cognitive abilities in comparison with a 
previously normal status and independently of the objective performance on 
neuropsychological tests (Jessen et al., 2014). This is an important construct because is 
supposed to be a sign of the preclinical AD stage (Figure 5.1.). During the past decades, 
researchers have analyzed the clinical value of SCD as a predictor of the onset of future AD 
in older adults (Rabin et al., 2017). Thus, a recent meta-analysis has shown that, 
independently of the objective memory performance, almost 25% of older adults who 
report SCD will progress to prodromal AD four years later. In addition, the rate of 
progression to dementia among those individuals who report SCD is two-fold during a 5-
year follow-up period (Mitchell et al., 2014). 
 
Figure 5.1. Theoretical temporal dynamic of objective and subjective cognitive decline in AD 
continuum. 
This graphic represents the hypothetical differences in AD progression over time between Subjective Cognitive Decline (SCD) 
and Objective Cognitive Performance (OCP). At final stage of preclinical AD, SCD seems to be a better marker than OCP. As 
disease progresses, cognitive performance tend to decrease and at prodromal stage both SCD and OCP are below cutoff. 
However, at last phase of prodromal AD SCD usually disappear leading to a deficit of self-awareness about the own disabilities 
namely anosognosia. 
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To increase the potential usefulness of SCD the international working group called 
Subjective Cognitive Decline Initiative (SCD-I) agreed to a common framework and research 
procedures to study the role of SCD as a preclinical marker of preclinical AD (Jessen et al., 
2014). As a result of these indications, cognitively healthy individuals who accomplish 
certain conditions of SCD have been proved to have a four times higher risk for progressing 
to prodromal AD in just one-year compared to those subjects without complaints 
(Fernández-Blázquez et al., 2016). Despite its outstanding clinical value, recently the SCD-I 
also pointed out some limitations of SCD when it comes to investigate this concept 
(Molinuevo et al., 2017; Rabin et al., 2015). These limitations could be summarized in three 
different blocks: 
1. Terminology has not been homogeneous across studies and terms such as 
“subjective memory complaints”, “subjective cognitive complaints”, “subjective 
cognitive decline” or “subjective memory impairment” have been used 
interchangeably to refer to the same underlying concept. This lack of consensus on 
a single definition of SCD might affect to the comparison of findings from different 
investigations. 
2. Methodology and tools to assess SCD are also heterogeneous what involves the 
context in which the sample is recruited (clinical versus community-based), the 
mode of administration of measures (structured interview conducted by a examiner 
versus self-reported questionnaires), the cognitive domains that must be examined 
(memory versus non-memory domains), the number of items to be used (one or 
two questions versus scales with a large number of items), the way to respond the 
questions (opened questions versus multiple choice), and the timeframe to collect 
data (shorter versus longer periods of time). This heterogeneity may lead to 
contradictory results of the studies. 
3. Operational criteria and cutoffs to consider who is truly reporting SCD have been 
totally different across studies. 
This heterogeneity in definitions, in approaches for measuring SCD, and in operational 
criteria emphasizes the necessity of searching for shared terminology and common 
frameworks of evaluation. To settle these limitations the SCD-I also proposed some 
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recommendations (Molinuevo et al., 2017). As a first step, it is important to select the most 
appropriate measures that should be related to the characteristics of the target population. 
Cognitive complaints may have different implications depending on the research context 
where they are gathered. For instance, the concerns on SCD in clinical samples may be 
higher than in community-dwelling individuals. Moreover, it would be suitable to rely on 
tools with adequate psychometric properties for the reference population. As a second 
step, the SCD´s measures must have appropriate content coverage regarding to the target 
population. In this way, all items should be well-written and understandable, avoiding 
double meanings and inquiring for difficulties often found in daily life. In a third step, 
measures should explore different cognitive and non-cognitive domains because the 
earliest symptoms of AD may affect beyond memory. In the fourth step, the response 
options for all measures should be selected depending on the aim of our study. When the 
purpose is to distinguish between groups, dichotomous items may be enough. However, if 
we are interested in monitoring the change of SCD over time, ordinal response options 
should be preferred. Finally, another critical point is to determine the reference period of 
time in which we want to examine the SCD. Generally, inquiring over short periods of time 
(no longer than one year) allow us to reduce problems with retrospectively recall or 
estimation of SCD. Nevertheless, we can of course ask for longer periods if we want to 
study the progression of SCD through the lifetime. 
However, as far as we know, there is another crucial limitation with regard SCD that has not 
been properly considered yet. This issue is related to the concept of the temporal stability 
of complaints over time. In psychometrical terms, when we are measuring subjective 
variables like SCD we are actually obtaining two different types of information: i) the 
construct of interest (i.e. SCD in our case); and ii) errors of measurement which comprised 
the error variance and include information regarding other irrelevant constructs (e.g. 
depressive symptoms associated with a particular complaint, personality traits, etc.) as well 
as short-term fluctuations due to shifts in self-perception itself. Thus, when repeated 
subjective measurements are collected from an individual the scores on two different 
occasions may be quite different (Nesselroade and Salthouse, 2004). If this occurs along the 
majority of subjects, then it means that the subjective variable does not have enough 
internal consistency. In other words, if two longitudinal measures are quite different and 
they do not converge, which one is the real to characterize the individual? This lack of 
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temporal stability, which can affect preferably to subjective measures rather than objective 
performance, represents an important bias to investigation. Thus, if a construct do not 
probe to be stable enough over time it should not be considered as a target for research. 
Only demonstrating that SCD is a robust and stable concept it could become a reliable 
preclinical marker for AD. 
To prove the stability of SCD, it is necessary to harmonize a protocol to gather all relevant 
information about cognitive complaints and to compare longitudinally the responses of the 
individuals. Specifically, we suggest collecting information by means of different 
approaches to ensure the greatest possible internal consistency. An interesting position 
would be to gather self-perceived data using two procedures: a face-to-face interview with 
a healthcare professional and a self-administered questionnaire of cognitive complaints. 
Likewise, it should be desirable combining both open-ended questions and structured 
scales in order to measure different features of SCD. The use of questionnaires is highly 
recommended to quantify SCD somehow and to monitor the progression of cognitive 
complaints over time. Additionally, a multiple choice approach should vary from dichotomic 
to ordinal Likert-type scales to grasp the dimensionality of SCD in the best way possible. 
Regarding the content of SCD to be collected, it should be measured clinical details of the 
self-experienced cognitive decline. Variables such as age at onset, time of progression, 
memory performance compared to other people, concerns associated with SCD, and 
frequency of particular cognitive complaints are relevant data that must be carefully 
obtained. Moreover, SCD should not be examined in isolation to examine the effect of 
complaints upon AD. Demographic variables such as age, gender, and education, as well as 
medical and lifestyle variables can be gathered very easily by means of a survey. These 
variables have the greatest interest due to their possible implication in the expression of 
SCD. Additionally, objective cognitive performance and diagnosis are critical to establish the 
current stage of an individual in the continuum of AD and the relationship between SCD 
and risk of developing MCI and AD. Finally, neuropsychiatric variables should be collected 
as well because of their mediator role between SCD and cognitive decline. 
In conclusion, self-report of subtle cognitive decline has been proposed to appear at the 
end of the preclinical phase of AD even in the absence of significant objective impairment 
detectable on standardized neuropsychological assessment (Rabin et al., 2017). This fact 
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explains why SCD is gaining an increasing prominence in neurodegenerative research as a 
potential marker for future MCI due to AD. In any event, this construct must deal with some 
limitations that have been already pointed out by the SCD-I (Molinuevo et al., 2017). 
However, in our opinion SCD has to face up to another challenge not brought to the table 
so far that is related to the temporal stability of complaints over time. If SCD does not 
probe to have enough internal consistency, then this construct cannot be considered as a 
reliable preclinical marker for AD. 
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6.1. Summary of objectives 
1. To examine the role of SCD as a possible precursor for MCI development. 
2. Since, single point measurements of SCD could result in high variability, our second goal 
is to look for a SCD stable data. 
3. To obtain robust results for this measure we have carried out a longitudinal study. 
4. To evaluate the clinical significance of SCD during the development of cognitive 
impairment through AD continuum. 
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6.2. Abstract 
Background: Early intervention to prevent, or delay, the transition from healthy cognition 
to cognitive impairment in older adults is an important goal. In this way, it is critical to find 
sensitive, reproducible and early markers to use low cost methods for the detection of that 
transition. One of those early markers for symptomatic manifestation of AD is Subjective 
Cognitive Decline (SCD). 
Objective: To examine the internal consistency of the concept of SCD and to evaluate its 
clinical significance on the progression through the Alzheimer´s disease continuum. 
Methods: 1,091 cognitively healthy individuals from the Vallecas Project´s cohort were 
followed for three years. Cognitive complaints were systematically collected and analyzed 
along with clinical data. All participants were classified in three groups at every visit based 
on specific features of their complaints. 
Results: Concordance analyses showed a good agreement in longitudinal classification of 
Subjective Cognitive Decline. The Multi-state Markov Model highlighted a unidirectional 
transition from the status of no cognitive complaints to Subjective Cognitive Decline. 
Interestingly, a more severe condition of Subjective Cognitive Decline, namely Subjective 
Cognitive Decline Plus, showed the highest risk of progression to mild cognitive impairment. 
Conclusions: The concept of Subjective Cognitive Decline is stable over time when it is 
operationally defined and consistently assessed. It provides not only a fast identification of 
individuals at higher risk of future mild cognitive impairment, but also it allows us to track 
longitudinal trajectories. 
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6.3. Introduction 
The investigation using biomarkers has pointed out that the first physiopathological 
changes associated with amyloid-β deposition might be observed several decades before 
the clinical diagnosis of Alzheimer´s Disease (AD), even in absence of symptoms [1]. As a 
result, the progression of AD is currently conceived as a continuum starting 20 years before 
the onset of clearly noticeable symptoms [2]. The National Institute on Aging-Alzheimer 
Association (NIA-AA) established three different stages of AD as progression occurs over 
time. First, there is a preclinical phase which is defined by the incipient presence of amyloid 
plaques, but objective cognitive function remains normal. At the end of this preclinical 
phase the individual might experience some kind of Subjective Cognitive Decline (SCD) that 
increases the risk of future dementia [3]. A second stage called prodromal Mild Cognitive 
Impairment (MCI) due to AD refers to a cognitive impairment that is not severe enough to 
significantly affect everyday activities. Finally, there is a third phase in which cognitive 
impairment worsens progressively leading to a functional impairment that defines an AD 
dementia syndrome. Since the publication of these guidelines in 2011, data have continued 
confirming that changes of biomarker measures represent a continuous process. Following 
this model, positive biomarkers can antecede the clinical symptoms by 15-20 years, and 
that fact changed the assumption of three clinical defined entities to a conception of 
disease continuum. In practical terms, the detection of the clinical and biological AD 
hallmarks of people who will convert from a cognitively healthy state to a latter MCI phase 
is a challenge of great interest, conceptualized as a research framework to investigate AD 
continuum [4]. 
Early intervention to prevent, or delay, the transition from healthy cognition to cognitive 
impairment in older adults is an important goal. In this way, it is critical to find sensitive, 
reproducible and early markers to use low cost methods for the detection of that 
transition. One of those early markers for symptomatic manifestation of AD is SCD [5]. This 
condition has been proved to precede MCI due to AD and it may serve for an early 
intervention in the onset of AD [6]. Indeed, a recent meta-analysis has shown that almost 
25% of older adults who report SCD will develop prodromal AD four years later [7]. In 
addition, the rate of progression to dementia among those individuals who report SCD is 
twofold during a 5 year following period. 
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SCD during preclinical phase of AD refers to a self-experienced persistent decline in 
cognitive abilities in comparison with a previously normal status and independently of the 
objective performance on neuropsychological tests. To increase the potential usefulness of 
SCD the international working group called Subjective Cognitive Decline Initiative (SCD-I) 
agreed to a common framework and research procedures to study the role of SCD as a 
preclinical marker of AD [8]. As a result of these indications, cognitively healthy individuals 
who accomplish certain conditions of SCD, namely SCD-Plus, have been proved to have a 
four times higher risk for progressing to prodromal AD in just one-year compared to those 
subjects without complaints [9]. Despite its outstanding clinical value, the identification and 
measurement of SCD is not an easy task because of some limitations pointed out by the 
SCD-I [5,6]. These limitations could be summarized in three different blocks: i) terminology 
has not been homogeneous across studies; ii) methodology and tools to assess SCD are also 
heterogeneous; and iii) operational criteria and cutoffs to consider who is truly reporting 
SCD have been totally different across studies. Thus, for instances, the previous limitations 
are probably the reason whereby the prevalence of SCD in older adults may range from 10 
to 80% depending on the studies [10–13]. Additionally, another issue which is pending to 
be solved is the stability over time of SCD [14]. 
In this work, we will test the internal consistency of SCD across time. As the stability is 
demonstrated, SCD could become a reliable, low-cost preclinical marker for AD. We 
therefore hypothesize that in a series of longitudinal evaluations the self-report of cognitive 
impairment would be stable across time. Additionally, we will analyze the validity of the 
SCD as a very early marker of AD examining the dynamic transition from the preclinical to 
prodromal AD stages. 
6.4. Materials and methods 
6.4.1. Participants 
The participants of this study comprised 1,091 cognitively healthy community-dwelling 
individuals aged 70 years and over at baseline. All of them were part of the Vallecas Project 
cohort, a community-based longitudinal investigation for early detection of AD [15]. The 
participants were volunteers that were recruited through radio and TV campaigns, leaflet 
distribution, and visits of the research team to social centers for the elderly. The study was 
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approved by the Research Ethics Committee of the Carlos III Institute of Health, Madrid, 
Spain. Informed written consent was obtained from all participants enrolled in this study. 
The participants underwent a detailed assessment protocol annually for three years. The 
protocol included past medical history, neurological and neuropsychological examination, 
as well as biochemical and genetic blood test. The complete visit was usually carried out 
within four hours with convenient breaks. The neuropsychological battery included 
complete information about all cognitive domains that covered the whole spectrum of 
cognition. For the purposes of this work we only analyzed the performance in the following 
tests: Free and Cued Selective Reminding Test (FCSRT) [16], Digit-Symbol Coding [17] and 
Clinical Dementia Rating (CDR) [18]. In addition, the Geriatric Depression Scale (GDS) [19] 
and the State- Trait Anxiety Inventory (STAI) [20] were also administered as part of the 
neuropsychological battery to quickly estimate mood and anxiety symptoms. 
Clinical diagnoses were always agreed between neurologists and neuropsychologists at 
consensus meetings; all diagnoses were always blind to previous diagnosis. MRIs were done 
to rule out the presence of macroscopic lesions or significant vascular damage which could 
interfere with cognitive performance. Then, every individual was independently diagnosed 
after each visit according to his/her age, gender, cognitive reserve, functional information, 
and cognitive scores. Nevertheless, rather than psychometrically invariable cut-offs, 
diagnosis were based on clinical impression. NIA-AA´s criteria [21] were applied to diagnose 
core MCI and mild dementia. Cognitively healthy subjects were given a score of 0 in the 
global CDR while MCI and mild dementia must score 0.5 and 1 respectively. All participants 
were diagnosed as cognitively healthy at baseline. 
6.4.2. SCD assessment 
SCD was assessed twice and independently within the same visit at the Vallecas Project. 
First, during the neurological examination participants were asked the following nine 
questions regarding specific cognitive domains: 1) Attention (“Are you easily distracted?”); 
2) Spatial orientation (“Do you get lost in familiar surroundings?”); 3) Episodic memory (“Do 
you often forget recent information or events?”); 4) Autobiographical memory (“Do you 
often forget autobiographical information?”); 5) Visual recognition (“Do you have trouble 
recognizing objects or faces?”); 6) Speech (“Do you have word-finding difficulties for 
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people’s names or common words?”); 7) Language comprehension (“Do you understand 
verbal and written instructions?”); 8) Executive functions (“Do you have difficulty driving, 
managing finances or planning daily activities?”); and 9) Praxis (“Do you have difficulty 
sequencing movements (e.g. taking the necessary steps to prepare a bath)?”). The previous 
questions were coded in a dichotomic way (yes/no). 
Second, during the neuropsychological assessment individuals also completed an ordinal 
scale of memory complaints composed of four items with four points each (ranged 0-3): 1) 
“How do you perceive your memory in comparison with that of others of your age?” (“3-
bad”; “2-somewhat worse”; “1-somewhat better”; “0-excellent”); 2) “How do you perceive 
your memory today compared with your young adulthood?” (“0-better”; “1-equal”; “2-
somewhat worse”; “3-much worse”); 3) “Do you perceive your memory today is worse than 
compared with ten years ago?” (“0-no”; “1-a little worse”; “2-somewhat worse”; “3-much 
worse”); and 4) “Do you perceive your memory today is worse than compared with one 
year ago?” (“0-no”; “1-a little worse”; “2-somewhat worse”; “3-much worse”). The sum of 
these items resulted in a total score of cognitive concerns (SCD scale) which ranged from 0 
(no complaints at all) to 12 (maximum complaints). Furthermore, five more open-ended 
questions were also collected: 5) Age at onset of cognitive complaints (“How old were you 
when your cognitive performance began to decline?"); 6) Years of SCD´s progression (“How 
long do you believe you are experiencing cognitive complaints?”); 7) Worries associated 
with self-perceived complaints (“Are you worried about your cognitive decline?”); 8) Type 
of onset of cognitive complaints (“How did you perceive the beginning of the cognitive 
decline? (e.g. suddenly, progressive, etc.)”); and 9) Self-experienced functional impairment 
associated with SCD (“Do you believe your cognitive failures are impeding your daily life 
activities?”). 
6.4.3. Classification of individuals in SCD groups 
We followed the guidelines proposed by the SCD-I [8] to examine the implication of specific 
SCD features as early signs of AD. According to these guidelines, individuals were grouped 
in three different categories pursuant to the extent of SCD reported in both clinical 
interviews: i) No complaints group (NCg); ii) Subjective Cognitive Decline group (SCDg); and 
iii) Subjective Cognitive Decline Plus (SCD-Pg). We decided to adopt a conservative criterion 
in order to ensure the most stable categorization possible of SCD groups. First, our primary 
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measure for SCD was the SCD scale because it was composed of items that delve into the 
self-perception of complaints over time compared to others and oneself. Therefore, scores 
0-1 on the SCD scale was considered as non-indicative of SCD while scores ranging 4-12 
were conceived as a strong signal of SCD. Intermediate 2-3 scores were thought to be at 
borderline and in those cases the information from the 9 yes/no-type questions was taken 
into account as a secondary measure to classify the participants. Only if the response was 
affirmative in at least one of those questions the individual was considered as SCDg. 
Otherwise, the individual was included in NCg. Specifically, the three SCD groups were 
operationally defined as follows: i) NCg: scores 0-1 on the SCD scale administered in the 
neuropsychological assessment OR scores 2-3 on the SCD scale, but none positive response 
to any of the 9 yes/no-type question from the neurological interview; ii) SCDg: scores 4-12 
on the SCD scale administered in the neuropsychological assessment OR scores 2-3 on the 
same scale plus at least a positive response to any cognitive domain from the neurological 
interview; and iii) SCD-Pg: only for cases categorized as SCDg specific features were 
considered such as: age at onset of SCD beyond 60 years, turning up of complaints within 
the last 5 years, worry associated with SCD, and feeling of worse performance than others 
of the same age group. When all these conditions accompany the self-experience of decline 
then an individual was classified as SCD-Pg. 
6.4.4. APOE genotyping 
APOE gene polymorphism status was studied with total DNA isolated from peripheral blood 
following standard procedures. Genotyping of APOE polymorphisms (rs429358 and rs7412) 
was performed by Real-Time PCR [22]. APOE was coded 1 for the APOE ε4 carriers, and 0 
for non-carriers. 
6.4.5. Statistical analyses 
Analyses were conducted using R version 3.1.1. [23], specifically packages mice [24] for 
multiple imputation and msm [25] for multi-state modeling. We used 2-sided significance 
tests for all analyses, with statistical significance set at p-value < 0.05. 
We performed a preliminary analysis of demographic, cognitive and clinical variables at 
baseline to find out their distribution and explore the nature and distribution of missing 
values. Nearly 10% of data were missed, but no profiles of missingness were identified (i.e. 
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the missingness spread over many individuals, variables and study visits). We therefore 
conducted a multiple imputation procedure under a fully conditional specification method 
in order to impute values as closer as possible to ideal predicted observations. Those 
imputed values were generated on the basis of existing variables through four different 
databases, one for each study visit; a total of four imputation procedures were thereby 
conducted. In this sense it should be noted that those individuals who did not attend to any 
visit were excluded from the corresponding databases. The imputation procedure replaced 
each missing observation with a set of plausible values representing uncertainty about the 
appropriate value to impute. The procedure was repeated five times and generated the 
corresponding five data sets whose coefficients varied from one set to another. The 
imputed data sets were analyzed using the usual procedure for complete data. Finally, the 
results of these analyses were combined to produce valid statistical inferences of data. 
We then applied the SCD´s operational criteria to classify the whole cohort in every visit. 
SCD groups were treated as independent variables with three levels (NCg, SCDg, and SCD-
Pg) whereas demographic, cognitive and neuropsychiatric data were used as dependent 
variables. Associations between categorical variables were analyzed with the Pearson´s χ2 
test when appropriate. In addition, due to differences of sample size among SCD groups, 
analyses of variance and post-hoc analyses was based on non-parametric Kruskal-Wallis 
tests with Bonferroni corrections when necessary. As estimates of the effect size partial eta 
squared (Ƞp2) for quantitative and Cramer´s V for categorical variables were calculated. 
In order to test the hypothesis related to the temporal stability of the self-experienced 
cognitive decline, we first calculated the Intraclass Correlation Coefficient (ICC) among the 
scores of the SCD scale over time insofar as this is a quantitative variable. Then the 
percentage of incongruent classifications over time was obtained. Since SCD groups were 
categorical, we used the Pearson´s χ2 for analyzing the association among them and also 
obtained squared weighted Cohen´s kappa and Fleiss´ kappa concordance coefficients for 
two or multiple observations respectively. For a variety of reasons weighted Cohen´s kappa 
has been considered a good statistic for that because it provides an estimate of the 
percentage agreement between ratings corrected for chance (i.e. target values are 
random). Indeed, the weighted kappa with squared function is identical to the Concordance 
Correlation Coefficient (CCC) for continuous data [26]. According to the values of kappa, it 
was considered: < 0.20 as poor agreement; 0.21-0.40 as fair agreement; 0.41-0.60 as 
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moderate agreement; 0.61-0.80; as good agreement; and 0.81-1.00 very good agreement 
[27]. 
Then, we conducted a preliminary analysis of the conversion rate among groups by SCD 
only with consistently cases identified through the follow-up. Irrespective of MCI diagnosis, 
those consistent cases were defined as follows: i) individuals who remained stable in the 
same group during follow-up (“Stable NCg”; “Stable SCDg”; “Stable SCD-Pg”); and ii) 
subjects who showed a forward transition in the preclinical spectrum from left to right 
during follow-up (“Transition from NCg to SCDg”; “Transition from SCDg to SCD-Pg”). 
Otherwise, when backward transitions were detected (i.e. transitions from SCD-Pg to SCDg 
or from SCDg to NCg) individuals were removed from the analyses. Then, for each group we 
examined the percentage of individuals who developed or not MCI during follow-up. 
Multi-State Markov Model 
As this study focused on the temporal dynamics of the preclinical stage of AD, we 
performed a Multi-state Markov Model in continuous time to better characterize 
transitions among the following four states: No SCD, SCD, SCD-P, and MCI. Here it is 
important to note that all MCI statuses considered were confirmed during follow-up. 
Analyses based on this approach are appropriate for modeling the course of health 
processes in continuous time because they are able to accurately capture the transition of 
individuals in forward and backward directions across discrete stages [28]. Then, 
considering the assumption of the AD continuum, Multi-state Markov Model enables us to 
describe the process in which individuals move through the preclinical AD stages in 
continuous time.  
In our study, we examined the stage-sequential dynamic of preclinical AD using Multi-state 
Markov Model in continuous time. The Markov assumption claims that the rate of 
transition from one state to another depends only on the current state. Although this 
assumption seems to be restrictive, it is necessary to compute the likelihood for 
intermittently observed data like ours. An alternative to deal with this assumption is to 
include time in the current state as an additional predictor in the model. However, since 
with intermittently observed states it is not possible to know how long a participant has 
been in a given state, the apparent restrictiveness of the Markov assumption was 
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ameliorated somehow by introducing age in the model. Thus, the transition matrix was 
calculated between any two unrounded ages and therefore accommodates variation in the 
time between participant visits [29]. 
We modeled therefore a Multi-state Markov Model with forward-backward algorithm to 
maximize likelihood estimation. Since we only observe states at a finite series of time and 
time interval between two consecutive visits in our longitudinal study varied across 
participants, a time-homogeneous model was preferred instead of a discrete one [30]. We 
then specified a multi-state model with four different states (No SCD, SCD, SCD-P, MCI) as 
well as the initial values for the transition intensity matrix that corresponded to 
[(0,0.5,0,0.01), (0.1,0,0.15,0.05), (0.05,0.5,0,0.2), (0,0,0,0)]. This matrix, which is really 
important because governs the whole model, represents the theoretical probabilities of 
transition from one state to another independently of the real data. Our model therefore 
assumed that individuals could move or recover from consecutive states, as well as convert 
from any state to MCI, which was conceived as the absorbing state. All transitions were 
interval-censored because we could not know the exact time in which individuals had 
transitioned. Multi-state Markov Model provided the estimated transition probability 
matrix and its 95% conﬁdence intervals to evaluate the probability of a change of SCD 
status membership over time conditional on previous status. The analysis of this matrix 
allowed us to better understand the temporal dynamics of preclinical AD over time and to 
test the hypothesis of SCD and SCD-Plus as two different statuses that increase the risk of 
future MCI. 
6.5. Results 
The participants were followed-up for a mean of 2.9 years (SD 0.8; median 3.2; range 1.0-
4.2). During this time, 84 (7.7%) individuals developed MCI and 16 (1.5%) progressed to 
dementia. Based on the cognitive trajectories of these 16 participants (marked memory 
impairment as a primary symptom during follow-up and MRIs excluding significant vascular 
damage) we could assume that there is a high probability of AD dementia type, but there is 
no available biomarker confirmation. 
Regarding cognitive concerns, 78% of participants reported some type of SCD at baseline; 
that is, they were classified as SCDg or SCD-Pg. The single measure ICC value for the scores 
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of the SCD scale during the whole follow-up showed a positive correlation of 0.522 (p-value 
<0.001). On the other hand, the average measure ICC was 0.814. Table 6.1. summarizes the 
descriptive statistics of the total sample and the three SCD groups at baseline. No 
differences in age, gender and ApoE among groups were found. Nevertheless, there was a 
trend for significance concerning education, having less years of education SCD-Pg than 
NCg. Differences in depression (GDS) and anxiety (STAI) were also found among all three 
groups. These results highlighted that neuropsychiatric symptoms were more frequent in 
both SCD groups compared to NCg; and these symptoms were especially marked for SCD-
Pg. Regarding cognitive assessment, statistical differences between groups were found for 
instrumental activities of everyday (FAQ), verbal episodic memory (FCSRT), speed 
processing (Digit Symbol Coding) and clinical rating (CDR sum of boxes). Interestingly, the 
SCD-Pg showed the worst cognitive performance, while only two indices of FCSRT differed 
significantly between NCg and SCDg. 
Table 6.1. Baseline demographic and clinical characteristics of the sample by Subjective 
Cognitive Decline groups. 
 NCg SCDg SCD-Pg p-value Post-hoc 
n 240 685 166 -  
Age, y, mean (SD) 74.48 (3.84) 74.87 (3.90) 74.39 (3.77) 0.208  
Education, y, mean (SD) 11.56 (5.81) 10.65 (5.84) 9.37 (5.21) 0.002 b 
Female, n (%) 155 (64.6) 429 (62.6) 115 (69.3) 0.272  
ApoE ε4, n (%) 41 (17.2) 119 (17.5) 30 (18.1) 0.409  
FAQ, mean (SD) 0.13 (0.38) 0.45 (0.81) 0.67 (0.92) <0.001 a,b,c 
SCD      
SCD score, mean (SD) 1.76 (0.93) 4.68 (1.85) 6.07 (2.07) <0.001 a,b,c 
Years of onset, y, mean (SD) 7.08 (5.15) 8.31 (6.16) 3.12 (1.42) <0.001 a,b,c 
Age at onset, y, mean (SD) 67.40 (6.34) 66.57 (7.32) 71.27 (4.10) <0.001 b,c 
Neuropsychiatric symptoms      
GDS, mean (SD) 0.95 (1.63) 1.62 (2.30) 2.36 (2.58) <0.001 a,b,c 
STAI trait, mean (SD) 13.19 (7.96) 17.00 (9.78) 21.84 (9.53) <0.001 a,b,c 
Cognitive performance      
FCSRT free immediate, mean (SD) 25.00 (6.32) 23.31 (6.25) 22.50 (5.78) <0.001 a,b 
FCSRT total immediate, mean (SD) 42.15 (5.42) 41.02 (5.56) 39.94 (5.49) <0.001 a,b,c 
FCSRT free delayed, mean (SD) 10.02 (2.47) 9.38 (2.69) 8.78 (2.44) <0.001 a,b,c 
FCSRT total delayed, mean (SD) 14.71 (1.69) 14.30 (1.84) 14.02 (1.83) <0.001 a,b 
Digit Symbol Coding, mean (SD) 21.02 (8.19) 19.07 (7.13) 17.86 (6.73) <0.001 a,b 
CDR sum of boxes, mean (SD) 0.00 (0.00) 0.00 (0.03) 0.00 (0.00) 0.553 a,b 
ApoE: Apolipoprotein E; CDR: Clinical Dementia Rating; FAQ: Functional Activities Questionnaire; FCSRT: Free and Cued 
Selective Reminding Test; GDS: Geriatric Depression Scale; NCg: No Complaints group; SCD: Subjective Cognitive Decline; 
SCDg: Subjective Cognitive Decline group; SCD-Pg: Subjective Cognitive Decline Plus group; SD: Standard Deviation; STAI: 
State-Trait Anxiety Inventory. 
p-values indicate the values assessed with non-parametric Kruskal-Wallis tests for each variable except sex and ApoE ε4, 
where contingency χ2 tests were performed. Non-parametric post-hoc: a=NCg vs SCDg; b=NCg vs SCD-Pg; c=SCDg vs SCD-Pg 
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Table 6.2. shows the percentage of concordance and discrepancies related to the 
classification of individuals in SCD groups. Since SCDg and SCD-Pg are both referred to a 
self-perception of complaints and that the boundaries between them are permeable, we 
collapsed them in a single level. Based on the assumption about the linear transition upon 
the AD spectrum, the agreements were defined according to two parameters: i) individuals 
who converted from NCg to SCDg; and ii) subjects who remained stable as SCDg over time. 
Discrepancies were then defined as those cases in which a reversal from SCDg to NCg 
occurs. As expected, the percentages of discrepancy increased with the duration of follow-
up from around 5% at one-year follow-up, to 17% at three-year follow-up. We also 
conducted some concordance analyses involving Cohen´s and Fleiss´ kappa indices. All 
values of kappa resulted significant (p<0.0001) and over 0.40, ranging from 0.46 for the 
three-year follow-up to 0.76 for the one-year period. These outcomes indicated that there 
was a good agreement in the longitudinal classification of SCD groups. 
Table 6.2. Concordance among Subjective Cognitive Decline groups over time. 
 
One-year 
follow-up 
Two-years 
follow-up 
Three-years 
follow-up 
 v0-v1 v1-v2 v2-v3 v0-v1-v2 v1-v2-v3 v0-v1-v2-v3 
Concordance 94% 95% 95% 88% 90% 83% 
Discrepancy* 6% 5% 5% 12% 10% 17% 
Cohen´s kappa 
(95% CI)† 
0.76 
(0.71-0.82) 
0.71 
(0.62-0.79) 
0.62 
(0.51-0.72) 
   
Fleiss´ Kappa†    0.53 0.53 0.46 
* Discrepancy is only referred to those cases in which transition from SCDg or SCD-Pg to NCg is observed. 
† All p-values < 0.0001 
Annual mean discrepancy related to SCDg to NCg = 7.7% 
Annual mean discrepancy related to SCD-Pg to NCg = 4.7% 
v0: baseline visit; v1: one-year follow-up visit; v2: two-year follow-up visit; v2: three-year follow-up visit. 
Regarding the association between SCD and conversion rate to MCI, in a preliminary 
analysis we classified all individuals according to the evolution of their complaints through 
the follow-up. Considering only consistent cases (i.e. those who remained stable or those 
who moved forward in the preclinical spectrum from left to right) and irrespective of MCI 
diagnosis, five new groups were thereby built as shown in Table 6.3. It should be noted that 
since backward transitions were removed from this analysis, only 591 participants were 
finally considered. The column “n over time” in Table 6.3. reflects the number of individuals 
who were retained in each group (for example, 117 participants transitioned from NCg to 
SCDg at any point of the follow-up). The column “% conversion to MCI” means the 
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percentage of the participants of each category who developed MCI (as in our previous 
example, 4 out 117 of the participants in the “Transition from NCg to SCDg” group 
developed MCI what represents 3.6% versus the 96.4% who remained cognitively intact). 
The outcomes showed that the percentages of conversion to MCI were increasing as it was 
observed a theoretical transition from left to right in the continuum: from 0% in “Stable 
NCg” to 42.9% in “Stable SCD-Pg”. Therefore, the rate of conversion to MCI showed a 
strong relationship to SCD-P. 
Table 6.3. Cumulative conversion rate to Mild Cognitive Impairment by transition among 
Subjective Cognitive Decline groups. 
 n over time % conversion to MCI 
Stable NCg 41 0.0% 
Transition from NCg to SCDg 117 3.4% 
Stable SCDg 331 6.3% 
Transition from SCDg to SCD-Pg 88 17.0% 
Stable SCD-Pg 14 42.9% 
MCI: Mild Cognitive Impairment; NCg: No Complaints group; SCDg: Subjective Cognitive Decline group; SCD-Pg: Subjective 
Cognitive Decline Plus group 
Table 6.4. Status prevalence of Subjective Cognitive Decline by visit and transition 
probability matrix for preclinical AD stages. 
However, transition among states in this preliminary test seemed to be partially biased 
because of two reasons: the loss of nearly half of the sample after removing backward 
cases as well as the extensive contingency tables necessary to explore individual trends on 
the SCD transition. To solve those issues a more sophisticated statistical approach was 
applied for studying the temporal dynamics of SCD with all cases. We performed a Multi-
state Markov Model to better understand the temporal dynamic of preclinical AD stages (-2 
Status prevalence by visit… No SCD SCD SCD-Plus MCI 
Baseline 0.225 0.630 0.145 0.000 
One-year follow-up 0.196 0.634 0.120 0.050 
Two-year follow-up 0.119 0.681 0.140 0.060 
Three-year follow-up 0.101 0.713 0.113 0.073 
     
Probability of transitioning to... 
conditional on... 
No SCD SCD SCD-Plus MCI 
No SCD 0.501 0.449 0.044 0.006 
SCD 0.072 0.784 0.120 0.025 
SCD-Plus 0.032 0.517 0.334 0.117 
MCI 0.000 0.000 0.000 1.000 
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log-likelihood=3,972.06; AIC=3,986.06). Table 6.4. shows the transition probability matrix 
across SCD statuses. These transition probabilities express the incidence of transitioning 
during the follow-up conditional on earlier membership in any specific the SCD status. 
Participants who did not report SCD at baseline had 50% of probabilities of remaining as no 
SCD during the three-year follow-up. In case of transition, they were most likely to 
transition to the SCD status, but not to SCD-Plus or MCI. Those in SCD status at baseline had 
78% of probabilities of remaining there at follow-up and their most likely transition was to 
SCD-Plus status. Indeed, probability of progression to SCD-Plus was approximately twice 
than reversion to No SCD status. Individuals in the SCD-Plus status at baseline were the 
least stable group remaining only 33% of individuals in the same status during the follow-
up. Their more likely transition was backward towards SCD status (52% of them) and the 
probability of reversion to No SCD was very unlikely. Most importantly, these outcomes 
pointed out that the SCD-Plus was the status in which the likelihood of progression to the 
following prodromal AD stage, MCI, was higher (12%) followed by SCD (3%) and No SCD 
(less than 1%). Figure 6.1. shows graphically the fitted survival probability of conversion to 
MCI over time for No SCD, SCD and SCD-Plus statuses. 
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Figure 6.1. Kaplan-Meier survival curves for rates of conversion to MCI by SCD statuses. 
SCD-Plus shows the highest risk of conversion to MCI over time. 
MCI: Mild Cognitive Impairment; SCD: Subjective Cognitive Decline 
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6.6. Discussion 
The purpose of this study was to determine whether SCD may be a suitable very early 
marker for AD in a large cohort composed of 1,091 participants aged 70 years and over with 
uniform ascertainment of risk factor and disease. All participants were cognitively healthy 
at baseline and during three years of follow-up we examined the appearance of SCD, its 
longitudinal internal consistency and the transition from normal cognition to MCI stage 
over time. 
Since the study and definition of SCD have been heterogeneously treated in the literature 
[6], and this is probably the reason whereby the prevalence of SCD in older adults may 
range from 10 to 80% depending on the studies [10–13], we decided to base our study on 
the guidelines provided by the SCD-I [8]. We operationally defined a robust procedure to 
measure and characterize SCD. Cognitive complaints were assessed twice and 
independently within the same visit; first during the neurological examination and then 
during the neuropsychological evaluation. The combination of all these data at baseline 
showed that 78% of individuals reported SCD. Although this prevalence is slightly higher 
than that of other similar studies [31], this fact could be explained due our cohort is a little 
older. Interestingly, during the follow-up we found that about half of individuals who did 
not report complaints at baseline did manifest cognitive concerns in the following years. 
We interpret this finding as an expected consequence of aging. Although the transition 
from non complaints status to SCD status have been previously described [32], to our 
knowledge our study is the first in which the assessment of SCD has been collected annually 
with a very strict and well-defined operational criteria as well as including two subgroups of 
complaints, namely SCDg and SCD-Pg, according to the guidelines given by the SCD-I [8]. 
The preliminary cross-sectional analyses among SCD groups at baseline did not find 
differences in age, gender and ApoE. Nevertheless, as expected the results did highlight 
that depressive and anxiety symptoms were more frequent in both SCD groups, especially 
for SCD-Pg, compared to NCg. Regarding neuropsychological assessment, SCD-Pg showed 
the worst cognitive performance compared to the other two groups though the scores in 
tests were in the range of normal cognition. 
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To test our first aim about proving the stability of the SCD construct over time, we focused 
on analyzing longitudinally the percentage of concordance and discrepancies related to the 
classification of individuals in SCD groups. As expected, the number of discrepancies 
increased with the duration of follow-up what may be explained by the greater number of 
options to group subjects. The concordance analyses with Cohen´s and Fleiss´ kappa indices 
showed a good agreement in the classification of SCD groups what confirmed that the 
concept of SCD has a considerable internal consistency over time when it is operationally 
defined and consistently assessed. Our hypothesis was therefore confirmed and SCD fulfils 
one of the requirements to be considered as a potential marker for early detection of AD 
[14]. 
For our second goal, to examine the association between SCD and conversion rate to MCI, 
in a preliminary analysis we obtained that the rate of conversion to MCI was directly related 
to the presence of SCD-P and dramatically increased up to almost 43% when SCD-P remains 
stable over time. This result is according to previous findings [33]. However, since the 
boundaries between the SCD groups may be permeable due to the intrinsic criteria used for 
classifying individuals, we performed a Multi-state Markov Model to test the AD continuum 
hypothesis in its preclinical stage and to better identify the underlying trajectory of SCD 
over time. The results showed a clear sequential trend transitioning from cognitively 
healthy individuals with No SCD to SCD/SCD-Plus and, finally, MCI. In the three-year follow-
up of this study, 50% of participants with No SCD at baseline progressed to a SCD stage 
characterized by the presence of a self-perception of cognitive failures. From this stage, 
almost 80% remained as SCD through the whole follow-up and 12% did progress to a SCD-
Plus phase which might be conceived as the previous stage of MCI. Interestingly, the 
possibility of reversion from SCD to No SCD during the follow-up was very unlikely (7%). 
Finally, we found that the greatest probability to convert to MCI was up to 12 times higher 
for individuals at SCD-Plus status. Overall, these results about change show a parsimonious 
and detailed scenario of how individuals move into and out of the different SCD categories. 
Most importantly, beyond biomarkers this is the empirical demonstration of the existence 
of a continuum in the preclinical phase of AD with three well-defined statuses that have 
different probabilities to develop future MCI. 
There are some limitations in this work that we want to address. First, the follow-up time 
may be not large enough to appreciate the expected changes that must appear in a disease 
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so insidious like AD in which progression may happen in a wider period of time. Since 
Vallecas Project is still in progress we will minimize this limitation through the longitudinal 
follow-up of our cohort by further analyzing whether transition probabilities of developing 
MCI increase for SCD-Plus against SCD and No SCD. Second, in our study we do not have 
available information on CSF/PET biomarkers to confirm that SCD and MCI are due to 
underlying AD pathology and thus we cannot rule out other ulterior neurological and 
psychiatric conditions which are well-known to lead to SCD and MCI. Nevertheless in the 
context of this project we do rely on complete clinical and cognitive profiles of every 
participant so we can obtain confirmation of the diagnosis in the follow-up, as well as the 
clinical trajectories that mostly match with AD. 
 
Figure 6.2. Hypothetical dynamic transition through AD continuum. 
This graphic represents the hypothetical dynamic of preclinical AD phases according to a major risk of developing future MCI. 
Overall, two main stages can be identified, namely No SCD and SCD, as well as a sub-stage called SCD-Plus within SCD. Based 
on our results, progression may occur from No SCD to SCD, but oposite transitions from SCD to No SCD are very unlikely. Once 
an individual is at the SCD phase there may be a progression to a severe form of cognitive concerns, the sub-stage SCD-Plus, in 
which the hazard of MCI is the highest compared to No SCD and SCD. Nevertheless, since the criteria for classifying SCD-Plus 
are very restrictive, permeability is possible between SCD and SCD-Plus and thus individuals might be gone through or back 
over time. 
AD: Alzheimer´s disease; MCI: Mild Cognitive Impairment; SCD: Subjective Cognitive Decline 
Our study has a powerful strength regarding the analytic approach to examine the role of 
SCD on cognitive decline. Unlike the majority of studies that follow a static, traditional, and 
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cross-sectional methodology -that is, grouping individuals based on SCD features just once 
at baseline and analyzing their risks ratios of progression through the AD spectrum-, our 
research implements a novel, comprehensive, and longitudinal approach to further 
investigate the temporal dynamics of SCD as well as transitions through preclinical stages 
during the whole follow-up. Thus, to our knowledge this is the first time that it has been 
observed the existence of a real transition within the preclinical AD stage until prodromal 
MCI (Figure 6.2.). Additionally, we would like to point out another remarkable strength of 
our study: the proposal of a methodological, systematic and reproducible way of recording 
SCD. This provides a consistent, robust and well operationally defined construct that allows 
monitoring preclinical AD stages. 
To summarize, self-report of subtle cognitive decline appears at the end of the preclinical 
phase of AD even in the absence of significant objective impairment detectable on 
standardized neuropsychological assessment. As a novel marker, SCD must address some 
challenges before being considered as a real predictor of future MCI and dementia. The 
most crucial challenge, internal consistency over time, has been now proved by our pioneer 
study, which is the first one as far as we know that analyzes the temporal dynamics of SCD. 
It has been also highlighted that there is a progressive transition from No SCD to SCD and 
SCD-Plus statuses. Thus every successive preclinical status indicates higher risk of future 
MCI, focusing on SCD-Plus as the one that requires special attention in terms of early 
preventive intervention. The strength of SCD measurements is that is a non-invasive, easy, 
and low-cost method for screening both patients attending to memory units and general 
population. This marker could facilitate not only a fast and easy identification of individuals 
at higher risk for a premature cognitive impairment, but it allows us to better track the 
longitudinal trajectory of individuals. SCD therefore could become extremely useful in 
coming years to measure the effectiveness of new clinical trials with AD modifying 
therapies at preclinical phases which are supposed to be still recoverable. 
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6.7. Summary of conclusions 
1. Measurements of SCD along time allow to determinate the stability of SCD and the 
strength of SCD data. 
2. It is suggested the use of SCD as a possible non-invasive, easy and low cost marker for 
the transition to MCI. 
3. We provided the temporal dynamics of the AD continuum in which SCD plays an 
important role as an early step.  
 
 
Experiment 3 
129 
6.8. References 
[1]  Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all 
Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. 
Alzheimers. Dement. 8, 312–336. 
[2]  Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns 
NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, 
Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, 
Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and Biomarker Changes in 
Dominantly Inherited Alzheimer’s Disease. N. Engl. J. Med. 367, 795–804. 
[3]  Wolfsgruber S, Wagner M, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, 
Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz H-J, Schröder J, Pantel J, 
Rienhoff O, Rüther E, Henn F, Wiltfang J, Maier W, Kornhuber J, Jessen F (2014) Memory 
concerns, memory performance and risk of dementia in patients with mild cognitive 
impairment. PLoS One 9, e100812. 
[4]  Rabin LA, Smart CM, Amariglio RE (2017) Subjective Cognitive Decline in Preclinical 
Alzheimer’s Disease. Annu. Rev. Clin. Psychol. 13, 369–396. 
[5]  Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel 
H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der 
Flier WM, Wagner M, Jessen F (2016) Implementation of subjective cognitive decline 
criteria in research studies. Alzheimer’s Dement. 13, 296–311. 
[6]  Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B (2014) Risk of 
dementia and mild cognitive impairment in older people with subjective memory 
complaints: meta-analysis. Acta Psychiatr. Scand. 130, 439–451. 
[7]  Jessen F, Amariglio RE, Boxtel M van, Breteler M, Ceccaldi M, Chetelat G, Dubois B, 
Dufouil C, Ellis KA, van der Flier WM, Glodzik L, Harten AC van, Leon MJ de, McHugh P, 
Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, 
Reisberg B, Rentz DM, Sachdev PS, Sayette V de la, Saykin AJ, Scheltens P, Shulman MB, 
Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M (2014) A 
Subjective Cogntive Decline as prelinical marker in AD 
130 
conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s 
disease. Alzheimer’s Dement. 10, 844–852. 
[8]  Fernández-Blázquez MA, Ávila-Villanueva M, Maestú F, Medina M (2016) Specific 
Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive 
Impairment. J. Alzheimer’s Dis. JAD 52, 271–281. 
[9]  Glodzik-Sobanska L, Reisberg B, Santi S De, Babb JS, Pirraglia E, Rich KE, Brys M, 
Leon MJ de (2007) Subjective Memory Complaints: Presence, Severity and Future Outcome 
in Normal Older Subjects. Dement. Geriatr. Cogn. Disord. 24, 177–184. 
[10]  Markova H, Andel R, Stepankova H, Kopecek M, Nikolai T, Hort J, Thomas-Antérion 
C, Vyhnalek M (2017) Subjective Cognitive Complaints in Cognitively Healthy Older Adults 
and Their Relationship to Cognitive Performance and Depressive Symptoms. J. Alzheimer’s 
Dis. 59, 871–881. 
[11]  Jungwirth S, Fischer P, Weissgram S, Kirchmeyr W, Bauer P, Tragl K-H (2004) 
Subjective Memory Complaints and Objective Memory Impairment in the Vienna 
Transdanube Aging Community. J. Am. Geriatr. Soc. 52, 263–268. 
[12]  Jorm AF, Butterworth P, Anstey KJ, Christensen H, Easteal S, Maller J, Mather KA, 
Turakulov RI, Wen W, Sachdev P (2004) Memory complaints in a community sample aged 
60-64 years: associations with cognitive functioning, psychiatric symptoms, medical 
conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter 
hyperintensities. Psychol. Med. 34, 1495–1506. 
[13]  Ávila-Villanueva M, Fernández-Blázquez MA (2017) Subjective Cognitive Decline as 
a Preclinical Marker for Alzheimer’s Disease: The Challenge of Stability Over Time. Front. 
Aging Neurosci. 9, 377. 
[14]  Olazarán J, Valentí M, Frades B, Zea-Sevilla MA, Ávila-Villanueva M, Fernández-
Blázquez MA, Calero M, Dobato JL, Hernández-Tamames JA, León-Salas B, Agüera-Ortiz L, 
López-Álvarez J, Larrañaga P, Bielza C, Álvarez-Linera J, Martínez-Martín P (2015) The 
Vallecas Project: a cohort to identify early markers and mechanisms of Alzheimer’s disease. 
Front. Aging Neurosci. 7, 181. 
Experiment 3 
131 
[15]  Buschke H (1984) Cued recall in amnesia. J. Clin. Neuropsychol. 6, 433–440. 
[16]  Wechsler D (1997) Wechsler Adult Intelligence Scale-III, The Psychological 
Corporation., San Antonio. 
[17]  Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for 
the staging of dementia. Br. J. Psychiatry 140, 566–572. 
[18]  Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) 
Development and validation of a geriatric depression screening scale: a preliminary report. 
J. Psychiatr. Res. 17, 37–49. 
[19]  Spielberger C, Gorsuch R, Leshene R (1970) Manual for the State-Trait Anxiety 
Inventory, Consulting Psychologists Press, Palo Alto, CA. 
[20]  Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, 
Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The 
diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from 
the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 
7, 270–272. 
[21]  R Development Core Team (2012) R: A language and environment for statistical 
computing, R Foundation for Statistical Computing, Vienna. 
[22]  Jackson CH, Sharples LD, Thompson SG, Duffy SW, Couto E (2003) Multistate 
Markov Models for Disease Progression with Classification Error. J. R. Stat. Soc. Ser. D (The 
Stat. 52, 193–209. 
[23]  Garcia-Ptacek S, Eriksdotter M, Jelic V, Porta-Etessam J, Kåreholt I, Manzano 
Palomo S (2016) Quejas cognitivas subjetivas: hacia una identificación precoz de la 
enfermedad de Alzheimer. Neurología 31, 562–571. 
[24]  Eckerström M, Göthlin M, Rolstad S, Hessen E, Eckerström C, Nordlund A, 
Johansson B, Svensson J, Jonsson M, Sacuiu S, Wallin A (2017) Longitudinal evaluation of 
criteria for subjective cognitive decline and preclinical Alzheimer’s disease in a memory 
clinic sample. Alzheimer’s Dement. 8, 96–107. 
  
  
7. DISCUSSION 
The initial signs of AD regarding to cognitive status can be divided into the objective 
performance level measurable by tests and the self-perception of cognitive decline. The 
ﬁrst has been a hot topic of research for many years, and thus the early manifestation of AD 
in the objective performance spectrum is well known. The latter subjective component of 
self-experienced cognitive decline in the context of AD has only recently become a topic of 
interest. Novel research has suggested that both objective and subjective decline occur 
through the AD continuum and that their contribution to dementia prediction varies 
depending on the stage of impairment. 
In the present investigation we have tried to stablish a complete background on the state of 
the art of SCD and studied the nature of the complaints. The following are the key findings 
found according to the objectives set out for this research in section 2. 
Objective 1. TO STUDY THE UNDERLYING STRUCTURE OF THE SCD IN A SAMPLE OF 
OLDER ADULTS. 
Our departure point was to analyze whether the expression of SCD in elderly people has a 
unidimensional structure or on the contrary there is a factorial underlying structure. 
Historically it has been implicitly assumed that the self-reported complaints are a 
monolithic concept referred almost exclusively to memory. The clinical and qualitative 
evidence however seems to indicate that there may be distinct types of cognitive 
complaints beyond memory that could have different clinical values in practice. 
Then, in our first experiment we examined the underlying structure of a widely used scale 
which is presumed to assess memory complaints, the EMQ (Sunderland et al., 1984), in a 
sample of older adults from Vallecas Project cohort. This questionnaire is perhaps one of 
the most extended scales that have been used to assess subjective complaints in a variety 
of populations, including older adults (Garrett, Grady, & Hasher, 2010; Ossher, Flegal, & 
Lustig, 2013). It consists of 28 items about memory failures that occur in everyday life and 
that must be scored according to a Likert-type scale. Despite Sunderland et al. (1984) 
emphasized the unidimensionality of the EMQ, the analysis of its individual items evidences 
that a high percentage of them do not exactly correspond to memory complaints. Rather, 
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some items would involve various cognitive domains such as visual perception (“failed to 
recognize, by sight, close friends or relatives”), attentional processing (“been unable to 
follow the thread of a story”), language production (“found that a word is on the tip of your 
tongue”), or executive functions (“forgotten a change in your daily routine”). In any event, 
investigations using the EMQ with older adults have exclusively focused on the overall score 
(Alegret et al., 2015), and have not addressed the role of the specific underlying factors 
upon differentiation between healthy controls and MCI. 
We used a combination of statistical approaches, namely EFA and IRT, to better capture the 
dimensionality of the questionnaire. Items 11 (failed to recognize, by sight, close friends or 
relatives), 19 (forgotten important details about yourself) and 27 (repeat to someone what 
you have just told them) were excluded from the EFA since their skewed distribution. The 
reason for that exclusion may have to do with the fact that these three items seem to 
reflect severe symptoms which appear in mild dementia rather than in earlier stages of AD 
(preclinical or prodromal phases). The final solution with the remaining 25 items comprised 
of a five-factor structure which explained up to 50% of EMQ´s total variance. Those factors 
were called as follows: i) FII was associated with fails in immediate retrieval, as well as 
naming impairment; ii) EF was related to distractibility, inhibition errors and monitoring; iii) 
PM refered to things that someone has to recall in the next future; iv) FCO had to do with 
forgetting personal details; and v) SO was associated with difficulties for spatial orientating. 
Furthermore the use of an IRT approach allowed us to find out the best 10-items that 
maximize the collection of information on cognitive complaints. 
Our results therefore highlighted an adequate internal consistency of the EMQ, as well as a 
well-established factorial structure. This outcome did not fit well with the Sunderland´s 
assumption on the unidimensionality of the questionnaire (Sunderland et al., 1984). Rather 
than the EMQ seemed to reflect a more complex scale than supposed which is able to 
measure various domains of cognitive complaints. Thus, these outcomes confirmed our 
hypothesis on the multidimensional structure of the SCD construct. 
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Objective 2. TO EXAMINE THE CROSS-SECTIONAL CLINICAL VALUE OF THE SCD IN 
DISTINGHISING BETWEEN HEALTHY ELDERLY CONTROLS AND INDIVIDUALS WITH 
MCI. 
Once it was demonstrated that SCD is a heterogeneous construct with a solid underlying 
structure, our second aim was to investigate whether specific cognitive complains were 
more useful than others to discriminate MCI. In the same experiment we went through to 
examine the association between the five factors previously obtained with the 
neuropsychological performance and the clinical diagnosis. As expected, the EMQ factors 
exhibited higher correlation coefficients with depressive and anxiety symptoms than 
cognitive performance. This outcome has been already found in different studies (Balash et 
al., 2013; Jessen, 2014) and it could be explained following the cognitive model of 
depression(Peckham, McHugh, & Otto, 2010). According to this model, individuals with 
depressive symptoms might exhibit some sort of information-processing biases toward 
negative information. Thus many older adults with depression may have a hypersensitivity 
to perceive their own cognitive failures and this could result in an overreporting of 
complaints. Moreover, another explanation is that by deﬁnition individuals with SCD score 
within normal ranges on neuropsychological testing. Neuropsychological tests assess 
performance at a single point in time whereas subtle subjective decline captures 
longitudinal change (Rabin, Smart, & Amariglio, 2017). In our work, FII and EF were 
interestingly the factors that correlated higher with cognitive performance. Specifically FII 
was strongly associated with episodic memory and EF with excutive functions. This 
outcome highlighted concurrent validity to the latent structure of the EMQ because the 
internal content of the factors is directly related to the cognitive domain assessed. By 
contrast, the fact that both FO and SO did not show differences in control subjects and MCI 
could be explained because the first one referred to a high prevalent oversight in the 
elderly population (“Forgetting where you have put something”, “Forgetting where things 
are normally kept or looking for them in the wrong place”) and the second was an 
idiosyncratic sign of mild dementia (“Getting lost or turning in the wrong direction on a 
journey, on a walk, or in a building where you have been before”). 
Regarding clinical diagnosis, our results proved that three types of cognitive concerns were 
able to distinguish between controls and MCI. Higher scores in specific complaints on 
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retrieval of immediate events, executive functioning and prospective memory were related 
to prodromal stages of dementia. Indeed, our results indicated that if two individuals, one 
control and one MCI, were selected at random, the score in any of these three factors 
would be higher for the MCI patient on 60% of times. All these findings emphasize that not 
all cognitive complaints have the same clinical significance for prediction of cognitive 
impairment. Individuals who present these particular complaints and do not yet have a 
diagnosis of MCI may need special attention in terms of close clinical follow-up or an early 
cognitive intervention. 
Then experiment 1 gave an answer to objectives 1 and 2. We demonstrated therefore that 
SCD is far away to be a monolithic entity. Rather it has an underlying structure that involves 
different cognitive domains and also that complaints have specific weights in distinguishing 
between healthy elderly controls and MCI. Complaints associated with episodic memory, 
executive functions and prospective memory give us a profile of subject at higher risk of 
developing MCI. 
Objective 3. TO ANALYZE THE LONGITUDINAL PREDICTIVE VALUE OF THE SCD AS A 
MARKER OF FAST CONVERSION TO MCI IN A SAMPLE OF OLDER ADULTS. 
The findings from the first experiment showed that specific cognitive complaints were able 
to distinguishing cognitively healthy individuals from MCI in a cross-sectional manner. Our 
following step was to search for specific features of SCD that enabled us to predict those 
individuals at high risk of developing MCI during a short period of time.  
The earliest research on SCD was based on longitudinal community-based studies that 
examined whether memory complaints at baseline predicted progression to dementia, with 
contradictory ﬁndings (Geerlings, Jonker, Bouter, Adèr, & Schmand, 1999; Schmand, Jonker, 
Hooijer, & Lindeboom, 1996; Tobiansky, Blizard, Livingston, & Mann, 1995). Many of these 
studies were conducted prior to the formulation of the concept of MCI, so it is likely that 
some SCD participants met criteria for MCI (Rabin et al., 2017). Thus, interpretation of early 
longitudinal studies should consider this methodological limitation. More recent studies 
have found that SCD is able to predict dementia, but over longer follow-up periods (Kaup, 
Nettiksimmons, LeBlanc, & Yaffe, 2015; Koppara et al., 2015; Reisberg et al., 2010; van 
Oijen, de Jong, Hofman, Koudstaal, & Breteler, 2007), in individuals with signiﬁcant concern 
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or worry (Jessen et al., 2010) or in participants recruited from memory clinics rather than 
community-based samples (Nunes et al., 2010; van Harten et al., 2013; Visser et al., 2009). 
Overall, there is overwhelming evidence on the role of SCD as a predictor of dementia 
when considering long-term periods but less data support its implication in the short-term. 
In experiment 2 we then tested whether different subtypes of SCD were able to predict fast 
conversion from cognitively healthy to MCI. In an attempt to cope with the methodological 
problems already commented on the heterogeneity of definitions and approaches to 
measure SCD (Molinuevo et al., 2017), we followed the guidelines from the SCD-I with the 
aim of harmonizing the study of SCD. According to these guidelines, we used the same 
common terminology and research procedures to identify and classify individuals with SCD 
at risk of preclinical AD (Jessen et al., 2014). 
Some common specific features are needed to stablish the profile of SCD according to the 
SCD-I recommendations: i) to collect information regarding features such as settings in 
which cognitive complaints are expressed; ii) association of SCD with medical help seeking; 
iii) number of years and age at onset of SCD; iv) subjective decline in memory and non-
memory domains; and v) association of SCD with experience of impairment. In addition, a 
set of particular features could be helpful to identify individuals at risk of clinical 
progression and then to make up a more severe form of SCD referred to as SCD Plus. Those 
features include a more acute subjective memory decline than any other cognitive domain, 
onset of complaints within the last 5 years, age at onset over 60 years, worries about SCD, 
and feeling of worse performance than other people from the same age group. This new 
category of SCD-Plus could allow us to explain the transition from a non symptomatic stage 
to the first symptomatic manifestation of AD. 
We replicated these guidelines in our Vallecas Project cohort. The goal of this experiment 
was to evaluate the clinical significance of SCD on the conversion from a cognitive healthy 
stage to a MCI in one year of follow-up. A total of 608 cognitively intact individuals were 
enrolled in the analyses. Depending on some SCD´s features participants were classified in 
three differente groups: i) No Complaints (NCg); ii) subjects with cognitive complaints in 
one or more cognitive domain (SCDg); and iii) subjects who besides complaints fulfilled the 
features of SCD Plus (SCD-Pg). 
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The results from this experiment showed that the conversion rate for the SCD-Pg (18.9%) 
was significantly higher than SCDg (5.6%) and NCg (4.9%). So, among other facts, what we 
found was that when we followed the guidelines proposed by the SCD-I for classifying 
groups according to their SCD´s features, the conversion rate of SCD-Pg was almost 20% in 
only one year. This outcome differed significantly from NCg and SCDg. Indeed, while the HR 
obtained for SCDg were similar to other studies (Geerlings et al., 1999; van Oijen et al., 
2007), individuals who reported SCD Plus had almost 5 times higher risk of developing MCI 
compared to those subjects without complaints. The inclusion of gender, memory 
performance and APOE genotyping in the survival analysis did not decrease the predictive 
power of the SCD-Pg. 
Overall, experiment 2 demonstrated that self-reported subtle cognitive decline in the 
absence of significant objective impairment on testing did have the ability to predict future 
decline in older individuals, even considering just a short period of time. SCD therefore 
showed a predictive value as an early marker of cognitive impairment. In practical terms, 
the interpretation of these findings suggests that individuals who might be characterized as 
SCD-Plus would need special attention regarding early cognitive and pharmacological 
intervention. 
Objective 4. TO INVESTIGATE THE RELIABILITY AND TEMPORAL STABILITY OF THE 
MEASUREMENTS OF THE SCD OVER TIME IN A SAMPLE OF OLDER ADULTS. 
Taking together all previous findings seem to point out cognitive concerns, and specially 
SCD-Plus, as a reliable marker of future AD when the SCD-I´s recommendations for tackling 
methological issues are considered (Jessen et al., 2014; Molinuevo et al., 2017). 
Nevertheless, at this moment of our line of investigation an important new concern arose 
before considering SCD as a solid target for research. To our knowledge this concern did not 
have ever brought to the table so far and it had to do with the reliability and temporal 
stability of the SCD´s measurements over time. In practical terms, if two longitudinal 
measures do not tend to match, which one would be the real to characterize the individual? 
This lack of temporal stability would represent an important bias to investigation. Only 
demonstrating that we can measure SCD as a robust, reliable and stable concept it could 
become a reliable preclinical marker for AD. 
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In our opinion paper, we provided some guidelines that should be taken into account in 
order to prove the stability of SCD. First, we posed that it is necessary to harmonize a 
protocol to collect all relevant information about cognitive complaints and to compare 
longitudinally the responses of the individuals. Variables such as age at onset, time of 
progression, memory performance compared to other people, concerns associated with 
SCD, and frequency of particular cognitive complaints are relevant data that must be 
carefully obtained (Jessen et al., 2014; Rabin et al., 2015). Second, it was proposed to 
gather self-perceived data using two procedures: a face-to-face interview with a healthcare 
professional and a self-administered scale of SCD. The use of scales and questionnaires is 
highly recommended to quantify SCD somehow and to monitor the progression of cognitive 
complaints over time since questionnaires tend to have higher internal consistency and 
validity than specific questions of SCD (Montejo et al., 2014; Rabin et al., 2015). 
Additionally, a multiple choice approach should vary from dichotomic to ordinal Likert-type 
scales to grasp the dimensionality of SCD in the best way possible (Burmester, Leathem, & 
Merrick, 2015). 
Apart from SCD information, demographic variables such as age, gender, and education, as 
well as medical and lifestyle variables must be gathered by means of a survey. These 
variables have the greatest interest due to their possible implication in the expression of 
SCD. Additionally, objective cognitive performance and diagnosis are critical to establish the 
current stage of an individual in the continuum of AD and the relationship between SCD 
and risk of developing MCI and AD. Finally, neuropsychiatric variables should be collected 
as well because of their mediator role between SCD and cognitive decline. 
With the previous recommendations in mind, we carried out a third experiment to test if 
the measurement of SCD over time is reliable and stable enough. Cognitive complaints 
were assessed twice and indepedently within the same visit at the Vallecas Project: i) 
neurological interview; and ii) neuropsychological assessment. We followed again the 
guidelines proposed by the SCD-I and applyed the SCD´s operational criteria to classify 
individuals in three different categories in every visit pursuant to the extent of SCD 
reported in both clinical interviews: NCg, SCDg and SCD-Pg. 
In order to test the hypothesis related to the temporal stability of the self-experienced 
cognitive decline, we first calculated the percentage of incongruent classifications over 
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time. We obtained ≈ 95% concordance comparing visit to visit in one year follow-up, ≈ 89% 
in two years follow-up, and 83% in three years follow-up. In order to analyze the reliability 
of the SCD classification over time we conducted concordance analyses involving squared 
weighted Cohen´s and Fleiss kappa indices. For a variety of reasons weighted kappa has 
been considered a good statistic for concordance because it provides an estimate of the 
percentage agreement between ratings corrected for chance (i.e. target values are random; 
Lin, Hedayat, & Wu, 2012). All values of kappa resulted significant (p<0.0001) and over 0.40, 
ranging from 0.46 for the three years follow-up to 0.76 for the one year period. These 
outcomes indicated a good agreement in the longitudinal classification of SCD groups, 
above all considering the subjective nature of the concept, what was taken as a proof of 
temporal stability. So, this is the first time to our knowledge that SCD has been 
demonstrated to be a reliable concept and to have appropriate internal consistency when it 
is measured as here. Thus, the proposal of a methodological, systematic and reproducible 
way of recording SCD is a remarkable strength of our study. This proposal provides a 
consistent, robust and well operationally defined construct that allows monitoring 
preclinical AD stages. 
Objective 5. TO DETERMINE THE EXPRESSION AND THE TEMPORAL DYNAMICS OF 
THE SCD THROUGH THE AD CONTINUUM. 
Finally, after proving that SCD is stable over time in a series of longitudinal assessments, we 
analyzed the validity of the SCD as a very early marker of AD. There is already 
overwhelming evidence about this fact through the literature, and thus it has been 
described that individuals might experience some type of cognitive decline up to 15 years 
before they develop MCI and AD (Reisberg et al., 2008). Furthermore, in the absence of 
objective cognitive impairment, it has been reported evidence about the relationship 
between SCD and some AD biomarkers such as brain amyloid deposition and cerebral 
hippocampal hypometabolism (Eckerström et al., 2017; Vannini et al., 2017). We however 
examined the role of SCD as predictor of cognitive impairment from an original approach 
which does not use so far: the analysis of the dynamic transition from preclinical stages of 
AD. Specifically, we tested the hypothesis of SCD and SCD-Plus as two different statuses 
that increase the risk of future MCI due to AD. 
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To do that, we performed a Multi-state Markov Model to better characterize transitions 
over time among the three supposed preclinical stages (No SCD, SCD, and SCD-Plus) up to 
MCI. Thus our study has a powerful strength regarding the analytic approach to examine 
the role of SCD on AD. Unlike the majority of studies that follow a static, traditional, and 
cross-sectional methodology -that is, grouping individuals based on SCD features just once 
at baseline and analyzing their risks ratios of progression through the AD spectrum-, a 
Multi-state Markov Model implements a novel, comprehensive, and longitudinal approach 
to further investigate the temporal dynamics of SCD as well as transitions through 
preclinical stages during the whole follow-up. Analyses based on this approach are 
appropriate for modeling the course of health processes in continuous time because they 
are able to accurately capture the transition of individuals in forward and backward 
directions across discrete stages (Jackson, Sharples, Thompson, Duffy, & Couto, 2003). 
Then, considering the assumption of the AD continuum, a Multi-state Markov Model 
enables us to describe the process in which individuals move through the preclinical AD 
stages in continuous time and to better identify the underlying trajectory of SCD over time. 
The main advantage of a Multi-state Markov Model is that we can assume that individuals 
can move or recover from consecutive SCD states, as well as convert from any SCD state to 
MCI. 
The results showed a clear sequential trend transitioning from cognitively healthy with No 
SCD to SCD/SCD-Plus and, finally, MCI. In the three-year follow-up of this study, 50% of 
participants with No SCD at baseline progressed to a SCD stage characterized by the 
presence of a self-perception of cognitive failures. From this stage, almost 80% remained as 
SCD through the whole follow-up and 12% did progress to a SCD-Plus phase which might be 
conceived as the previous stage of MCI. Interestingly, the possibility of reversion from SCD 
to No SCD during the follow-up was very unlikely (7%). Finally, we found that the greatest 
probability to convert to MCI was up to 12 times higher for individuals at SCD-Plus status. 
Overall, as depicted in Figure 6.2., these results about change showed a parsimonious and 
detailed scenario of how individuals move into and out of the different SCD categories. 
Every successive preclinical status indicates higher risk of future MCI, focusing on SCD-Plus 
as the one that requires special attention in terms of early preventive intervention. Most 
importantly, beyond biomarkers this is the empirical demonstration of the existence of a 
Subjective Cogntive Decline as prelinical marker in AD 
142 
continuum in the preclinical phase of AD with three well-defined statuses that have 
different probabilities to develop future MCI. 
The strength of SCD measurements is that is a non-invasive, easy, and low-cost method for 
screening both patients attending to memory units and general population. This marker 
could facilitate not only a fast and easy identification of individuals at higher risk for a 
premature cognitive impairment, but it allows us to better track the longitudinal trajectory 
of individuals. SCD therefore could become extremely useful in coming years to measure 
the effectiveness of new clinical trials with AD modifying therapies at preclinical phases 
which are supposed to be still recoverable. 
Inclusive approach 
AD is the most prevalent cause of dementia in old population and, at the present, there is 
not cure for the disease. Identification of the specific features at early stages of the disease 
is essential for a possible intervention, or prevention, of the main pathological 
characteristic related to the disorder: the cognitive impairment. 
It has been highlighted that subjects showing a MCI convert with a higher rate to AD than 
those without MCI. The criteria to define MCI and the parameters used for the 
identification were deeply discussed, but in 2011 the NIA-AA gave some recommendations 
that resulted in a clearer way to look at the transition from normal aging to dementia, 
through MCI (Albert, Dekosky, et al., 2011; see also Cheng, Chen, & Chiu, 2017). This 
approach opened the door to objectively diagnose MCI patients at the earliest stage of 
cognitive impairment. Randomized controlled trials were carryed out with those patients, 
but pharmacological treatments failed to find any effect at delaying cognitive decline. That 
is one of the reasons why the focus of the investigation for stopping the disease process has 
moved in the last years to stages before MCI in which it is supposed that the disease-
modifying therapy may success. 
Since the end of the 20th century it is well known that many patients might experience a 
subjective decline in memory or other cognitive domains even prior to objective cognitive 
impairment. Self-report of subtle cognitive complaints have been proposed to appear at the 
end of the preclinical phase of AD even in the absence of significant objective impairment 
detectable on standardized neuropsychological assessment (Sperling et al., 2011b). This 
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self-experience of cognitive decline represented an opportunity to extend the spectrum of 
AD to at earlier stage. That explains why the study of cognitive complaints was gaining an 
increasing prominence in the research of neurodegenerative disorders.  
Despite the overwhelming epidemiological data in favour of the role of cognitive concerns 
as a risk factor for subsequent MCI and dementia in older adults (Mitchell et al., 2014), this 
construct had to face up to some limitations such as the absence of an operational 
definition as well as the lack of harmonized criteria and assessment protocols. The insight 
and self-experience of cognitive decline is phenomenologically complex and may differ 
among individuals. Indeed from 2000 heterogeneous terminology emerged to refer to this 
sort of pre-MCI stage -“subjective cognitive impairment”, “subjective memory complaints”, 
“subjective memory impairment”, “subjective cognitive complaints”-. Moreover, there is a 
great variability in the assessment procedures which is reflected on the different questions, 
response options, nature of items, and mode of administration across studies. This 
heterogeneity is likely affecting the outcomes obtained in each study and also determines 
the comparison of results. Because of this scenario, in 2014 the SCD-I published a position 
paper agreeing to a common terminology and research procedures to investigate the 
phenomenom (Jessen et al., 2014). Since then, we rely on a homogeneous framework to 
better study the implication of cognitive complaints in dementia due to AD. The term SCD 
was suggested and defined as a self-experienced persistent decline in cognitive capacity in 
comparison with the subject’s previously normal status, during when the subject had 
normal age-, gender-, and education-adjusted performance on standardized cognitive tests. 
This represents a new step for the transition from normal cognition to MCI (Rabin et al., 
2017). Additionally, based on the evidence the SCD-I suggested the term SCD-Plus, a 
specific form of SCD that could be at higher risk of later MCI. The main characteristics that 
define SCD-Plus are as follows: a subjective decline in memory rather than other cognitive 
domain, onset of SCD within the last 5 years, 60 years of age at SCD onset, worries 
associated with SCD, and feelings of worse performance than others in the same age group.  
Our results were the first in confirming the hypothesis of the higher risk associated with the 
SCD-Plus criteria. We obtained that the SCD-Plus group had a significantly higher risk of 
developing MCI in just 13 months (18.9%; adjusted HR=4.2), compared with SCD and No 
SCD individuals (near 5%). We also confirmed the robustness and reliability of the SCD 
construct. We insisted on the necessity for both systematic evaluation and operationally 
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definition of cognitive complaints, and we demonstrated that SCD is stable over time. In our 
opinion, these results give the construct sufficient robustness and pave the way for further 
investigation on the implication of SCD through the AD continuum. 
In addition, SCD is not only a good predictive marker of deterioration without the need for 
the use of invasive and expensive biomarkers, but also our results change the concept of 
the SCD in a certain way. Figure 7.1., which is based on the work of Jack et al., 2010, 
describes the temporal evolution of AD biomarkers in relation to each other and to the 
onset and progression of clinical symptoms. What we have introduced in this model is SCD-
Plus as one of the earliest phases in AD. We hypothesize that SCD-Plus would be located as 
the third marker and its appearance would occur after tau deposition, but just before brain 
structure starts changing. 
 
Figure 7.1. Revised dynamic biomarkers of the AD pathological cascade model (based on the 
model proposed by Jack et al., 2010). 
On the basis of the available evidence in 2010, Jack et al. proposed the use of specific AD biomarkers for disease 
staging in vivo. The disease model embodied the following temporal dynamic: (1) biomarkers become abnormal 
in a temporally ordered manner as the disease progresses; (2) Aβ identified by CSF Aβ42 or PET amyloid imaging 
occurs early in the disease, long time before the appearance of clinical symptoms; (3) tau-mediated neuronal 
injury identified by CSF appears later in the disease spectrum; (4) brain changes captured by structural MRI are 
the last biomarker to become abnormal; however, those brain changes would retain a closer relationship with 
cognitive performance than other biomarkers; and (5) cognitive and functional deterioration are the last 
symptoms that appear in this model. We hypothesize that there would be a third curve namely SCD-Plus that 
would occur after tau deposition, but just before brain structure starts changing, in the preclinical AD stage. 
Aβ: β-amyloid; AD: Alzheimer´s Disease; MCI: Mild Cognitive Impairment; SCD: Subjective Cognitive Decline. 
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From our perspective SCD goes beyond being considered an unspecific symptom that may 
or not may appear in the stage prior to MCI, to being considered as a real stage within the 
continuum of AD in which asymptomatic subjects present a higher risk of conversion. In this 
way we would reach one of the clear and unanimous objectives in AD research: very early 
diagnosis when the subject is still asymptomatic to implementation of preventative 
measures in selected target population, namely SCD-Plus. 
Future directions 
As confirmed throughout this thesis, SCD must be considered as a stage prior to latter 
cognitive impairment. Just like us, research has mainly focused on SCD´s features that 
characterize those individuals who will convert to MCI over time. Although this is a very 
important point, in our opinion it would be interesting to examine three more groups of 
individuals and their relationship with SCD and MCI: i) subjects with SCD that do not 
progress to MCI across time; ii) individuals who do not report any kind of SCD but they do 
develop MCI; and iii) people who show a backward transition from SCD to No SCD. We 
firmly believe that the analyses of those three additional groups of individuals will shed 
light to capture a wider scenario on the SCD and will help to better understand the nature 
od the SCD. 
Also, we would like to underline that nowdays only SCD is an available maker of cognition 
that has demonstrated to be effective for detecting major risk of future MCI. Thus, although 
standard cognitive tests have long been considered the gold standard for the diagnosis and 
prediction of AD progression, there are no objective cognitive tests capable to distinguish 
susceptible profiles of cognitive impairment. The sensitivity of classical tests is suboptimal 
at detecting the subtle cognitive changes that characterize the preclinical phase of AD. To 
account for this fact some reasons can be listed: standard paper-pencil cognitive tests do 
not allow us to rigorously control for parameters such as stimuli presentation velocity 
which could be relevant for the assessment; we cannot accurately record some responses 
nor reaction times neither; and these tests are also frequently affected by ceiling-effects 
specially for people with presumed high cognitive reserve. Cognitive neuropsychology must 
be therefore challenged to improve the sensitivity of the current standardized tests through 
the development of a new generation of cognitive instruments (Rentz et al., 2013). These 
newly developed measures will need to be simple, cost-effective, and capable of capturing 
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the subtle cognitive changes that can differentiate healthy aging from preclinical AD. These 
tests also need to be useful across educational levels as well as proving sensitive to change 
over the short timeframe of a clinical trial. New cognitive tasks must be supported on the 
current evidence derived from knowledge gained through translational efforts in 
neuroscience. Specifically, the instruments must be designed to target the neural pathways 
involved in the basic components of memory including encoding (learning of new 
information), retrieval (accessing information) and storage (recognition of information), as 
well as semantic encoding and top-down high level of attentional processing that may be 
vulnerable in preclinical AD (Badhwar et al., 2017; Hafkemeijer, van der Grond, & 
Rombouts, 2012). 
We would like to continue this line of investigation by combining it with non-invasive 
biomarkers and within our reach, which is why the future line of this thesis is directed 
towards the combination of the complaints groups with the Default Mode Network study. If 
it were to be replicated, as in our case it is possible to differentiate between groups the 
characterization of individuals at risk would result robust and detailed. 
 
Figure 7.2. Preliminary data of partial correlations among brain regions according to mean 
connectome for SCD-Plus. Blue color indicates negative correlation, red color positive 
correlation (Gómez-Ramírez et al., unpublished observations). 
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Overall, the identification of SCD as a dynamic and stable marker of MCI and AD conversion 
is the major contribution of our investigation. This marker characterizes a stage in the 
preclinical AD flow and could be used in clinical settings for the early diagnosis of MCI. 
Currently, we are studying the neurophysiological underpinnings of this marker. The 
Neuroimaging Department of CIEN Foundation is working on a complementary experiment 
using resting state fMRI (Figure 7.2.). The hypothesis is that hyperconnectivity is a common 
network response to any neurological insult. During the earliest asymptomatic stages of AD, 
for instance the SCD stage, the combined effects of neuronal hyperconnectivity and 
increase in Aβ production culminates in the accumulation of Aβ deposits which ultimately 
cause synaptic dysfunction. This hyperconnectivity can be detected using connectivity maps 
in resting state fMRI and we expect that they correlate with the appearance and 
progression of SCD. 
  
 
  
8. FINAL CONCLUSIONS 
This research has focused on the analysis of the association between SCD and AD by means 
of three different and consecutive experiments. The main final conclusions derived from 
our research might be summarized in the following points: 
1. Self-reported cognitive complaints have a multidimensional structure what means that 
there exist distinct types of cognitive and non-cognitive complaints beyond memory. We 
therefore support the notion that SCD is not a monolithic entity when it is measured by 
using questionnaires that involve a considerable number of different items. 
2. Not all cognitive complaints have the same clinical value in distinguishing between 
cognitively healthy older adults and MCI. Specifically, complaints associated with episodic 
memory, executive functions and prospective memory seem to be greater in MCI than in 
controls. 
3. In agreement with the SCD-I two profiles of SCD can be distinguished: i) SCD, when 
individuals report complaints to some extent in one or several cognitive domains; and ii) 
SCD-Plus, when subjects besides report complaints fulfilled a set of features related to a 
subjective decline in memory rather than other cognitive domain, onset of SCD within the 
last 5 years, 60 years of age at SCD onset, worries associated with SCD, and feelings of 
worse performance than others in the same age group. 
4. When implementing the recommendations provided by the SCD-I on the terminology 
and methology for studying SCD, approximately 70% of older adults aged 70-85 show some 
type of cognitive complaint as measured in a community-based investigation such as the 
Vallecas Project. In particular, 61% of individuals can be classified as SCD and 9% as SCD-
Plus. 
5. The transition from a cognitively intact stage to MCI in just one year of follow-up is 
mediated by SCD. Thus, the conversion rate was especially high for SCD-Plus (19%) 
compared to No SCD (5%) and SCD (6%). Adjusted Cox proportional hazard regression 
models indicate that SCD-Plus has 4 times higher risk of fast conversion to MCI than those 
older adults who do not report SCD. 
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6. SCD is a reliable concept and has appropriate internal consistency over time when it is 
operationally defined and systematically measured. 
7. The analysis of the SCD´s temporal dynamics for a three-year follow-up period highlights 
the existence of two main stages into the preclinical AD phase -No SCD and SCD- as well as 
a sub-stage called SCD-Plus that falls within SCD. 
8. Progression may occur from No SCD to SCD, but oposite transitions from SCD to No SCD 
are very unlikely. Once an individual is at the SCD phase there may be a progression to a 
severe form of cognitive concerns, the sub-stage SCD-Plus, in which the risk of MCI is the 
highest compared to No SCD and SCD. Nevertheless, since the criteria for classifying SCD-
Plus are very restrictive, permeability is possible between SCD and SCD-Plus and thus 
individuals might be gone through or back over time. 
9. Our findings therefore provide evidence on the use of SCD as an earlier phase that 
precedes MCI through the AD continuum. We provide a theoretical tracking of the 
preclinical AD phase not in a static way instead we draw a dynamic transition of what is 
occuring across time. 
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